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Summary
Vaccinia virus (VACV) is the prototypic poxvirus and is complex in both
composition and life cycle. In contrast to most viruses, poxviruses produce
two types of infectious particles with different roles in virus dissemination:
Mature virions (MVs) mediate host-to-host transmission, whereas extracel-
lular virions (EVs) accomplish virus dissemination in an infected organism.
While MVs are enveloped by a single lipid membrane, EVs exhibit an un-
usual composition – they consist of an MV-like particle that is wrapped with
a second membrane.
Like all viruses, poxviruses depend on the host cell machinery to reach
their final site of replication in the cytosol. Host cell entry of MVs is known to
involve macropinocytosis and fusion of viral membranes with cellular mem-
branes of endocytic compartments. Due to their topology, EVs require an
unusual entry strategy and the outermost membrane is thought to be lost by
non-fusogenic disruption, whereas the inner membrane is removed by fusion.
Hence, EV and MV entry both result in the release of viral cores containing
the DNA genome into the host cell cytosol.
One aim of this thesis was to understand the cellular entry process of
VACV EVs, chapter 2 (see page 27), and MVs, chapter 4 (see page 87), in
detail. In the case of EVs, we wanted to investigate whether this process
involves endocytosis, where and how the EV membrane is lost, and which
cellular factors and processes were exploited in the course of this process.
Furthermore, we intended to study the processes that occur after release of
viral cores into the cytosol and allow early gene expression.
The results of our investigations on the cellular entry mechanism of VACV
EVs are presented in chapter 2 (see page 27). EV entry into HeLa cells was
studied using fluorescence microscopy and electron microscopy in combina-
tion with flow cytometry. We show that complete EVs are internalized by
macropinocytosis and that this step is actively triggered by EVs. Acidi-
fication of macropinosomes induces disruption of EV membranes and this
exposes the underlying MV-like particle. The latter presumably fuses with
cellular membranes and releases the viral core into the host cell cytosol.
v
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A further issue of this thesis was to support a high-throughput RNAi
silencing screen, which identifies host cell factors required during vaccinia
virus infection, with electron microscopy analysis. Validation and analysis
of clustered hits revealed previously unknown processes during virus entry
including a new mechanism for genome uncoating and was confirmed by
EM. Viral core proteins were found to be ubiquitinated already during virus
assembly. After entering the cytosol of an uninfected cell, the viral DNA
was released from the core through the activity of the cell’s proteasomes.
Next, a Cullin3-based ubiquitin ligase-mediated round of ubiquitination and
proteasome action was needed to initiate viral DNA replication.
Our efforts to clarify the mechanisms underlying core activation after
fusion are presented in chapter 4 (see page 87) and the main research aspect
of this thesis. Morphological changes in viral structures were observed by
conventional and cryo-electron microscopy to occur immediately after viral
fusion and may involve the reduction of disulfide bonds in proteins that
comprise the viral core wall. Lateral bodies, proteinaceous structures that
are packaged into VACV MVs and EVs in addition to the cores, dissociate
from viral cores upon fusion. Both processes, core activation and dissociation
of lateral bodies, require cellular factors or components. They cannot be
recapitulated by removal of membranes and reduction in vitro.
We identified F18 as a major structural protein of the lateral bodies, which
are left back at the membrane after fusion. We found that the decomposition
of lateral bodies by the host cell proteasome releases at least one immediate
effector protein into the host cell, the dual specific viral phosphatase VH1.
Furthermore, we identified a number of disulfide-bonded core proteins and
found that some of them are reduced during activation. This possibly con-
tributes to subtle changes that finally allow early gene transcription in the
core.
We thus have compelling reasons to propose a new viral delivery mecha-
nism for immediate effector proteins that is very likely used to release addi-
tional, so far unknown, effector proteins.
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Chapter 1
Introduction
1.1 Vaccinia Virus
1.1.1 The poxvirus family
Poxviruses are large cytoplasmic DNA viruses that replicate entirely in the
host cell cytoplasm and co-evolved with animals from insects (entomopox-
viruses) to vertebrates (chordopoxviruses). They encode 130-328 genes, among
which 66 are shared by all poxviruses and 119 are found in all chordopox-
viruses. Poxviruses share a set of 41 genes with other nucleo-cytoplasmic
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GTPV-Pellor-036
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Figure 1.1 Poxvirus phylogeny based on the DNA polymerase sequence. Complete linkage
tree based on ClustalW alignment created with Viral Orthologous Clusters [248]. uncl. =
unclassified.
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large DNA viruses and a common origin has been suggested [109]. Among the
nine distinguished chordopoxvirus genera (see Figure 1.1), orthopoxviruses
are the best studied and contain vaccinia virus (VACV), the prototype
poxvirus, variola virus (VARV), the etiologic agent of smallpox, and mon-
keypox virus (MPXV), which induces morbidity similar to smallpox in hu-
mans. Besides that, only molluscum contagiosum virus (MOCV), a mollus-
cipoxvirus, is considered a human pathogen and causes benign skin lesions.
Many other poxviruses, however, can elicit zoonotic infections in humans
[241, 131].
Poxvirus infection in host organisms can occur through the airway (VARV),
skin lesions (MOCV), or ingestion (entomopoxviruses) [53, 155]. Infection
may be restricted locally, often in the skin (MOCV, VACV after intradermal
inoculation) or spread systemically (VARV). Systemic infections may, as in
the case of VARV, involve multiple rounds of virus spread at the site of entry,
in secondary lymphoid organs and in the skin. During virus spread, diverse
cell types such as epithelial cells, fibroblasts, and cells of the hematopoi-
etic lineage are infected. Thus poxviruses possess a relatively broad cellular
tropism within a host species. Poxvirus infection in non-permissive cells is
in most cases blocked at post entry steps [145].
1.1.2 Vaccinia virus
VACV was successfully used as a live vaccine against smallpox and most of
our current knowledge on the molecular biology of poxvirus infections has
been learned through the study of this virus. However, its origin and natu-
ral host remains obscure [163]. Confusion is in part caused by the use of the
term cowpox virus (CPXV) to describe a variety of divergent orthopoxviruses
infecting cattle. In fact, different CPXV isolates were found to be more dis-
tantly related than other accepted orthopoxvirus species and may comprise
up to five different orthopoxvirus species [28]. While CPXV from the British
Isles was presumably used as a live vaccine against smallpox in initial vaccina-
tion attempts, VACV was recently found to be closely related to CPXV iso-
lates found in continental Europe, which are only distantly related to CPXV
from the British Isles [28]. VACV strains preserved as freeze-dried vaccines
were ultimatively used in the worldwide WHO vaccination campaign that
lead to the eradication of smallpox in 1979. VACV-related viruses are cur-
rently circulating in cattle in Brazil as well as buffaloes in India; both may be
derived from vaccine strains [130, 271]. The two most commonly used VACV
laboratory strains, Western Reserve (WR) and International Health Depart-
ment strain J (IHD-J), are both neurotropic in mice as a result of multiple
intra-cerebral mouse passages of VACV vaccine strains [266, 105, 70].
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1.1.3 Replication and assembly of infectious particles
The 195 kbp dsDNA genome of VACV encodes for around 200 proteins, which
are expressed in a hierarchical and temporally controlled fashion. This is co-
ordinated by early, intermediate, and late transcription factors that recognise
specific promoter elements upstream of the coding sequences [163]. Early
transcription factors and the viral RNA polymerase complex are packaged
into the cores of infectious particles and early viral genes are immediately
transcribed and expressed following release of viral cores into the host cell
cytoplasm (see chapter 1.1.6). Early genes encode host modulatory factors
as well as viral enzymes that set the stage for core uncoating and DNA repli-
cation [274]. In addition, intermediate transcription factors are produced
that allow the next set of viral genes to be transcribed and translated. After
uncoating, the DNA genome is replicated by viral enzymes in distinct cy-
toplasmic replication sites [119, 141]. The two strands of poxvirus dsDNA
genomes are connected by terminal loops and their replication involves the
formation of DNA concatamers. Replicated DNA genomes are the template
for the transcription of viral intermediate genes encoding proteins for DNA
packaging and organisation, structural proteins of the viral core, and late
transcription factors [276]. Late transcription then drives the expression of
additional structural components needed for the formation of viral particles.
Included are early transcription factors and the RNA polymerase complexes
that are packaged into newly formed progeny virus [276].
Members of the poxvirus family are unique in that they produce two types
of progeny virus: mature virions (MVs) and extracellular virions (EVs) [163].
When intact, both viral particles do not share common viral surface epitopes,
although they share the same viral core and genome.
1.1.3.1 Mature Virions
MVs are the less complex infectious virus form produced by VACV-infected
cells. They contain a viral core with the DNA genome and two proteinaceous
lateral bodies, which are surrounded by one lipid bilayer containing at least
25 viral proteins [163]. MV membrane proteins are highly cross-linked by
disulfide bonds and the combined treatment with detergents and reducing
agents is required to solubilize them [65]. MV assembly starts with the
accumulation of electron dense viral material and the occurrence of crescents
– curved single lipid bilayer sheets, which are supported by scaffold proteins
(see Figure 1.3 and 1.4) [163]. Crescent membranes may be derived from
membranes of the endoplasmic reticulum and it was speculated that they
are generated de novo or by rupture of cytosolic vesicles [46, 89, 41]. The
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Nucleus
TGN or early
 endosomes
WV
EV Actin tails
lysis of
infected cell
Virus factory
IVMV
MV
Figure 1.2 Vaccinia virus replication cycle. IV = immature virion, EV = extracellular
virion, MV = mature virion, WV = wrapped virion, TGN = trans-golgi network.
Figure 1.3 Vaccinia virus parti-
cles. C = crescent, IV = immature
virion, Nu = immature virion with
nucleoid, MV = mature virion,
WV = wrapped virion, EV =
extracellular virion. Illustration
from [163].
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Figure 1.4 Vaccinia virus MV morphogenesis. C = crescent, IV = immature virion, IVN
= immature virion with nucleoid, MV = mature virion. Reproduced with permission,
from Chichon et al., 2009, Biology of the Cell, 101 (7), 401–414 [38]. © the Biochemical
Society.
first virus intermediates with a closed viral membrane are immature virions
(IVs). They contain viral core proteins and a single membrane, which is
coated by the scaffolding protein D13 on the outside [46]. D13, interestingly,
is a structural homologue of capsid proteins found in all large icosahedral
dsDNA viruses [103, 11]. When the condensed viral DNA is visible in electron
micrographs, IVs are called immature virions with nucleoid (IVN) [163]. It
was speculated that viral DNA may not be visible in IVs due to the position
of the cross section or due to the un-condensed state of the DNA [46, 41].
In this case, DNA would be packaged during IV formation, whereas DNA
acquisition after IV membrane closure would require DNA transport across
membranes.
A complex maturation process transforms IVs into MVs and this mor-
phogenesis leads to the formation of distinct viral cores and lateral bodies
within the viral envelope (see Figure 1.3 and 1.4) [46]. Maturation involves
proteolytic cleavage of core and membrane proteins by the VACV cysteine
protease I7. Cleavage of the membrane protein A17 results in loss of the
D13 and the respective protein coat that surrounds IVs. The viral metal-
loprotease G1 is also required for final steps in morphogenesis, but its sub-
strates are currently unknown [46]. Maturation also includes the formation
of disulfide bonds in MV membrane proteins as well as several core proteins
[46, 216, 135]. Oxidation of membrane proteins within the reducing host cell
cytosol is catalysed by a cascade of viral enzymes. Electrons of the respec-
tive substrates are transferred to the viral oxidoreductases G4, which again
reduces a dimer of the sulphydryl oxidase E10 and A2.5. Possibly using the
cofactor FAD, electrons are ultimatively transferred to O2 (see Figure 1.5)
[216]. That disulfide bonds in VACV proteins are stable in the reducing host
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cell cytosol demands that the involved residues are not solvent-accessible
or secluded from the cytosol by compartmentalisation, since the cytosol re-
mains reducing in the course of the infection [135]. The catalytic mechanism
of disulfide bond formation in core proteins has not yet been studied in detail.
Finally, MV maturation involves the acquisition of additional MV membrane
proteins, e.g. A27 and L1. While all mentioned steps are a prerequisite for
successful MV formation, their exact order is not known [46].
MVs accumulate in the host cell cytosol and eventually leave the cell upon
lysis. They are the more abundantly produced infectious form and are, due
to their stability, thought to mediate host-to-host transmission of poxvirus
infection [222].
In entomopoxviruses, avipoxviruses and some orthopoxviruses, MVs can
be clustered into cytosolic proteinaceous A-type inclusions (ATIs). ATIs
are released by host cell lysis and may protect virus particles in the harsh
extracellular environment [163]. Formation of ATIs requires the viral ATI
protein and incorporation of MVs into ATIs is dependent on A26, which
links A27 on the MV membrane to ATI proteins [95]. VACV and VARV
only encode a truncated form of the ATI protein, A25, and consequently do
not form ATIs [5, 163].
1.1.3.2 Extracellular Virions
EVs are composed of an MV-like particle that is surrounded by an additional
membrane that includes unique EV proteins. EVs and MVs contain the same
viral core and the inner membrane of an EV is similar, but not identical, to
the MV membrane. The outermost membrane contains cellular proteins and
at least 6 unique EV membrane proteins: A33, A34, A56, B5, F13, and K2
[175, 223, 221].
To form EVs, a distinct subset of MV-like particles is wrapped with two
additional membranes that are derived from the trans-golgi network (TGN),
early endosomes, or a hybrid compartment. This process results in wrapped
virions (WVs), intermediates which are surrounded by three membranes. The
outer membrane of WVs contains EV membrane proteins and three viral
proteins only found in WVs: A36, F12, and E2 [223, 61]. The outermost
WV membranes fuse with the plasma membrane to release EV particles by
O2
H2O2
FADH2
FAD
E10R
E10R
A2.5L
A2.5L
G4L
G4L
L1R / F9L
L1R / F9L
S-S
S-S
S-S
S-SSH       SH SH       SH
SH       SH SH       SH
Figure 1.5 Vaccinia virus disul-
fide bond formation pathway. Il-
lustration adapted from [216].
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exocytosis.
Purified EVs do not contain A25 (truncated N-terminus of ATI protein)
and A26, two proteins tethered to the MV membrane via A27. It is therefore
likely that the MV-like particles that are wrapped to form EVs are distinct
from the majority of MVs [246, 94]. In accordance with this, peak EV pro-
duction precedes peak MV production [246]. A27 on the MV-like membrane
is required for microtubule-dependent transport of virus particles to the site
of wrapping, the microtubule organising centre [198]. It is tempting to spec-
ulate that the accessibility of A27 – in MVs bound to A25/A26 – is critical
for EV formation. Wrapping itself is dependent on A27 as well as F13, B5,
F12, and E2 in what become the outer two WV membranes [223, 60]. WVs
are transported to the plasma membrane along microtubule and this requires
kinesin-1 and A36 [192, 61]. F12 has been implicated in this process as well
[158]. WVs undergo actin-dependent movement in the cell cortex and this
requires F11-mediated inhibition of RhoA-mDia signalling [9].
Once released by exocytosis, the majority of EVs remains cell-associated
and only few EVs are released into the surrounding liquid. The amount of
released EVs is virus strain and cell-type specific. A point mutation in the
EV protein A34 of VACV strain IHD-J that is not found in VACV strain
WR or VARV leads to the enhanced release of EVs [187, 176]. In addition,
infected cells of the rabbit epithelial cell line RK13 released more EVs into
the medium than HeLa cells [176]. Cell-associated EVs can induce the for-
mation of actin tails, which project viral particles away from the producer
cell towards adjacent cells [223].
Fusion of the outermost WV membrane deposits viral proteins below cell-
associated EVs. One of them, A36, can be phosphorylated by Src kinases and
recruits a signalling complex containing of Grb2, Nck, WIP, and N-WASP
[74, 157, 205, 259]. Locally restricted activation of Arp2/3 complexes induces
actin polymerisation below EVs, resulting in protruding actin tails with EVs
at their tip. This process can also be induced by super-infecting EVs that
attach to VACV-infected cells expressing the viral proteins A33 and A36 [59].
EVs are the less abundant infectious form, but are crucial for virus spread
within an infected organism [177]. EVs on the tip of actin tails are though
to mediate virus spread within a tissue and efficient plaque formation in
monolayers of tissue culture cell lines [223]. Free EVs are responsible for
tissue-to-tissue spread within an infected organism and mediate infection of
more distant cells in monolayers of tissue culture cells. In the latter case,
this results in the formation of satellite plaques appearing as “comet tails”of
plaques [223, 222]. In line with their role in virus spread through body fluids,
EVs incorporate host cell complement control proteins and are more difficult
to neutralise by antibodies than MVs [252, 129].
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1.1.4 Host cell entry of MVs
Viruses are obligate intracellular pathogens and have to deliver their genome
and accessory proteins to their final site of replication in the host cell. Viral
entry involves virus binding to surface receptors on the host cell and either
direct penetration of the plasma membrane, or virus-induced endocytosis
followed by membrane penetration from endocytic organelles. Membrane
penetration may include fusion of viral and cellular membranes, or non-
fusogenic mechanisms such as pore formation, injection, translocation, or
physical disruption of cellular membranes [143].
VACV MVs and EVs share no common viral or cellular surface proteins
and their membranes are of different cellular origin. Thus, both infectious
forms of VACV have to be able to gain access to the host cell cytoplasm
independently. While MVs are surrounded by a single lipid bilayer and
can penetrate cellular membranes by a simple fusion event, EVs contain
two membranes and have a more complex entry strategy that involves non-
fusogenic disruption of one and fusion of the other membrane [162]. Since
MVs and EVs contain the same viral core and genome, both entry pathways
converge when the viral core is released into the host cell cytosol, where un-
coating (see section 1.1.6 on page 16) and viral replication (see section 1.1.3
on page 3) occurs.
1.1.4.1 Binding
The first step in virus entry is the attachment of the viral particle to the cell
surface. Cellular factors in the plasma membrane contribute to both enrich-
ment of viruses on cells (attachment factors) and promotion of subsequent
entry steps such as activation of fusion proteins, signalling, or endocyto-
sis [143].
Binding of VACV MVs was analysed in multiple studies and it has become
evident that MVs employ several and partly redundant binding modes. This
explains why poxviruses can infect many different cell types in an infected
animal and why pure MVs are able to bind to all cell lines tested. Gly-
cosaminoglycans (GAGs) at the cell surface can be hijacked as attachment
factors by MVs. Binding to heparan sulphate was proposed to be mediated
by the MV membrane proteins A27 [44, 96] and H3 [133], and binding to
chondroitin sulphate conferred by D8 [97]. The dependence on GAGs for
binding and infection, however, varies with cell type, virus strain, and ex-
perimental conditions [16, 29, 261]. There is evidence for GAG-independent
cell binding mediated by the MV membrane protein L1 [73] and the MV
membrane-associated protein A26 mediates binding to the extracellular ma-
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trix glycoprotein laminin [39]. A monoclonal antibody with an unknown cel-
lular epitope has been shown to inhibit MV binding and infection, although
it may prevent virus binding sterically [40, 250]. The finding that MVs move
along filopodia towards the cell body suggests that at least one of the at-
tachment factors can undergo retrograde flow along the actin cytoskeleton
[148, 99]. MVs have also been reported to bind to liposomes directly, sug-
gesting GAG- and protein-independent binding mechanisms exist [182, 173].
Although details of the host cell attachment factors exploited by MVs
remain to be determined, it is evident that several redundant attachment
modes have evolved to secure binding to a broad range of host cells.
1.1.4.2 Phagocytosis
Phagocytosis is a specific form of endocytosis involving the vesicular internal-
isation of solid particles, such as bacteria or dead tissue cells and therefore
distinct from other forms of endocytosis such as pinocytosis, the vesicular
internalisation of liquids.
Phagocytosis is the cellular process of engulfing solid particles by the cell
membrane to form an internal phagosome. The phagosome fuses sequentially
with the different organelles of the endocytic pathway. First early endosomes,
then late endosomes and finally lysosomes. The latter two organelles, that
are often together termed as “lysosomes”allow the delivery of hydrolases and
the protein ATPase to the phagosome, thereby providing a low pH hydrolytic
environment in this organelle. The contents are subsequently degraded and
either released extracellularly via exocytosis, or remain intra-cellularly to
undergo further processing. This process is commonly named “phagosome
maturation”.
It is mainly carried out by specialised cells that are “professional”phagocytes.
In mammals there are three classes of white blood cells that act as profes-
sional phagocytes: macrophages, neutrophils and dendritic cells [72]. These
three types of cells develop from a common precursor cell, and they defend
us against infection by ingesting invading microorganisms. Macrophages also
play an important part in scavenging senescent and damaged cells and cellu-
lar debris. Phagocytosis is considered a centrepiece in mechanisms of innate
immunity.
Whereas the endocytic vesicles involved in pinocytosis (receptor mediated
endocytosis) are small (50-100 nm), phagosomes have diameters that are
determined by the size of the ingested particle, and they can be almost as
large as the phagocytic cell itself. The phagosomes fuse with lysosomes,
and the ingested material is degraded; indigestible substances will remain in
lysosomes, forming residual bodies.
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In order to be phagocytosed, particles must first bind to the surface of
the phagocyte. Not all particles that bind are ingested, however. Phagocytes
have a variety of specialised surface receptors that are functionally linked to
the phagocytic machinery of the cell. Unlike pinocytosis, which is a consti-
tutive process that occurs continuously, phagocytosis is a triggered process
that requires activated receptors transmitting signals to the cell interior to
initiate the response. The best characterised triggers are antibodies, which
protect us by binding to the surface of infectious micro-organisms to form a
coat in which the tail region of each antibody molecule (called the Fc region)
is exposed on the exterior. This antibody coat is then recognised by specific
Fc receptors on the surface of macrophages and neutrophils. The binding of
antibody-coated particles to these receptors induces the phagocytic cell to
extend pseudopods that engulf the particle and fuse at their tips to form a
phagosome [72].
Several other classes of receptors that promote phagocytosis have been
characterised – such as those that recognise complement (a class of molecules
that circulate in the blood and collaborate with antibodies in targeting un-
desirable cells for destruction) and those that directly recognise sugars such
as mannose that present oligo-saccharides on the surface of many microor-
ganisms.
1.1.4.3 Endocytosis
In eukaryote cells, the routes that lead inward towards the lysosomes from the
cell surface start with the process of endocytosis, by which cells take up fluid,
specific ligands such as hormones, macromolecules, particulate substances,
and, in specialised cases, even other cells [81, 180].
Material to be ingested is progressively enclosed by a small portion of the
plasma membrane, which first invaginates and then pinches off to form an
intracellular vesicle containing the ingested substance or particle. Two main
types of endocytosis are distinguished on the basis of the size of the endo-
cytic vesicles formed: pinocytosis (most prominently clathrin-coated vesicles)
[52, 180], which involves the ingestion of fluid and solutes via small vesicles
(50-150 nm in diameter), and phagocytosis, which involves the ingestion of
large particles, such as microorganisms or cell debris, via large vesicles called
phagosomes, generally >250 nm in diameter. A related mechanism that
allows cells to take large amounts of volume in relatively large vesicles is
macropinocytosis [120, 149].
Although most eukaryotic cells are continually ingesting fluid and solutes
by pinocytosis, large particles are ingested mainly by specialised phagocytic
cells.
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Fusion of enveloped viruses with cellular membranes can occur at the
plasma membrane or after endocytic uptake of viral particles. While fusion
at the plasma membrane seems to be less demanding on the cellular machin-
ery needed, fusion after endocytic uptake has several striking advantages:
(i) Cellular transport mechanisms ferry the virus particle to the point of fu-
sion, the cortical actin cytoskeleton barrier is thus avoided. (ii) No traces
that could be recognised by the immune system are left behind in the plasma
membrane. (iii) Active conformations of the fusion proteins, often sensitive
to neutralising antibodies, are not accessible to the immune system [143, 218].
Conflicting results on MV entry had previously been obtained and both
fusion at the plasma membrane and endocytic internalisation of MVs was
visualised by electron microscopy [51, 34, 239]. However, the application of
large numbers of viral particles for electron microscopy experiments may have
led to the observation of less important or even artificial entry pathways at
the plasma membrane and in most cases defied thorough quantification. Re-
cent studies using internalisation assays and inhibitors of distinct endocytic
processes confirmed that the main entry route of VACV MVs in HeLa and
several other cell types is endocytosis [239, 148, 99, 152, 199]. In the case of
strain WR, artificial fusion with plasma membranes induced by brief acidifi-
cation allowed infection in the presence of endocytosis inhibitors, indicating
that these only blocked endocytosis and no other aspects of viral replication
[148].
To be internalised, MVs exploit macropinocytosis (see Section 1.2.3 on
page 21). This form of endocytosis is signalling-induced and involves dra-
matic actin rearrangements to engulf large amounts of bulk fluid. Cargo is
therefore taken up in a receptor-independent fashion. MV-induced macro-
pinocytosis is dependent on phosphatidylserine (PS) in the MV membrane
and requires epidermal growth factor receptor (EGFR) signalling [148, 152].
In intact cells, PS is confined to the inner leaflet of the plasma membrane and
its exposure on apoptotic bodies marks them for endocytic uptake [249]. MVs
resemble apoptotic bodies in this aspect and since the latter can be cleared
from tissue by macropinocytosis, it was postulated that VACV MVs employ
apoptotic mimicry [91, 148]. Despite the discovery of several PS receptors,
the receptor used by MVs remains elusive and so does the question whether
the hypothetical receptor binds phosphatidylglycerol or the D-stereoisomer
of PS, two lipids not found in the MV membrane, which can functionally sub-
stitute the naturally occurring PS [126]. Uptake of apoptotic bodies elicits
anti-inflammatory signals in the cells [69]; it is intriguing to speculate that
VACV infection could benefit from such modifications of the host immune
system.
Macropinocytosis is initiated by the formation of dynamic membrane pro-
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Figure 1.6 Summary of VACV
MV entry. VACV MVs bind to
host cells and trigger macropinocy-
tosis through phosphatidylserin (PS)-
dependent signalling processes. In-
ternalisation is followed by acidifica-
tion of macropinosomes, activation of
EFCs, fusion, and release of cores into
the host cell cytosol.
trusions that may appear as lamellipodia, circular ruffles, or blebs. Macro-
pinocytosis induced by MVs of strain WR, in fact, helped to define the latter
type of membrane protrusions. Whether the massive induction of filopodia
caused by MVs of strain IHD-J is involved in macropinosome formation is
currently unclear [148]. A fraction of the signalling-triggered membrane pro-
trusions folds back to form macropinosomes of irregular size and shape, which
internalise bulk fluid and virus particles. Important cellular factors involved
in this process include cholesterol, Na+/H+ exchangers, tyrosine kinases,
protein kinase C (PKC), members of the Rho GTPase family, p21-activated
kinase 1 (PAK1), and myosins [136, 148, 99, 152]. They all act in concert
to mediate the required actin rearrangements as well as subsequent steps
of macropinosome formation. An additional cellular factor, VPEF/FAM21,
is required for MV infection. Unlike previously suggested, it is a cytosolic
protein and has recently been shown to be involved in Arp2/3-dependent
vesicle scission [99, 78]. Macropinocytotic uptake into HeLa cells induced by
MVs of the two VACV strains WR and IHD-J exhibited slight differences
in the involved signalling cascades [151]. This suggests that different types
of macropinocytosis exist and can be induced by subtly different triggers.
Macropinocytic uptake of MVs was confirmed in several cell types, including
monocyte-derived dendritic cells (MDDCs) [199]. Macropinocytosis, how-
ever, does not need to be triggered in MDDCs and is constantly active to
monitor the environment as part of the immuno surveillance function of these
cells [169]. Contrary to that, MV entry into CHO cells is most likely inde-
pendent of macropinocytosis [151].
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1.1.4.4 Fusion
Enveloped animal viruses undergo fusion events with cellular membranes to
deposit the viral core or capsid into the host cell cytosol. The process is
catalysed by viral fusion proteins in the virus envelope [143].
In the case of poxvirus MVs, the fusion activity is found in the single
MV membrane and fusion is thought to be mediated or catalysed by a large
macromolecular assembly of viral proteins, the entry/fusion complex (EFC)
[213]. The EFC consists of stoichiometric amounts of the trans-membrane
proteins A16, A21, A28, G3, G9, H2, J5, and L5. Associated with this are
three further viral membrane proteins: F9, L1, and O3 [202, 22, 18]. All
mentioned viral membrane proteins except for J5, which has not yet been
tested, are required for efficient fusion of VACV MVs [171, 214, 215, 172,
213, 110, 213, 238]. A twelfth MV membrane protein, I2, is also required
for fusion, although interaction with the other components has not yet been
shown [168]. I2 and O3 are conserved in all chordopoxviruses, whereas all
other factors are found in all sequenced poxvirus genomes, suggesting that a
common fusion mechanism is used by all poxviruses [109]. The architecture
of the EFC and the molecular details of the fusion reaction remain elusive.
However, binary complexes between A28 and H2, A16 and G9, as well as G3
and L5 have been observed [166, 258, 267].
Two protein complexes have been shown to negatively regulate the EFC.
A56-K2 dimers are localised to the plasma membrane of infected cells and to
EV membranes [244]. They prevent super-infection of infected cells with MVs
and are thought to prevent back-fusion of disrupted EVs with the plasma
membrane of producer cells [245, 257]. In accordance with this function,
VACV strains lacking A56 or K2 form extensive syncytia at neutral pH [105,
243]. This is mediated by progeny EVs at the plasma membrane, a fraction of
which contains disrupted EV membranes. Exposed EFCs in the underlying
MV membrane consecutively mediate virus-cell and cell-cell fusion (fusion
from within).
Dimers of A25 and A26, which are tethered to the MV membrane through
A27 and the trans-membrane protein A17, are thought to inhibit premature
EFC-mediated fusion at neutral pH [35, 94]. Fusion of WR MVs containing
A25/A26 with cellular membranes requires passage through acidified endo-
cytic vesicles, whereas VACV strains lacking either of the two components
do not need to traffic through low pH compartments and cause syncytia at
neutral pH. While some laboratory VACV strains, such as MVA and IHD-W,
naturally lack full length A25 or A26, VARV encodes A25 and A26 proteins
at similar lengths as VACV WR [246, 35]. Fusion of VACV WR MVs with
the plasma membrane and syncytia formation can be induced by acidifica-
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tion of bound virus particles (pH optimum 4.5-5.0), suggesting that such a
treatment overcomes inhibition of fusion by A25/A26 [239]. However, treat-
ment of MVs with low pH or proteases before binding accelerates infection,
but does not override the need to passage through acidic compartments for
successful infection [237]. This suggests that two steps in MV entry are de-
pendent on low pH, which can both take place when bound MVs are treated
with acidic solutions. Of note, A27, one of the proteins required to tether
A25/A26 to the MV membrane, is lost when MV infection is accelerated by
papain treatment [237].
MVs of several VACV strains do not need endocytic acidification for
infection and their fusion with the plasma membrane cannot be induced by
low pH [16, 261, 152]. Of note, MVs of VACV strain IHD-J are independent
of low pH, but still enter cells through a macropinocytic mechanism [152].
The entry pathways of other pH-independent VACV strains have not been
characterised in detail.
1.1.5 Host cell entry of EVs
Studies on EV entry have been hampered by the intrinsic instability of the
outer EV membrane: not all released EVs contain an intact outer membrane
and intact EV membranes are efficiently disrupted during freeze-thawing and
EV purification strategies using different gradient material [107, 252]. To in-
vestigate genuine EV entry, intact EVs have to be discriminated from EVs
with disrupted outer membranes as well as contaminating MVs. For infection
experiments, MV-neutralising antibodies can be employed to block infection
by MVs and EVs with disrupted outer membranes [107, 252]. Microscopic
studies can only discriminate MVs from intact or disrupted EVs by visualis-
ing proteins in the EV membrane [250].
1.1.5.1 Binding
VACV MVs and EVs do not share any common epitopes and have been
shown to use different attachment factors [250]. However, no cellular attach-
ment factors for free EVs have been found so far. The serum protein Gas6
was shown to link phosphatidylserine in lentivirus membranes to the TAM
receptor tyrosine kinase Axl on cells [159]. That Gas6 incubation boosts EV
infection led to the speculation that similar mechanisms may be exploited
by this virus form. Artificially disrupted EVs did not bind to naive T cells.
However, the same virus particles bound to T cells after activation and trans-
port of newly synthesised cellular receptors to the plasma membrane [32]. It
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is, however, unclear if factors in the EV or in the MV membrane mediated
attachment.
1.1.5.2 Endocytosis or entry at the plasma membrane?
The presence of two membranes imposes unique requirements on EV entry
because fusion of both membranes with cellular membranes would release the
viral core into a compartment equivalent to the outside of the cell. It is there-
fore assumed, that the outer membrane is lost in a non-fusogenic process and
that the inner membrane, containing the MV fusion machinery, undergoes
fusion with cellular membranes. This is supported by the following observa-
tions: (1) EV entry depends on the EFC in the inner membrane, which is
similar to MV membranes [214, 215]. (2) The outer EV membrane can be
artificially disrupted by treatment with low pH and anionic polysaccharides
in vitro [107, 252, 128]. (3) Electron micrographs show MV-like particles
fusing with the plasma membrane in proximity of shed EV membranes [128].
Intact EVs were initially proposed to enter cells by endocytosis followed
by acid-induced disruption of the EV membrane. This model of EV entry
was based on the observations that (1) EV infection could take place in
the presence of antibodies targeting proteins in the MV/MV-like membrane,
(2) lysosomotropic agents inhibited EV infection, and (3) low pH triggered
EV membrane disruption in vitro [107, 252]. A more recent study, however,
concluded that EV membranes are disrupted upon contact with GAGs at
the cell surface and that the released MV-like particle subsequently fuses
with the plasma membrane. This model is supported by the finding that
(1) the postulated events could be visualised by electron microscopy on cells
producing GAGs, but not on cells deficient in GAG synthesis, and (2) EV
membranes were disrupted by soluble anionic polysaccharides [128].
Entry of EV particles pushed to adjacent cells by actin tails has not
been studied in detail. However, cell-associated and free EVs have the same
composition and may follow similar entry routes.
1.1.5.3 EV disruption and fusion
Both proposed models for EV entry concur in that loss of the EV membrane
occurs by non-fusogenic disruption [107, 252, 128]. The mechanism of EV
membrane disruption in vivo or after low pH- or GAG-exposure in vitro is
unclear. GAG-mediated EV disruption depends on the EV proteins B5 and
A34, although A34 may only be required to recruit sufficient amounts of B5 to
the EV membrane [128, 193]. Acidic residues in the membrane-proximal stalk
region of B5 have been proposed to be required for GAG-induced membrane
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disruption [193]. Since EFCs in the inner MV-like membrane are crucial
for EV infection [214, 215], it is assumed that the exposed MV-like particles
subsequently undergo fusion with cellular membranes to release the viral core
into the cytosol.
1.1.6 Core disassembly
Proteinaceous cores or capsids protect viral genomes and need to be uncoated
to release the viral DNA or RNA. Often, viral capsids are in an intrinsically
meta-stable state and disassembly is energetically favourable under certain
conditions. Meta-stability may either be generated by structural rearrange-
ments that occur during capsid maturation, or be induced by triggers in
the host cell [79]. Uncoating induced by the latter mechanism may allow
intracellular transport of viral cores or capsids within the host cell before
disassembly begins.
Both MV and EV entry result in the release of viral cores into the host
cell cytosol by fusion of viral and cellular membranes. Released cores un-
dergo at least two distinct disassembly steps, activation and uncoating, that
ultimately release the viral dsDNA genome from the core structure. This
allows for DNA replication and production of progeny virus.
1.1.6.1 Activation
During or shortly after fusion, VACV cores undergo morphological changes
that can be visualised by electron microscopy [51]. While viral cores in MVs
or EVs possess biconcave cores as well as two lateral bodies, released cores
are oval and lateral bodies are not visible. The nature of the morphologi-
cal changes is currently unknown. However, treatment of virons with DTT
in vitro led to similar morphological changes and the disulfide-bonded core
proteins L4 and 4a were shown to be reduced in the course of infection, sug-
gesting that reduction of core disulfide bonds may play a role in this process
[135]. In addition, protein F18 found in cores of MVs and EVs has been
shown to be absent from released viral cores [178].
VACV cores contain complexes of the viral RNA polymerase and early
transcription factors pre-assembled on early promoters of the viral DNA.
Early gene transcription and mRNA export from viral cores starts immedi-
ately after core release [272]. Early transcription can be artificially induced
by treating MVs with mild detergents and reducing agents in the presence
of NTPs [219]. The set of viral proteins required for early transcription from
artificial templates in vitro has been defined. However, in the context of the
viral core, transcription has additional requirements. MVs lacking L3, VP8,
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or H1, or MVs containing temperature sensitive (ts) mutants of E6 or E8 are
unable to undergo efficient artificial core transcription [190, 265, 134, 21, 118].
However, none of these proteins bear a catalytic activity known to be required
for transcription. Lysates of MVs lacking L3 or VP8, and lysates of MVs in-
corporating mutant E8 contain all required catalytic activities to transcribe
early genes from artificial DNA templates. A relationship between morpho-
logical changes and the onset of transcription is conceivable, but has not been
formally shown.
Released viral cores accumulate in the perinuclear region of the host cell
and this localisation has been attributed to microtubule-dependent transport
mechanisms or VACV-induced cell contractions [30, 212]. Early viral mRNAs
have been reported to move along microtubule as well, and accumulate in
distinct sites of early gene translation [142].
1.1.6.2 Uncoating
In a second core disassembly step, viral DNA has to be released from the
proteinaceous core to allow DNA replication as well as intermediate and late
gene expression.
Viral DNA in intact cores is insensitive to DNase treatment and uncoat-
ing was defined as the step that renders DNA sensitive to DNase [113, 114].
VACV DNA next to remnants of opened or empty viral cores has been ob-
served in electron micrographs and this mode of DNA release suggests that
the viral core structure does not need to be completely disassembled for DNA
release [51, 178]. The viral core and DNA-binding protein VP8 was shown
to remain associated with released viral DNA [178].
Uncoating of viral cores requires the expression of early viral genes. Thus,
viral cores accumulate when transcription or translation is inhibited [112].
A viral uncoating factor has been partly purified and characterised using an
in vitro uncoating assay [179]. However, the protein itself was not identified.
The activity was found to be sensitive to protease inhibitors, but no early
expressed viral protease has so far been identified or predicted.
1.2 Endocytosis
1.2.1 Overview of endocytic processes
The term endocytosis summarises different cellular transport pathways that
result in the internalisation of cargo from the extracellular space or the
plasma membrane into vesicles that fission into the cytosol [62, 152, 101].
Transported cargo is found in both the formed vesicle and the membrane
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Figure 1.7 Endocytic mechanisms. Overview of described endocytic mechanisms with
examples of viruses that exploit them. Abbreviations: Adeno 2/5, adenovirus 2/5; Adeno
3, adenovirus 3; CME, clathrin-mediated endocytosis; HPV-16, human papillomavirus
16; HSV-1, herpes simplex virus 1; LCMV, lymphocytic choriomeningitis virus; mPy,
mouse polyomavirus; SFV, Semliki Forest virus; SV40, simian virus 40; VSV, vesicular
stomatis virus. Illustration from [152]. Annual review of biochemistry Copyright 2010 by
ANNUAL REVIEWS, INC.. Reproduced with permission of ANNUAL REVIEWS, INC.
in the format Dissertation via Copyright Clearance Center (Order Detail ID: 57761303).
that surrounds it, and includes nutrients and their carriers, receptor-ligand
complexes, fluid and solutes, lipids, membrane proteins, extracellular-matrix
components, cell-debris, bacteria, viruses, and toxins [101]. Endocytosis con-
trols protein and lipid composition of the plasma membrane and the extracel-
lular space, and defines the availability of cargo molecules within the cell. It
is involved in numerous cellular processes such as nutrient uptake, signalling,
pathogen entry, cell adhesion and migration, cell growth and differentiation,
and drug delivery [62].
Different mechanisms to form primary endocytic vesicles have evolved and
they are classified mainly by the required cellular components, or the cargo
(see Figure 1.7 and paragraph 1.2.2). Many types of endocytosis are exploited
by viruses to gain access to the dynamic endosomal network, in which they
transiently reside to be ferried to the site of membrane penetration. Using
endocytosis has a number of advantages for the virus (summarised in para-
graph 1.1.4.3). As defined and traceable cargo whose successful uptake leads
to infection and can easily be quantified, viruses have proven invaluable tools
to study endocytosis.
Endocytosis feeds cargo into early endosomes (EE) or equivalent com-
partments. Most knowledge on the subsequent processes has been gained
through the study of clathrin-mediated endocytosis (CME), but trafficking
of primary endocytic vesicles generated by other mechanisms is poorly stud-
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Figure 1.8 Overview of classical endosomal system. Illustration from [150]. Annual re-
view of biochemistry Copyright 2010 by ANNUAL REVIEWS, INC.. Reproduced with
permission of ANNUAL REVIEWS, INC. in the format Dissertation via Copyright Clear-
ance Center (Order Detail ID: 57761308).
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ied. Many of them, however, are assumed to merge with classical EE and
thus exhibit intracellular trafficking similar to cargo of CME (see Figure 1.8)
[152]. The bulk of the endocytosed material is shuttled back to the plasma
membrane directly or via recycling endosomes, mostly from tubular domains
of EE. A fraction of the cargo is destined to enter the degradative arm of
the endosomal system via maturing endosomes, late endosomes (LE), en-
dolysosomes, and lysosomes. The content of these organelles undergoes a
number of changes. The lumenal pH becomes more and more acidic and
at the same time concentrations of other ions change, hydrolases accumu-
late, and a fraction of the endosomal membrane and their protein content
is internalised as intralumenal vesicles. Together, intralumenal conditions
allow for the degradation of soluble and membrane-resident molecules by
acid-activated hydrolases. These and other processes involving trafficking,
fusion, and fission of endosomal vesicles are regulated by cytosolic proteins
that are transiently associated with endocytic vesicles. Key regulators define
the identity of the endocytic compartments and recruit effector proteins that
modify it. Among them are members of the Rab family of small GTPases.
Whereas Rab5 recruits effector proteins to EEs, similar roles are performed
by Rab7 in LEs, while both are present in maturing endosomes. A plat-
form for the recruitment of cellular effectors is also the lipid membrane of
the respective vesicles itself. In particular phosphoinositides are modified by
kinases and phosphatases to form docking sites for various proteins. While
phosphatidylinositol 3-phosphate is mainly found in EEs, phosphatidylinos-
itol 3,5-bisphosphate is predominantly found in LEs [101].
Endocytosis is regulated at the level of cargo internalisation and a com-
plex network of regulator and effector proteins subsequently directs traffick-
ing and maturation of endosomes. The versatile endosomal system allows
the cell to fine-tune the plasma membrane composition and cellular uptake
according to the cell’s need.
1.2.2 Mechanisms of endocytosis
Primary endocytic vesicles are produced by a number of different mechanisms
(see Figure 1.7), which all involve the formation membrane invaginations and
division of vesicles from the plasma membrane. They differ in the cellular
components that regulate their induction, induce membrane curvature, deco-
rate invaginations and vesicles in the form of coats, and catalyse their fission.
The best understood and presumably most prevalent form of endocytosis
is clathrin-mediated endocytosis (CME). In CME, primary vesicles are de-
rived from clathrin coated-pits that contain macromolecular assemblies of re-
ceptor proteins, adaptor complexes and clathrin coat structures. Those pits
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are either assembled de novo around receptor-bound cargo or are present
in the plasma membrane in a preformed state. Scission of clathrin-coated
vesicles requires the GTPase dynamin-2 and the clathrin coat is rapidly dis-
assembled after vesicle formation.
Clathrin-independent endocytic mechanisms often involve more complex
signalling events and may require lipid rafts and cholesterol. Both caveolin
and flotillin can form proteinaceous coats around invaginations at the plasma
membrane or vesicles, although their role in endocytosis is a matter of intense
debate [62, 152]. A number of mechanisms have been described that lead to
the scission of small uncoated primary endocytic vesicles. The pathways are
defined by the combination of required cellular factors and include lipid-raft
mediated endocytosis, the IL-2 pathway, the CLIC/GEEC pathway, the Arf6
pathway, as well as other uncategorised entry pathways involved in the entry
of lymphocytic choriomeningitis virus (LCMV) and human papillomavirus
16. Membrane curvature is induced by different proteins or the modified
lipid composition. Scission may in these processes be catalysed by dynamin-
2 or other, so far unidentified proteins.
Two types of endocytosis, macropinocytosis and phagocytosis, are dis-
tinct from other endocytic pathways in that they allow the internalisation
of large volumes of fluid or large particles, respectively. Macropinocytosis
is introduced in more detail in the next paragraph. Phagocytosis describes
a number of related processes that allow the engulfment of large particles
during which receptor interactions with the cargo guide the formation of
primary vesicles that tightly wrap around the internalised particle. Cells of
the immune system like macrophages, dendritic cells, and neutrophiles in-
ternalise pathogens by phagocytosis. Apoptotic bodies may in addition be
phagocytosed by fibroblasts, epithelial cells, or endothelial cells. Phagocyto-
sis shares the need for complex signalling events and dramatic cytoskeleton
rearrangements with macropinocytosis [72].
1.2.3 Macropinocytosis
In contrast to other endocytic processes for the internalisation of soluble
cargo, macropinocytosis results in the uptake of large quantities of bulk fluid
into primary vesicles of heterogeneous sise termed macropinosomes. Few
cells of the immune system, such as dendritic cells, constitutively sample
their environment by macropinocytosis [169, 170, 197]. In most other cell
types, macropinocytosis is a growth factor-induced process that is triggered
by stimulation of the respective receptor tyrosine kinases (RTKs). The ac-
tivated RTKs are thus removed from the plasma membrane, preventing fur-
ther signalling. Macropinocytosis is also induced and exploited by several
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Figure 1.9 Macropinosome formation. Overview of different steps of macropinocytosis,
which involves membrane protrusions in the form of lamellipodia, circular ruffles, or blebs
(a), macropinosome closure (b), and fission of macropinosomes (c). Yellow stars highlight
sites of vesicle closure. Reprinted by permission from Macmillan Publishers Ltd: NATURE
CELL BIOLOGY [149], copyright 2009.
viruses, such as VACV MVs, adenovirus 3, adenovirus 35, echovirus 1, cox-
sackievirus B, herpes simplex virus 1, human immunodeficiency virus, and
ebola virus, as well as bacteria, e.g. legionella, salmonella, shigella, and
mycobacteria [120, 149, 6, 115, 165, 196, 55].
Induction of macropinocytosis is initiated by ligand-induced RTK activa-
tion or virus-induced receptor clustering, both of which may be accompanied
by signal amplification and transmission by small GTPases of the Ras super-
family. For many pathogens exploiting macropinocytosis, the initial trigger
for macropinocytosis has not yet been identified. Complex downstream sig-
nalling events subsequently mediate the formation of large plasma membrane
protrusions that may have the form of lamellipodia, circular ruffles, or blebs
(see Figure 1.9). Some of these may fold back and, through a membrane
fusion step, internalise the incorporated fluid and, if present, virus particles
[120, 149].
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While the involvement of several kinases and small GTPases has been
implicated in macropinocytosis upon various stimuli and in different cells,
not all of them have been confirmed to be required in all cases. It is clear,
however, that macropinocytosis depends on dramatic rearrangements of the
actin cytoskeleton and a key regulator of these processes seems to be the small
GTPase Rac1, or – in some cases – Cdc42. High metabolic activity below the
plasma membrane causes local acidification, which needs to be neutralised by
the sodium proton exchanger NHE1 to allow for efficient signalling of Rac1
and other small GTPases [122]. Activity of p21-activated kinase 1 (PAK1)
downstream of Rac1 is critical for all stages of macropinocytosis. At the same
time, cellular membranes are modified by posphoinositide 3-kinases (PI3K)
to create docking sites for other signalling and effector proteins. Closure
of macropinosomes seems to require myosin motors and either the activity
of CtBP1/BARS, which is activated by PAK1, or dynamin 2. In addition,
protein kinase C (PKC) is required for macropinocytosis, although the exact
role of PKC signalling has not yet been defined [149].
The availability of small compound inhibitors allows the inhibition of
various cellular process involved in macropinocytosis. Many growth factor
receptors are targets of anti-cancer drugs and e.g. activation of the epithe-
lial growth factor receptor (EGFR) is sensitive to Iressa [270]. Na+/H+
exchangers are inhibited by amiloride and amiloride derivatives like ethyliso-
propyl amiloride (EIPA) [255]. Rac1 and other small GTPases can be in-
hibited by peptide inhibitors [76] or over-expression of dominant negative
mutants, while PAK1 activity is blocked by IPA-3 [56] or over-expression of
the PAK1 autoinhibitory domain. Cytochalasin D prevents actin polymer-
ization [47], and jasplakinolide is an efficient activator of actin polymerisation
and stabilises the polymers [23]. Activity of myosin II motors can be inhib-
ited with blebbistatin [229], while smooth muscle myosin light chain kinase
(smMLCK), which is required for myosin activity, is blocked by ML-7 and
similar compounds [139]. PI(3)K and PKC are e.g. blocked by wortman-
nin [186] and calphostin C [121], respectively. Most cellular factors required
for macropinocytosis are involved in multiple cellular processes. Thus, only
the requirement of the combination of the mentioned factors in addition to
morphological and functional evidence, e.g. membrane protrusions and fluid
phase uptake, define a process as macropinocytosis.
Once formed, macropinosomes can undergo homotypic fusion and mat-
uration steps that are poorly defined and may depend on the trigger and
the cell type. A large fraction of fluid and membranes needs to be recycled
back to the plasma membrane and this may involve the formation of tubular
domains and sorting nexin family members. Other cargo, in particular when
internalized for immuno-surveillance or receptor down regulation, enters the
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degradative pathway and is finally degraded in lysosomes. Maturation of
macropinosomes includes the modification of phosphoinositides in the outer
leaflet of vesicles membranes, acquisition of Rab GTPases and their effectors,
and acidification [120, 149]. To what extent macropinosomes cross-talk to
the classical endosomal system with EEs and LEs, however, remains unclear.
A part of this introduction has been printed or published in [209] and
[211].
1.3 Aim and structure of the thesis
1.3.1 EV entry
The membrane topology of poxvirus EVs demands a unique entry process.
It is common belief in the field that EVs lose their outer membrane by a
nonfusogenic process and that the EFC in the then exposed inner membrane
catalyses or regulates fusion with cellular membranes. However, the location
of EV membrane disruption and whether it involves endocytosis was contro-
versial (see Figure 1.1.5.2). This thesis aimed at clarifying the entry route of
VACV EVs with a focus on cellular processes hijacked by EVs to accomplish
host cell entry. In a follow up project, insights into the activation of viral
cores released into the host cell cytosol were supposed to be gained.
The experimental approach taken for this study has to be chosen in a
way that all possible entry routes can be distinguished. When the mem-
brane topology of EVs is taken into account, three different entry pathways
are conceivable (illustrated in Figure 1.10): EVs may lose their outer mem-
brane upon contact with the plasma membrane (possibilities A and B) or
after endocytic uptake of intact EVs (C). Loss of the EV membrane at the
plasma membrane may be followed by (A) endocytic internalisation of re-
leased MV-like particles and fusion with limiting membranes of endocytic
vesicles, or (B) direct fusion of the released particles with the plasma mem-
brane. Internalisation of intact EVs (C) would be followed by loss of the
EV membrane in endocytic vesicles and subsequent fusion of the released
MV-like particle with cellular membranes.
The study of EV entry has been published in The EMBO Journal (2011),
issue 30, pages 3647 - 3661.
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Figure 1.10 Possible entry routes of EVs [211].
1.3.2 RNAi screen for host factors required for in VACV
infection
RNAi screening in VACV infection was a small side project. A high-throughput
RNAi silencing screen was used to identify host cell factors required during
vaccinia virus infection (see page 61). We validated and analysed the clus-
tered hits which revealed an previously unknown processes during virus entry
including a new mechanism for genome uncoating. For clarification, we in-
vestigated the morphology of stabilised cytoplasmic cores after entry using
electron microscopy, which was my contribution to this study.
The results of this section has been published in CellReports (2012), issue
1-12, doi:10.1016/j.celrep.2012.09.003.
1.3.3 VACV LBs deliver effector proteins
Furthermore, little is known about the exact timing or core activation, whether
cellular and viral factors are required for this process, or whether the molec-
ular changes are intrinsically laid down in the matured viral core. Indeed,
not even the molecular components of the lateral bodies and the exact ar-
chitecture of the core wall have been elucidated to date. In this study, we
used fluorescence and electron microscopy in combination with biochemical
approaches to visualise viral core activation and elucidate some of the molec-
ular details. Data of VACV core activation is presented in chapter 4 (see
page 87) and will be submitted to a peer-reviewed journal.
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2.1 Abstract
Vaccinia virus (VACV), the model poxvirus, produces two types of infectious
particles: mature virions (MVs) and extracellular virions (EVs). EV parti-
cles possess two membranes and therefore require an unusual cellular entry
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mechanism. By a combination of fluorescence and electron microscopy as
well as flow cytometry, we investigated the cellular processes that EVs re-
quire to infect HeLa cells. We found that EV particles were endocytosed, and
that internalization and infection depended on actin rearrangements, activity
of Na+/H+ exchangers, and signalling events typical for the macropinocytic
mechanism of endocytosis. To promote their internalization, EVs were ca-
pable of actively triggering macropinocytosis. EV infection also required
vacuolar acidification, and acid exposure in endocytic vacuoles was needed
to disrupt the outer EV membrane. Once exposed, the underlying MV-like
particle presumably fused its single membrane with the limiting vacuolar
membrane. Release of the viral core into the host cell cytosol allowed for
productive infection.
2.2 Introduction
To successfully replicate, viruses have to deliver their genome and accessory
proteins into the cytosol or nucleus of a host cell. This implies that virus
particles or their packaged genome must cross the plasma membrane (PM) or
the limiting membrane of endocytic vacuoles. In the case of animal viruses
that have a lipid bilayer envelope, the critical step of membrane penetra-
tion involves fusion of the viral membrane with a cellular membrane. The
packaged genome is thus released into the cytosol [143].
Vaccinia virus (VACV) is the prototypic poxvirus and is closely related to
variola virus, the causative agent of smallpox [53]. Poxviruses are enveloped
DNA viruses that use a fusion mechanism to enter cells [213]. They are
unusual because they exist in two different, infectious forms [163]. In addi-
tion to single membrane containing particles (mature virions, MVs) [50, 92],
particles are produced that contain two concentric membranes (extracellular
virions, EVs) [223]. MVs are released after lysis of infected cells and mediate
host-to-host transmission [163, 222]. EVs leave the cell by exocytosis and
are required for virus spread within a tissue or from tissue to tissue [177].
An EV particle consists of an MV-like particle surrounded by an additional
membrane containing cellular proteins and at least six viral proteins unique
to the EV [175, 176, 223]. With two membranes, a conventional mechanism
of entry is not possible. Loss of the outer membrane by fusion would release
a particle into the cytosol that is still covered by the inner membrane. Such
a particle is unlikely to cause productive infection.
Recent studies have shown that the majority of MVs enter cells by en-
docytosis and penetration occurs by membrane fusion in intracellular vac-
uoles [239, 237]. The entry process involves macropinocytic internaliza-
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tion induced by phosphatidylserine (PS) exposed on the MV membrane
[280, 106, 148, 99, 150].
Available information on EV entry suggests that the outer of the two
membranes is simply lost or ruptured revealing the underlying MV-like mem-
brane, which then undergoes fusion with the plasma membrane or the limit-
ing membrane of a vacuole [162]. The core could thus be delivered into the
cytosol without a membrane. The model proposing rupture of the outer mem-
brane of the EV is based on the following observations: (1) The entry/fusion
complex (EFC) present in the inner of the two membranes is essential for
EV infection [214, 215]. (2) The outer membrane of the EV is fragile and
sensitive to in vitro treatment with reduced pH and anionic polysaccharides
[107, 251, 128]. EV disruption with anionic polysaccharides has been shown
to depend on two EV specific proteins, A34 and B5 [128, 193]. (3) Electron
micrographs of cell surface bound EVs show the presence of ruptured EV
membranes covering MV-like particles [128].
However, it has been observed that antibodies directed against MV-
membrane proteins that neutralize MV infection, fail to neutralize infection
by EVs [107, 251]. This suggests that upon rupture of the outer EV mem-
brane, the underlying MV-like particle is inaccessible to antibodies. One
explanation could be that EV rupture takes place at the PM and the dis-
rupted outer membrane covers the PM-bound MV-like particle. Another
possibility is that rupture occurs only after endocytic internalization of the
intact EV particle. Several studies have addressed the EV entry process us-
ing epithelial cell lines and human monocyte-derived dendritic cells (DCs)
with conflicting results [107, 251, 136, 128, 193, 199].
In this study, we used flow cytometry-based assays and microscopy in
combination with different perturbants of cellular proteins and functions to
analyse EV infection of HeLa cells. We found that VACV EVs induced their
own endocytic uptake by macropinocytosis. Acidification of endocytic com-
partments was needed to trigger disruption of EV membranes, presumably
followed by fusion of the underlying virus particles with limiting membranes
of endocytic organelles. This would release virus cores into the cytosol and
allow productive infection.
2.3 Results
2.3.1 Quality of EV particles
In our study, we used EVs released into the medium as free particles by
infected cells. They correspond to the population of VACV particles respon-
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sible for long-range spread in the infected organism [177]. The outer mem-
brane of EVs is fragile and easily disrupted during purification [107, 253]
(our unpublished results). We therefore used freshly produced EVs of VACV
strains WR and IHD-J in clarified supernatants of infected RK13 cells with-
out further purification.
To quantify the fraction of intact EVs, we used the monoclonal antibody
(MAb) 7D11, which binds to the L1 protein in the MV membrane, and
selectively neutralizes MVs and broken EVs (Figure 2.1 A) [269]. Using
plaque assays, we determined that MVs of VACV strains WR and IHD-J
were neutralized by 5µg/mL 7D11. Depending on the preparation, 10–40 %
of WR and IHD-J infectivity in the supernatant was insensitive to 7D11 and
therefore represented infectivity caused by intact EVs. In contrast, WR ∆
A34R, a deletion mutant of the EV membrane protein A34 known to contain
stabilized EV membranes [128, 102], was ∼ 90 % insensitive to 7D11.
To confirm the presence of intact EVs in the supernatant, we analysed
VACV particles released from RK13 cells by confocal microscopy. To discrim-
inate between MVs and EVs, we used a recombinant IHD-J strain expressing
two different fluorescent fusion proteins: mCherry was fused to the core pro-
tein A5 and GFP to the EV-specific outer membrane protein F13. Both MVs
and EVs therefore contained a red fluorescent core and could be visualized
as discrete spots. The majority of particles in the supernatant of infected
RK13 cells (83 %) was also positive for the outer EV membrane (green fluo-
rescent). Some green fluorescent particles without a red fluorescent core were
observed, likely representing EV membranes that had lost the core (15 spots
per 100 virus cores, data not shown).
To determine the fraction of intact EVs, cell supernatants containing
recombinant IHD-J viruses were pre-incubated with 7D11, applied to a cover
slip, and stained with a fluorescently labelled secondary antibody. MVs and
broken EVs with exposed L1 were expected to be stained whereas intact EVs
were not. Figure 2.1 C shows a field with MVs (mCherry and 7D11 staining;
open arrowhead), disrupted EVs (mCherry, GFP, and 7D11 staining; closed
arrowhead), and intact EVs (mCherry and GFP, arrow). Analysis of more
than 600 virus particles in three independent experiments showed that 17 %
of the viruses were MVs, 69 % were disrupted EVs, and 14 % were intact EVs
(Figure 2.1 B). This amount of intact EVs corresponded to the fraction of
7D11-insensitive EVs determined by plaque assay for the same supernatants
(data not shown).
After analysing EV particles for both infectivity and integrity, we con-
cluded that MAb 7D11 could be used to discriminate between intact and
broken EVs. It was evident that the majority of IHD-J and WR EVs re-
leased into the supernatant did not possess an intact second membrane. In
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Figure 2.1 Quality of EV particles. (A) Clarified supernatants of RK13 cells infected
with VACV IHD-J, WR, or WR ∆ A34R were titrated on BSC-40 cells after incubation
with or without Mab 7D11. As a control, purified MVs of the same strains were subjected
to the same treatment and titration. Plaque numbers were normalized to untreated virus
samples. Results represent the average of three independent experiments (mean ± SEM).
(B) Clarified supernatants of RK13 cells infected with IHD-J mCherry-A5 F13-GFP were
incubated with 7D11, bound to cover slips, and fixed. 7D11 was visualized with Alexa
fluor (AF) 647 goat anti-mouse and images recorded by confocal microscopy. Virus parti-
cles were detected by their fluorescent core and assigned to the following categories: MV
-7D11 (mCherry), MV +7D11 (mCherry and 7D11 staining), EV -7D11 (mCherry, GFP),
or EV +7D11 (mCherry, GFP, and 7D11 staining). Average values of three independent
experiments are shown ± SEM. (C) Representative images from B. Examples of a neutral-
ized MV (MV +7D11, open arrowhead), an intact EV (EV -7D11, arrow), and a disrupted
EV (EV +7D11, closed arrowhead) are highlighted.
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most instances – judging by the presence of F13-GFP – the disrupted EV
membrane remained associated with the virus particle. Disruption of the
outer membrane did not interfere with the infectivity of EVs.
2.3.2 EV particles are endocytosed
For productive infection, both EV membranes must be removed during the
entry process. While it has been suggested that removal of the outer mem-
brane of EVs happens already on the PM [128], it is conceivable that the EV
particles are endocytosed first with loss of the outer EV membrane taking
place in endocytic compartments.
To test whether EVs can be internalized with their outer membrane still
in place, we used recombinant IHD-J EVs containing F13-GFP to infect HeLa
cells for 30 min at 37 ◦C. Samples were stained for the EV membrane protein
B5 under non-permeabilizing conditions to distinguish between external and
intracellular EVs (Figure 2.2 B). A fraction of EV particles (green spots;
white arrows, inset) was inaccessible to antibody staining, indicating they
were internalized. To control for changes in the B5 epitope or inappropriate
staining, the same procedure was performed either with cells in which the
virus had not been allowed to internalize (bound EVs, Figure 2.2 A) or
with cells permeabilized with saponin after fixation (Figure 2.2 C). In both
conditions, all EV particles were stained for B5.
To assure that intact EV particles, and not only dissociated EV mem-
branes without cores were internalized, HeLa cells were infected with
IHD-J mCherry-A5 F13-GFP EVs and subjected to B5 staining under non-
permeabilizing conditions (Figure 2.2 D). That a sub-population of the dual-
coloured EVs was not stained (white arrows, inset) indicated that EV parti-
cles were internalized with the outer membrane. Virus cores or MVs with-
out an EV membrane (closed arrowhead) and internalized EV membranes
without a core (open arrowhead) were also observed. These may represent
intermediates of the EV entry process or may have been internalized from
the inoculum.
To confirm these findings, HeLa cells incubated with IHD-J F13-GFP
EVs for 30 min were analysed by electron microscopy for the presence of
internalized particles with EV membranes. Ultra-thin sections of cells were
subjected to negative staining to visualize the EV membrane. Immunogold
labelling directed against GFP was used to detect the F13-GFP fusion protein
in the EV membrane (Figure 2.3 and 2.4). Gold-labelled EV particles were
found both at the PM, often next to membrane protrusions (Figures 2.3 A
and 2.4 A and B), and in intracellular vesicles (Figures 2.3 A and B and
2.4 A-F). In some particles, two membranes could be clearly distinguished
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Figure 2.2 EV internalization by fluorescence microscopy. IHD-J F13-GFP EVs (A–C)
or IHD-J mCherry-A5 F13-GFP EVs (D) were bound to HeLa cells on ice for 1 h (MOI
15). EV particles were stained with VMC-20 (anti-B5) directly (A) or after incubation at
37 ◦C for 30 min (B–D). VMC-20 staining was either performed under non-permeabilizing
(non-perm.) conditions to visualize bound virions (A, B, and D) or under permeabilizing
(perm.) conditions to visualize bound and internalized virions (C). Images were recorded
by confocal microscopy and representative maximum projections of Z-stacks are shown.
Arrows in the inset of B highlight F13-GFP-containing EV membranes not accessible to
VMC-20 staining. In the inset of (D), EV particles (arrows) and an EV membrane without
a core (open arrowhead), all not accessible to VMC-20 staining, as well as a virus core or
MV without an EV membrane (closed arrowhead), are highlighted. Scale bars = 10 µm.
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Figure 2.3 EV internalization by electron microscopy. IHD-J F13-GFP EVs were bound
to HeLa cells on ice for 1 h (MOI 300). Cells were incubated at 37 ◦C for 30 min, fixed,
and subjected to cryo-sectioning and immuno labelling with anti-GFP and protein A-gold.
Images were recorded by transmission electron microscopy and representative pictures are
shown. Arrows in (F) highlight MV and EV membranes. Mi: mitochondrion; Nu: nucleus.
Scale bars = 200 nm.
(arrows in Figures 2.3 B and 2.4 D) confirming that full EV particles were
endocytosed. In a few particles (Figure 2.4 F), the EV membrane was partly
disrupted. EV membranes devoid of cores were also observed bound to the
PM. They may have originated from free membranes in the inoculum, or
from particles disrupted at the PM.
Internalization of EVs was confirmed using flow cytometry. IHD-J F13-
GFP EVs were bound to HeLa cells on ice and incubated either on ice or at
37 ◦C for a further 30 min. Bound virus particles were removed by trypsin
digestion and the cells subjected to flow cytometry to determine the cell-
associated fluorescence from internalized particles (Figure 2.5 A and B). The
low temperature control showed that bound EVs could be almost completely
removed by trypsin, whereas cells incubated at 37 ◦C were green fluorescent,
confirming the presence of internalized IHD-J F13-GFP EVs. When cells
were detached with EDTA, fluorescence of both bound and internalized EVs
could be measured (Figure 2.5 A and C). Fluorescence intensities with and
without incubation at 37 ◦C were comparable, confirming that GFP fluores-
cence and virus binding was not affected by incubation at 37 ◦C.
These experiments showed that cell-bound EVs were rapidly internalized
by endocytosis. Although disrupted EVs were not distinguished from intact
EVs in these experiments, we could show by fluorescence microscopy, electron
microscopy, and flow cytometry that the outer membrane of EVs was not lost
prior to internalization.
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Figure 2.4 EV internalization by electron microscopy. Internalization of IHD-J F13-GFP
EVs by HeLa cells was analysed by transmission electron microscopy and immunogold
labelling of GFP as described in Figure 2.3. Panels B, D, and F represent magnified views
of virus particles in panels A, C, and E, respectively. Arrows in D highlight the two viral
membranes of internalized EVs.
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Figure 2.5 IHD-J F13-GFP EVs (MOI 175) were bound to HeLa cells on ice for 1 h
and cells incubated at 0 or 37 ◦C for 30 min. To detect internalized EVs (int.), bound
virions were removed and cells detached with trypsin; to measure total cell-associated
virions (total), cells were detached with EDTA. Cells were fixed, and green fluorescence
quantified by flow cytometry. Representative histograms of untreated samples are shown
in (A); green fluorescence intensity from three independent experiments was quantified
and the average of measured geometric means of internalized (B) and total (C) EVs is
displayed ± SEM.
2.3.3 EVs are internalized by macropinocytosis
To analyse the endocytic mechanism responsible for EV internalization, and
to test whether endocytosis was required for infection by intact EVs, we in-
fected HeLa cells in the presence of a spectrum of small compound inhibitors
known to affect endocytic processes. GFP-expressing viruses and flow cy-
tometry were used to quantify infection by VACV EVs of the strains IHD-J
and WR (Figure 2.6 A and C).
To assure that infection by intact EVs was specifically analysed, we pre-
treated EV-containing supernatants with Mab 7D11 for all infection exper-
iments. Since cells infected with VACV WR released less EVs into the
medium than cells infected with strain IHD-J, WR EV supernatants were
concentrated by sedimentation prior to MV neutralization. This did not sig-
nificantly reduce the fraction of intact EVs (data not shown). In all cases,
MVs were used as controls. IHD-J and WR MVs have been found to in-
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Figure 2.6 HeLa cells were left untreated or treated with DMSO (highest used concen-
tration), staurosporine (Stau), genistein (Geni), wortmannin (Wort), calphostin C (CalC),
rottlerin (Rott), IPA-3, Iressa (Ires), chlorpromazine (Chlo), ML-7 (all 30 min), cytocha-
lasin D (Cyto), jasplakinolide (Jasp), or EIPA (all 15 min). MVs or EVs of IHD-J GFP
(A), WR GFP (C), or WR ∆ A34R GFP (D) were pre-incubated in the presence of drugs
and in the case of EVs with 7D11 (MOI 2). Cells were infected and green fluorescent
cells quantified 4 h p.i. by flow cytometry. Infection levels were normalized to untreated
samples. (B) EV (IHD-J F13-GFP) and MV (IHD-J EGFP-A5) internalization in the
presence of various drugs was quantified as described in Figure 2.5. The geometric mean
of green fluorescence intensity of 0 ◦C samples was subtracted from 37 ◦C samples and
internalization normalized to untreated samples. All experiments were performed three
times independently, mean values ± SEM are shown.
duce macropinocytosis in host cells, and to utilize this pathway as a route of
productive infection [148].
Inhibition of clathrin-mediated endocytosis by chlorpromazine affected
neither IHD-J EV nor MV infection (Figure 2.6 A). Infection with EVs and
MVs was only moderately affected by the general protein kinase inhibitor
staurosporine, and it was not influenced by the tyrosine-kinase inhibitor ge-
nistein or the posphoinositide 3-kinase inhibitor wortmannin. In contrast,
infection with both EVs and MVs was dramatically blocked by Iressa, an
inhibitor of the epidermal growth factor receptor (EGFR); by the protein
kinase C (PKC) inhibitor calphostin C (CalC); by IPA-3, an inhibitor of
p21-activated kinase 1 (PAK1); and by the smooth muscle myosin light chain
kinase (smMLCK) inhibitor ML-7. Rottlerin, originally described to specifi-
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cally inhibit PKCδ [85], but later found to have multiple effects [54, 227, 234],
nearly abolished infection. Perturbation of actin dynamics with cytocha-
lasin D (Cyto) and jasplakinolide (Jasp) strongly reduced EV infection; the
block of infection was, however, even more pronounced for MVs. An inhibitor
of Na+/H+ antiporters, EIPA, also efficiently prevented infection with both
EVs and MVs. The requirement of PAK1, smMLCK, PKC activity, actin
dynamics, and sodium-proton exchangers strongly suggested an endocytic
process categorized as macropinocytosis [149].
To determine if the inhibitors of infection blocked macropinocytic uptake
of EVs, we quantified internalization of IHD-J EVs and MVs using flow
cytometry (Figure 2.6 B). For EV internalization experiments, IHD-J EVs
containing F13-GFP were used without neutralization as 7D11 treatment did
not affect endocytic uptake of neutralized, disrupted EVs (data not shown).
For MV internalization experiments, MV particles incorporating EGFP-A5
in the core were employed (Figure 2.7). Bound MVs, in contrast to EVs,
were only partially removed by trypsin digestion (sample MV 0 ◦C (int.)).
Signal intensity of cells incubated at 37 ◦C was significantly higher than that
of cells kept at 0 ◦C allowing for quantification after background subtraction.
Rottlerin, IPA-3, Cyto, Jasp, and EIPA efficiently blocked internalization of
both EVs and MVs, confirming that the observed effects on infection occurred
due to impaired endocytic uptake.
The inhibitors that blocked IHD-J EV infection were then tested against
WR EVs (Figure 2.6 C). Inhibition of EGFR, PAK1, smMLCK, PKC, actin
dynamics, and Na+/H+ antiport caused a strong reduction of WR EV in-
fection. These results indicated that EVs of both IHD-J and WR strains
exploited macropinocytosis for infection.
Throughout these infection experiments, neutralized MVs and neutral-
ized disrupted EVs were present in the inocula. Thus, it was conceivable
that these particles – although neutralized by antibody binding – stimulated
macropinocytosis resulting in the co-internalization of intact EVs. To test
whether MVs stimulated the internalization of EVs, we performed infection
assays with a GFP-expressing version of the mutant virus WR ∆ A34R, a
virus that produces ∼90 % intact EVs (Figure 2.6 D). EV infection was re-
duced by the same panel of drugs as infection by EVs of wild-type IHD-J
and WR. It was sensitive to Iressa, CalC, rottlerin, ML-7, IPA-3, actin per-
turbants, and EIPA, indicating that EV uptake by macropinocytosis was not
influenced by the presence of neutralized, disrupted EVs or neutralized MVs.
Along the same lines, we tested if the addition of excess amounts of neutral-
ized MVs would boost infection by WR ∆ A34R EVs (Figure 2.8). Even
when a 25-fold excess of neutralized MVs was used, no boost in EV infection
was observed. These results indicated that VACV EVs of IHD-J and WR
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Figure 2.7 MV internalization by flow cytometry. IHD-J EGFP-A5 MVs (MOI 75) were
bound to HeLa cells on ice for 1 h and cells subsequently incubated at 0 or 37 ◦C for 30 min.
To detect internalized MVs, bound virions were removed and cells detached with trypsin
(int.); to quantify total cell-associated virions, cells were detached with EDTA (total).
Cells were fixed, and green fluorescence quantified by flow cytometry. Representative
histograms of untreated samples are shown in (A); green fluorescence intensity from three
independent experiments was quantified and the average of measured geometric means of
internalized (B) and total (C) MVs is displayed ± SEM.
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Figure 2.8 WR ∆ A34R GFP EVs were incubated with 7D11 for 1 h at 37 ◦C (MOI 2).
EVs and increasing amounts of neutralized MVs of the same strain were added to HeLa
cells and incubated at 37 ◦C for 30 min. Cells were washed, incubated in full medium, and
harvested 4 h p.i.; infection was quantified as in Figure 2.6. Experiments were performed
three times independently and normalized to untreated samples, mean ± SEM is shown.
strains are capable of triggering macropinocytosis resulting in internalization
and productive infection of host cells.
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2.3.4 EV particles induce macropinocytosis
Macropinocytosis can be distinguished from other types of endocytosis by a
dramatic rearrangement of the actin cytoskeleton and by enhanced cellular
fluid-phase uptake [149]. To investigate cellular phenotypes of macropinocy-
tosis, WR ∆ A34R was used. The integrity of the EV membrane on WR ∆
A34R EV particles allowed us to distinguish between EV- and MV-induced
changes. If EVs use macropinocytosis for their internalization, increased
uptake of fluid phase markers would be expected. To test this, uptake of
10 kDa dextran-Alexa fluor (AF) 488 into serum-starved HeLa cells after
stimulation with EVs and MVs was quantified by flow cytometry (Figure
2.9 A). Indeed, uptake of dextran during a 10 min pulse was increased by 42
and 51 %, respectively. In addition, we observed IHD-J F13-GFP EVs co-
localizing with 10 kDa dextran AF 594 in large intracellular vesicles (Figure
2.10), suggesting EV particles are internalized into macropinosomes.
Uptake of fluid by macropinocytosis requires the formation of dynamic
membrane protrusions. These protrusions occur as lamellipodia, circular ruf-
fles, or blebs. Functionally, they all lead to the formation of macropinosomes
of irregular size and shape [149].
To determine if EVs induce the formation of membrane protrusions, HeLa
cells were treated with EVs of WR ∆ A34R EGFP-A5. MVs known to induce
blebbing [148] were used as a control. Virus particles were bound to HeLa
cells and incubated at 37 ◦C for 40 min. Cells were fixed and analysed by dif-
ferential interference contrast (DIC) and wide-field fluorescence microscopy
(Figure 2.9 B and C). A low level of membrane blebbing was observed in
mock-treated cells (3 %), whereas 20–70 % of all cells treated with different
amounts of EVs or MVs exhibited extensive, systemic bleb formation.
The finding that WR ∆ A34R EVs triggered both fluid-phase uptake and
extensive blebbing confirmed the capacity of EVs to induce macropinocytosis
at a level similar to that seen for MVs.
Uptake of MVs by macropinocytosis has been shown to be triggered by
PS, a phospholipid enriched in the MV membrane. When PS in the MV
membrane is masked by the PS-binding protein annexin V (ANX5), MV in-
fection is almost completely blocked [148]. If EVs induce macropinocytosis
through a similar mechanism, EV infection would be expected to be blocked
by ANX5 as well. To test this, EVs and MVs of WR ∆ A34R GFP were pre-
treated with ANX5 and used for infection experiments (Figure 2.11). While
MV infectivity was reduced to 38 % by ANX5, EV infection was not affected.
This suggested that VACV EVs induce macropinocytosis through a different
trigger than MVs.
2.3. RESULTS 41
0
10
20
30
40
50
60
70
80
mock WR ΔA34R EV 
(MOI 10)
WR ΔA34R EV 
(MOI 100)
WR ΔA34R MV 
(MOI 10)
%
 b
le
bb
in
g 
ce
lls
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
mock WR ΔA34R EV 
(MOI 18)
WR ΔA34R EV 
(MOI 180)
WR wt MV          
(MOI 200)
re
la
tiv
e 
up
ta
ke
 o
f D
ex
tra
n-
AF
48
8
A B
C
 VACV-induced fluid phase uptake
                               mock                             WR ΔA34R EV                   WR ΔA34R MV
               (MOI 10)           (MOI 10)
DIC
DNA
Actin
EGFP-
  A5
VACV-induced cell blebbing 
        VACV-induced cell blebbing
Figure 2.9 EVs and cellular phenotypes of macropinocytosis. (A) WR ∆ A34R EVs
and WR wt MVs were bound to serum-starved HeLa cells on ice for 1.5 h and pulsed for
10 min at 37 ◦C with 10 kDa dextran AF 488. Cells were washed, harvested, fixed, and
geometric means of green fluorescence quantified by flow cytometry. Dextran uptake was
normalized to uptake by unstimulated cells and mean values ± SEM of three independent
experiments are shown. (B)–(C) WR ∆ A34R EGFP-A5 MVs or concentrated EVs were
bound to HeLa cells at RT. Cells were incubated at 37 ◦C for 40 min, fixed, stained, and
analysed by DIC and wide-field fluorescence microscopy. The number of total and blebbing
cells from three independent experiments (∼ 250 cells per condition and experiment) was
counted and mean ± SEM is shown (B). Representative images are shown in (C). Scale
bars = 20µm.
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Figure 2.10 EVs in dextran-containing macropinosomes. HeLa cells were preincubated
with full (A) or serum-free medium (B) for 4 h. IHD-J F13-GFP EVs in 0.2 % BSA/RPMI
were bound to cells on ice for 1 h (MOI 25) and incubated for 30 min at 37 ◦C in presence of
0.5 mg/mL 10 kDa dextran AF 594 (A), or dextran and 25 µg/mL transferrin AF 647 (B).
Images were recorded by confocal microscopy and representative maximum projections
of Z-stacks are shown. Arrowheads highlight EV particles in dextran-containing vesicles.
Scale bars = 5 µm.
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2.3.5 EV infection requires acidification of endocytic
vacuoles
Macropinocytosis leads to the uptake of fluid and particles into endocytic
vacuoles that subsequently undergo acidification [149]. To determine if low
pH was needed for EV infection, we blocked acidification of endocytic or-
ganelles in HeLa cells using the vATPase inhibitor bafilomycin A1 (BafA)
and the carboxylic ionophore monensin A (MonA) (Figure 2.12 A-F). At
concentrations that did not significantly affect infection by MVs, both com-
pounds reduced EV infection in a dose-dependent manner. IHD-J and WR
∆ A34R EV infection was reduced by 80 % at the highest concentrations.
WR EV infection was only reduced by up to 65 %. Infection with IHD-J
EVs was also blocked by BafA in several other cell lines including A549N,
BSC-40, RK13, and Vero (data not shown).
Thus, acidification of endocytic vesicles was required for efficient infection
by intact EVs, whereas MVs were less sensitive to the perturbants of vacuolar
acidification at the concentrations used.
2.3.6 Acidification has a role in EV membrane disrup-
tion
To determine which step(s) in the entry process required low pH, we quan-
tified endocytic internalization of IHD-J EVs and MVs in the presence of
BafA and MonA (Figure 2.13 A). Internalization into EIPA-treated cells was
used as a control. BafA did not affect EV or MV internalization. MonA
reduced internalization moderately, and EIPA strongly. This suggested that
the effect of BafA on infection occurred after EV internalization.
To determine if the BafA-sensitive intracellular step of EV entry involved
disruption of the outer membrane of EVs in endocytic compartments, we first
tested whether EV membranes could be disrupted by low pH treatment in
vitro as previously reported [252]. When supernatants containing IHD-J and
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Figure 2.12 Experimental setup as in Figure 2.6; HeLa cells were pretreated with BafA
(A–C) or MonA (D–F) for 1 h; controls with solvents at the highest used concentrations
were included. Infection with IHD-J GFP (A, D), WR GFP (B, E), or WR ∆ A34R GFP
(C, F) in the presence of drugs was quantified by flow cytometry; mean ± SEM of three
independent, normalized experiments are shown.
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Figure 2.13 (A) EV (IHD-J F13-GFP) and MV (IHD-J EGFP-A5) internalization in
the presence of BafA, MonA, and EIPA was quantified as described in Figure 2.6 B. (B)
IHD-J, WR, and WR ∆ A34R EVs were incubated at pH 5.0 or pH 7.4 and 37 ◦C for
5 min. EVs were titrated with or without 7D11 at pH 7.4 as described in Figure 2.1 A.
The percentage of intact EVs was calculated by normalizing plaque numbers after 7D11
neutralization to plaque numbers in untreated samples; mean values ± SEM of three
independent experiments are presented. (C) HeLa cells were left untreated or treated
with BafA for 1 h. EVs of IHD-J GFP, WR GFP, or WR ∆ A34R GFP were preincubated
in the presence of drugs and 7D11 for 1 h at 37 ◦C (MOI 2). Virus particles were bound
to cells on ice. Cells were shifted to 37 ◦C in pH 7.4 or pH 4.5 medium for 5 min and
then incubated in full medium with drugs for 4 h. Infected cells were quantified by flow
cytometry. The percentage of infected cells was normalized to the untreated samples. All
experiments were performed three times independently, mean values ± SEM are shown,
asterisks mark significant differences (P 〈 0.05).
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WR EVs were incubated with pH 5 buffer at 37 ◦C for 5 min, the fraction of
7D11-resistant intact EVs dropped by 62 % and 42 %, respectively (Figure
2.13 B). The fraction of intact WR ∆ A34R EVs was not significantly altered,
suggesting that EV membranes of this mutant cannot be disrupted by low
pH in vitro. When fluorescent EV particles of strain IHD-J mCherry-A5
F13-GFP were subjected to the same treatment and bound to cover slips,
however, no significant loss of F13-GFP fluorescence was detected (data not
shown), suggesting that disrupted EV membranes remained associated with
the underlying virus particle.
The observed increase in 7D11 sensitivity upon low pH treatment sug-
gested that the BafA-sensitive step of EV entry may involve rupture of the
EV membrane within acidified endocytic compartments. If this were the
case, infection in the presence of BafA might be rescued if EV membranes
were artificially disrupted before internalization. To test this, 7D11-treated
EVs were bound to HeLa cells in the cold and cells treated for 5 min at 37 ◦C
with pH 7.4 or pH 4.5 medium. Infection was quantified 4 h post treatment
(Figure 2.13 C).
After neutral or low pH treatment, infection of untreated cells with EVs
of strains IHD-J (32 % and 31 %), and WR (20 % and 20 %) was similar
(absolute data not shown). In BafA-treated cells, however, IHD-J and WR
infection was increased by 72 and 43 % in cells exposed to low pH when com-
pared to controls. That acid-induced disruption of EV membranes partly
rescued infection in cells with impaired macropinosomal acidification sug-
gested that EV membrane disruption was indeed the step in EV entry that
was inhibited by BafA. Infection with WR ∆ A34R EVs in the presence of
BafA was not increased after low pH treatment. This was consistent with
the finding that low pH did not trigger disruption of the EV membrane of
this strain in vitro.
If EV membrane disruption required acidification of endocytic vesicles,
intact EV particles would be expected to accumulate in those compartments
when acidification is inhibited by BafA. To test this, we infected HeLa cells
with IHD-J mCherry-A5 F13-GFP EVs for 3 hours in the absence or presence
of BafA. Disrupted EVs were not neutralized with 7D11 in this experiment
as they would accumulate in macropinosomes making them indistinguish-
able from accumulated intact EVs. To prevent early gene expression, which
hampers microscopic analysis due to transient cell rounding, microscopy ex-
periments were performed in the presence of actinomycin D (ActD) (typical
cells shown in Figure 2.14 A and B). Significantly more EVs were observed
in cells infected in the presence of BafA (arrows B, inset) than in cells with
unperturbed acidification. EV membranes without viral cores were also de-
tected (filled arrowhead, inset). These may be the remnants of disrupted
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Figure 2.14 EV accumulation in the presence of BafA. HeLa cells were infected with
IHD-J mCherry-A5 F13-GFP EVs (MOI 25) in the presence of 5 µg/mL ActD and 25 nM
BafA where indicated. Particles were bound to pretreated cells on ice and incubated
in full DMEM with drugs at 37 ◦C for 3 h. Samples were fixed and stained for actin.
Images were recorded by confocal microscopy and representative maximum projections of
Z-stacks are shown. Arrows in the insets of B highlight EVs, the arrowhead marks a free
EV membrane. Scale bars = 10 µm.
EVs, whose underlying MV-like particles underwent fusion. Viral cores con-
taining mCherry-A5 that were released into the cytosol could not be reliably
detected with our confocal microscopy setup. When bound EV particles were
stained under non-permeabilizing conditions, we found that the majority of
EV particles that had accumulated in the presence of BafA was internalized
(Figure 2.15).
If disruption of intact EVs is inhibited in the presence of BafA, it reasons
that no MV-like particles would be exposed and therefore no viral cores could
be released into the host cell cytosol by fusion. To analyse core release, we
used IHD-J EGFP-A5 EVs and exploited that VACV cores accumulate in
the presence of ActD [178]. Using this approach, we detected and quantified
the percentage of free viral cores within the cytoplasm 3 h post infection.
To differentiate between viral cores released by fusion and viral particles in
endocytic vesicles or bound to the cell (EVs, released MV-like particles, or
MVs), virions were stained for the presence of the MV membrane protein
L1 (Figure 2.16 A–C and Figure 2.17). In addition, EVs were treated with
7D11 prior to infection, preventing any core release from disrupted EVs or
contaminating MVs. Untreated MVs and MVs neutralized with 7D11 were
used as controls. In the absence of BafA, 36 % of the total cores in cells
infected with intact EVs were released into the cytosol. In the presence of
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Figure 2.15 Intracellular accumulation of EVs in presence of BafA. HeLa cells were
infected with IHD-J mCherry-A5 F13-GFP EVs (MOI 25) in the presence of 5µg/mL
ActD without (A) or with (B) 25 nM BafA. Particles were bound to pretreated cells on
ice for 1 h, washed with PBS, and incubated in full medium with drugs for 3 h. Bound
EV particles were stained with VMC-20 (anti-B5) under non-permeabilizing conditions.
Images were recorded by confocal microscopy and representative maximum projections
of Z-stacks are shown. Arrows in the inset of B highlight internalized EV particles not
accessible to VMC-20 staining. A bound EV (open arrowhead), and a free membrane
(closed arrowhead) are visualized as well. Scale bars = 10 µm.
BafA, the percentage of free cores was reduced to 4 %, indicating that BafA
prevented release of EV-derived viral cores into the cytosol. MV core release
was only moderately affected by BafA treatment, whereas MV neutralization
with 7D11 almost completely abolished the release of cores.
Taken together, the results suggested that acidification of endocytic vac-
uoles was required for a step of EV entry after endocytic uptake and before
release of viral cores. Since fusion of MVs was not inhibited by the con-
centration of BafA used, the acid-dependent step of EV entry is most likely
the disruption of the EV membrane within endocytic compartments. This is
further supported by the fact that artificial disruption of the EV membrane
could bypass the need for low pH in endocytic vesicles and by the observation
that EVs accumulated within BafA-treated cells.
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Figure 2.16 Core release in the presence of BafA. HeLa cells were infected with 7D11-
treated IHD-J EGFP-A5 EVs (MOI 8 after 7D11 incubation) in the presence of 5µg/mL
ActD and 25 nM BafA where indicated. Particles were bound to pretreated cells on ice
and incubated in full DMEM with drugs at 37 ◦C for 3 h. Samples were fixed and stained
for L1 (Mab 7D11) and actin. (A)-(B) Images were recorded by confocal microscopy and
representative maximum projections of Z-stacks are shown. Arrows in the insets of A and
B highlight released viral cores, arrowheads point at viral particles that were stained for
the MV membrane marker L1. Scale bars = 10 µm. (C) The percentage of released cores
after infection with 7D11-treated EVs, MVs, and 7D11-treated MVs in the presence of the
indicated drugs was quantified in three independent experiments. Controls with bound
virus (0 h) were included. Core release from 7D11-neutralized MVs was only quantified in
the presence of ActD. Mean values ± SEM are shown.
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Figure 2.17 Exemplary images of core release assay. Additional exemplary images of
core release assay quantification in Figure 2.16C. HeLa cells were infected with IHD-J
EGFP-A5 7D11-treated EVs (MOI 8 after 7D11 incubation) (A), MVs (MOI 45) (B–D),
or 7D11-treated MVs (equivalent to MOI 45 before neutralization) (E) in the presence
of 5 µg/mL ActD and 25 nM BafA where indicated. Particles were bound to pretreated
cells on ice for 1 h, washed with PBS, and fixed after binding (A–B) or after incubation in
full medium with drugs for 3 h (C–E). L1 (Mab 7D11) and actin were stained and images
were recorded by confocal microscopy. Representative maximum projections of Z-stacks
are shown. Arrows in insets highlight released viral cores, closed arrowheads mark viral
particles stained for the MV membrane marker L1. Scale bars = 10 µm.
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2.4 Discussion
With this series of experiments, we aimed at characterizing the entry path-
way of VACV EVs. We could show that EVs were rapidly internalized by
endocytosis, and that the mechanism was virus-induced, macropinocytic,
and essential for infection by intact EVs. We found that loss of the outer EV
membrane occurred after endocytic internalization, and concluded that acid-
ification of endocytic compartments was required for this step of EV entry.
Presumably, as shown in the schematic view of the entry program in Figure
2.18, the inner membrane with the EFC was exposed after EV membrane
rupture. It could then undergo fusion with the limiting membrane of the
macropinosome, resulting in core release into the cytosol.
Judging by the insensitivity to MAb 7D11, only a relatively small frac-
tion (10–40 %) of EVs released from VACV-infected RK13 cells and other
cell types (data not shown) contained an intact outer membrane. Although
previous studies have reported higher proportions of intact EVs (65–75 %)
[107, 252, 128, 17], it is evident that many of the EVs released from cells
possess outer membranes that are not fully sealed [102]. Although we could
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Figure 2.18 Mechanism of VACV EV entry. VACV EVs induce fluid phase uptake by
macropinocytosis and are internalized with the bulk fluid. The pH in macropinosomes
decreases in the course of their maturation, which triggers disruption of the outer EV
membrane. Exposed EFCs in the membrane of MV-like particles catalyse or regulate
fusion with limiting endocytic membranes and thereby release virus cores with the genome
into the cytosol allowing for successful replication.
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occasionally detect free outer membranes in our preparations, the ruptured
EV membranes typically remained associated with the particles. Rupture
of the EV membranes did not affect the virus infectivity, but it made them
susceptible to antibodies against MV antigens.
Using fluorescence and electron microscopy, we could show that EVs were
internalized into HeLa cells prior to loss of their outer membrane. In the flu-
orescence microscopy experiments, we used recombinant viruses in which the
core and the EV membrane were visualized by different fluorescent proteins.
By EM, we could identify intra-vacuolar virus particles with two membranes
resolved, and with immunolabeling of GFP fused to the outer membrane
protein F13. The internalization of EVs could also be confirmed by flow
cytometry.
The mechanism of endocytosis used by EVs to enter cells was studied
using a set of pharmacological inhibitors known to block endocytic processes
[149]. It was found that EV infection was dependent on EGFR, PKC, sm-
MLCK, PAK1, actin dynamics, and sodium proton exchangers. It was not
affected by staurosporin, genistein, and wortmannin, three kinase inhibitors
known to inhibit various endocytic mechanisms. Taken together, the in-
hibitor profile strongly suggested that infection by intact EVs involved ma-
cropinocytosis [149]. We could furthermore show that internalization of EVs
was blocked by inhibitors of PAK1, actin dynamics, and sodium proton ex-
changers, and observed EVs in intracellular vesicles positive for the fluid
phase marker dextran. Macropinocytic uptake was confirmed by experiments
using WR ∆ A34R, a mutant virus producing almost exclusively intact EVs.
It was found to induce an MV-independent elevation in fluid phase uptake
and induced PM ruffling in the form of blebs.
A role for macropinocytosis was consistent with a recent report show-
ing that MV and EV internalization, as well as early gene expression, in
monocyte-derived DCs depends on macropinocytosis [199]. However, the
authors only visualized uptake of viral cores and did not follow the fate of
EV membranes. Furthermore, DCs unlike most other cell types maintain
ongoing, constitutive macropinocytosis without the requirement for external
triggers [169, 170, 197]. This is part of their function as immune cells re-
sponsible for antigen capture and presentation. In other cell types, including
the HeLa cells used here, macropinocytosis is a transient, ligand-triggered
process [149]. Thus, our data showed a role for macropinocytosis in cell lines
that do not undergo continuous, constitutive macropinocytosis. For produc-
tive infection of HeLa cells, EVs apparently induced the complete program
of macropinocytosis starting with signal transduction, PM blebbing, and in-
creased fluid uptake.
That MVs are also internalized by macropinocytosis has been recently
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shown with a variety of virus strains and cell types [148, 99, 126, 151, 160].
This is perhaps not surprising considering that EVs and MVs might be ex-
cluded from most other endocytic pathways in non-phagocytic cells due to
their size. However, the mechanism of macropinocytosis induction was likely
to be different for the two particle types as they do not contain common
viral proteins on the surface and there is no evidence for common cellular
components. In contrast to MV infection, EV infection was not inhibited by
the PS-binding protein ANX5. Evidently, EVs did not share the apoptotic
mimicry mechanism employed by MVs [148]. The requirement for macro-
pinocytosis is, however, shared with a number of virus families including
herpes- and filoviruses for which the mechanism of triggering is not clear
[48, 6, 188, 115, 165, 196]. Macropinocytosis as a cellular mechanism is a
potential drug target for new antiviral agents.
The effect of BafA and MonA showed that EV-induced infection of HeLa
cells required organelle acidification. While internalization was not inhib-
ited by BafA, the drug prevented the release of viral cores from intact EVs.
That disruption of the outer EV membrane barrier within endocytic vesicles
was the affected step, was supported by several observations. First, we con-
firmed previous reports that the EV membrane is sensitive to low pH in vitro
[107, 252]. Second, we observed that artificial disruption of the EV mem-
brane partially rescued infection in the presence of BafA. Third, we found
that infection with EV suspensions in the absence of MAb 7D11 (containing
60–90 % disrupted EVs) was significantly less sensitive to BafA or MonA
(data not shown). Fourth, EVs with both membranes accumulated intra-
cellularly in the presence of BafA. Fifth, release of viral cores from MVs was
not inhibited by the utilized BafA concentrations, suggesting fusion was not
affected. MV-like particles wrapped in the EV membrane differ from MVs
in that they lack A26 [246]. MVs of VACV strains lacking A26 were capable
of fusing at neutral pH in conditions in which MV infection was sensitive to
BafA [35], strengthening the conclusion that fusion of MV-like particles is
insensitive to BafA. Although low pH seemed essential for EV disruption, we
cannot exclude the possibility that the interaction with glycosaminoglycan
(GAG)-chains contributes to disruption as previously suggested [128]. How-
ever, when the murine cell line L and its GAG-deficient derivative sog9 [12]
were infected with IHD-J or WR EVs, infection levels in both cell lines were
similar, suggesting that GAGs were not required for efficient EV infection.
Inhibition of EV infection by BafA was similar in L and sog9 cells (data not
shown).
The mutant WR ∆ A34R is interesting because the outer membrane of
its EVs is not as susceptible to disruption by GAG-chains [128] and low pH
(Figure 2.13 B) as that of wild-type virus. EVs of this virus lack the EV
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membrane protein A34 and incorporate reduced amounts of two other EV
membrane proteins, B5 and A33 [64, 181]. Acidic residues in the membrane-
proximal stalk region of B5 are required for GAG-triggered EV disruption
[193], and it is possible that both GAG- and low pH-mediated EV rupture
share a mechanism that depends on B5 and A34. That WR ∆ A34R EVs
are infectious despite their resistance to low pH-mediated disruption implies
that loss of the outer membrane can be triggered by other mechanisms. Nev-
ertheless, infection remained sensitive to acidification inhibitors, suggesting a
need for WR ∆ A34R EVs to pass through acidified endocytic compartments
for productive infection.
The immune system of poxvirus infected organisms is challenged by two
distinct infectious entities, EVs and MVs, that expose no common epitopes.
The outer EV membrane serves as a protective shield under which an MV-like
particle can hide during virus spread through body fluids. Consistent with
such a role, the EV membrane contains complement control proteins [252],
and EVs are more difficult to neutralize with antibodies than MVs [129]. The
key viral proteins involved in membrane fusion remain hidden and protected
until needed. The cue for disruption of the outer EV membrane is the low pH,
which the virus is likely to encounter for the first time in the macropinosome.
Our results thus indicate that the protective outer membrane of an incoming
EV is shed at the latest possible time point, i.e. when the virus has been
internalized and is no longer accessible to extracellular factors.
2.5 Material and methods
2.5.1 Cell lines
BSC-40 (African green monkey) and HeLa (human) cells were cultivated in
DMEM (Gibco BRL) supplemented with 10 % heat-inactivated FCS, gluta-
max, and penicillin-streptomycin; for BSC-40 cells non-essential amino acids
and sodium pyruvate were added as well; RK13 (rabbit) cells were culti-
vated in MEM (Gibco BRL) supplemented with 10 % heat-inactivated FCS,
glutamax, non-essential amino acids, penicillin-streptomycin, and sodium
pyruvate.
2.5.2 Viruses
Recombinant Vaccinia viruses were generated based on VACV strain West-
ern Reserve (WR), VACV WR ∆ A34R (a kind gift of Bernard Moss, NIH,
Bethesda, MD, USA) [268], and VACV strain International Health Depart-
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ment J (IHD-J) as previously described [148]. Briefly, GFP-expressing strains
were generated using vectors based on the plasmid pJS4 [33]. Strains encod-
ing EGFP-A5 or mCherry-A5 in the endogenous locus were constructed us-
ing vectors based on pBluescript II KS (Fermentas, St. Leon-Rot, Germany)
bearing the EGFP or mCherry coding sequence flanked by the respective
VACV WR genomic regions. VACV strains expressing F13-GFP were a
kind gift of Rafael Blasco (INIA, Madrid, Spain) [77]. To build strains en-
coding both mCherry-A5 and F13-GFP, BSC-40 cells were co-infected with
mCherry-A5 and F13-GFP viruses; dual-colored recombinants of the parental
viruses were selected through four rounds of plaque purification on BSC-40
cells.
MV particles were produced in BSC-40 cells and purified from cytoplasmic
lysates as described elsewhere [148]. EV particles were produced in RK13
cells and collected from the supernatant. Confluent tissue culture flasks were
infected with the respective MVs in serum-free medium at an MOI of 1 for
1 h. Cells were washed with PBS and overlayed with full medium. 24 h post
infection, supernatants were collected and loose cells sedimented by two low
speed centrifugation steps (400 g, 10 min, 4 ◦C). EV-containing supernatants
were either used directly or concentrated by sedimentation (40 min, 38,000 g,
4 ◦C) and re-suspended in full or serum-free medium.
2.5.3 Antibodies
Hybridoma cells to produce the mouse MAb 7D11 (anti-L1) [268] were kindly
provided by Bernard Moss with permission of Alan Schmaljohn (University
of Maryland, Baltimore, MA, USA). MAbs were purified from hybridoma
supernatants by BioGenes (Berlin, Germany). MAb VMC-20 (anti-B5) from
ascites fluid was a kind gift of Roselyn J. Eisenberg and Gary H. Cohen (Uni-
versity of Pennsylvania, Philadelphia, PA, USA) [4]. Rabbit polyclonal anti-
GFP was purchased from Rockland (Gilbertsville, PA, USA). Fluorophore-
coupled goat anti-mouse secondary antibodies were obtained from Invitrogen
(Carlsbad, CA, USA).
2.5.4 Drugs and reagents
Actinomycin D, bafilomycin A1, calphostin C, cytochalasin D, chlorpro-
mazine, ethylisopropyl amiloride (EIPA), 3-indolepropionic acid (IPA-3), ge-
nistein, ML-7, monensin A, rottlerin, staurosporine, and wortmannin were
obtained from Sigma-Aldrich; jasplakinolide was purchased from Enzo Life
Sciences (Farmingdale, NY, USA) and Iressa from LC laboratories (Woburn,
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MA, USA); AF 594-coupled phalloidin (Invitrogen) was used for actin stain-
ing, Draq 5 (Biostatus, Shepshed, UK) for DNA staining.
2.5.5 EV plaque assay
To assay the fraction of intact infectious EVs, virus samples were incubated
with or without 5µg/mL MAb 7D11 at 37 ◦C for 1.5 h. Serial dilutions
were prepared and 50µL of each added to confluent BSC-40 cells in 6-wells
covered with 1 mL DMEM. After 1 h at 37 ◦C, cells were washed with 1 mL
PBS and overlayed with 2 mL full DMEM (WR) or full DMEM with 1.5 %
carboxymethyl cellulose (IHD-J). Cells were stained after 48 h to 72 h (0.1 %
crystal violet, 2 % formaldehyde in ddH2O).
2.5.6 Microscopic analysis of EV particles
The integrity of EVs on the particle level was analysed using confocal mi-
croscopy. EV particles of strain IHD-J mCherry-A5 F13-GFP from clarified
supernatants were incubated with 5 µg/mL MAb 7D11 at 37 ◦C for 1 h and
bound to cover slips. Samples were fixed with formaldehyde and stained
with AF 647 goat anti-mouse. Z-stacks were recorded using a Zeiss LSM510
Meta confocal system. Particles were detected using the ImageJ particle
detector & tracker plug-in [204] on Z projections (radius = 3, cutoff = 0, per-
centile 0.07 [green]/0.1 [blue]/0.05 [red]) and coordinates compared with a
custom-written Matlab program (distance cut-off 〉 3 pixels [540 nm]).
2.5.7 Confocal microscopy internalization experiment
To assay the internalization of EVs, IHD-J EV particles (3x concentrated
supernatants) were bound to HeLa cells on cover slips for 1 h on ice. Cells
were either stained directly or incubated in full medium at 37 ◦C for 30 min.
Cells were cooled down, washed, and incubated with VMC20 (1:10,000 in
PBS/1 % BSA) on ice for 2 h. Cells were fixed and stained with AF 647 goat
anti-mouse and AF 594 phalloidin (where indicated). Control samples were
fixed and permeabilized before staining. Z-stacks were recorded using a Zeiss
LSM510 Meta confocal system.
2.5.8 Electron microscopy internalization experiment
To visualize internalized EVs, IHD-J F13-GFP EV particles (60x concen-
trated supernatants) were bound to HeLa cells on ice for 1 h. Cells were in-
cubated in full medium at 37 ◦C for 30 min, and fixed in 4 % formaldehyde and
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0.1 % glutaraldehyde in 1x PHEM buffer [208] for 90 min. Cryo-sectioning
and immuno labelling was performed as described elsewhere [235, 220]. In
brief, ultra-thin sections (50-70 nm) from gelatin-embedded and frozen cell
pellets were obtained using a FC7/UC7-ultramicrotome (Leica, Vienna, Aus-
tria). Immunogold labelling was carried out on thawed sections with anti-
GFP antibodies (1:200) and 10 nm protein A-gold (UMC Utrecht University,
Utrecht, The Netherlands) (1:50); a mixture of uranyl acetate and methyl
cellulose was used for embedding and negative staining. Sections were exam-
ined with a CM10 Philips transmission electron microscope with an Olympus
”Veleta” 2k x 2k side-mounted TEM CCD camera.
2.5.9 Flow cytometry internalization assay
Subconfluent 12-wells of HeLa cells were used for flow cytometry-based in-
ternalization assays. Cells were pretreated with inhibitors for 15–60 min in
full DMEM; EVs (IHD-J F13-GFP, 0.25 mL 35 x concentrated supernatants)
or MVs (IHD-J EGFP-A5, 7.5 · 107 pfu in 0.25 mL) in serum-free medium
were bound to cells on ice for 1 h. Cells were washed and incubated with
full medium (+ inhibitors) at 37 or 0 ◦C for 30 min. Cells were washed with
PBS and incubated with 0.25 % Trypsin/EDTA at 37 ◦C for 10 min to detach
cells and remove bound virus. Alternatively, cells were detached with 1 mM
EDTA/PBS at 0 C for 30 min. Cells were re-suspended and washed in 7 %
FCS in PBS, fixed and analysed using a Becton Dickinson (BD) FACSCalibur
flow cytometer and the FlowJo software package.
2.5.10 Flow cytometry infection assay
Confluent 12-wells of HeLa cells were infected for flow cytometry-based in-
fection assays. Pretreatment with inhibitors was performed for 15–60 min in
full MEM (as used for RK13 cells and present in EV supernatants). MVs
(2 · 106 pfu in 0.5 mL) and EVs (0.5 mL EV supernatant or concentrate) were
prepared in full MEM (+ inhibitors). Disrupted EVs and contaminating MVs
in the EV samples were neutralized with 5µg/mL 7D11 for 1 h at 37 ◦C and
added to cells. After 30 min at 37 ◦C, cells were washed and overlayed with
1 mL full MEM (+ inhibitors). 4 h post infection, cells were prepared for flow
cytometry. Cells were analysed using a BD FACSCalibur flow cytometer and
the BD CellQuest Pro software or the FlowJo software package.
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2.5.11 Fluid phase uptake assay
Virus-induced fluid phase uptake was quantified as described previously [147].
Sub-confluent HeLa cells in 24-well plates were serum-starved in 0.2 % BSA/
DMEM for 4 hour. WR wt MVs or WR ∆ A34R EVs in 0.2 % BSA/RPMI
were then bound to the cells in the cold for 90 min. Cells were washed
and pulsed for 10 min at 37 ◦C with 0.5 mg/mL 10 kDa dextran AF 488
(Invitrogen) in RPMI/BSA. Cells were washed with BSA/RPMI, PBS (2x),
100 mM NaOAc (pH 5.5)/50 mM NaCl, and PBS. Cells were detached with
0.25 % trypsin (25 min on ice, 1 min at RT), resuspeded with 7 % FCS in PBS
and fixed in 4 % formaldehyde over night at 4 ◦C. Fluorescence of cells was
quantified using a BD FACSCalibur flow cytometer and the FlowJo software
package.
2.5.12 Blebbing assay
To quantify the induction of blebbing, HeLa cells were grown on cover slips
to 50 % confluency. MV or EV suspensions (0.5 mL) of VACV WR ∆ A34R
EGFP-A5 in 2 % BSA/PBS were added to cells at RT for 1 h. Cells were
washed and incubated with full medium at 37 ◦C for 40 min. Samples were
fixed with 4 % formaldehyde at RT, and DNA and actin stained with Draq 5
and AF 594 phalloidin. Microscopy images were recorded using an Olym-
pus CellˆR imaging station with DIC setup. Total and blebbing cells were
counted manually (ntotal ∼ 250 cells/condition and experiment).
2.5.13 Annexin V binding
Exposed PS on virion membranes was masked with ANX5 to test the re-
quirement of PS on infection. A modified version of the manufacturer’s
protocol (Vybrant Apoptosis Assay kit # 2; Molecular Probes) was used for
labelling. In brief, sedimented virions were washed twice with ANX5-binding
buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl2, pH 7.4), resuspended in
200µL ANX5-binding buffer and split into two samples. Samples were left
untreated or treated with 20µL AF 647 ANX5 for 1 h at RT. Virions were
washed twice with ANX5-binding buffer, re-suspended in DMEM and used
for infection experiments.
2.5.14 EV disruption
To disrupt EV particles in vitro, 20 µL EVs (clarified supernatant of infected
RK13 cells) were mixed with 180 µL 10 mM Na-citrate (pH 5.0), incubated at
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37 ◦C for 5 min and neutralized with 100 µL 1 M Hepes pH 7.4. For controls,
Hepes was added to virus samples premixed with low pH buffer. Integrity of
EVs was quantified by plaque assay as described above. To rescue infection
by low pH treatment, 7D11-treated EV particles were bound to drug-treated
HeLa cells on ice for 1 h in the presence of drugs. Cells were incubated
for 5 min with full DMEM containing 30 mM MES (pH 4.5) or full DMEM
(pH 7.4) at 37 ◦C. Cells were washed twice and treated as described in the
flow cytometry infection assay. SigmaPlot (Systat software) was used to
compare sample groups by t-test.
2.5.15 Core release assay
To detect and quantify viral cores, HeLa cells on cover slips were pre-treated
with inhibitors in full DMEM for 30 min. IHD-J EGFP-A5 EVs (0.25 mL
4x concentrated EV supernatant) or MVs (1.3 · 107 pfu in 0.25 mL) in 2 %
BSA/PBS were pretreated with or without 5 µg/mL 7D11 for 1 h at 37 ◦C.
Virions were bound to cells on ice for 1 h in the presence of drugs. Cells were
washed with PBS and incubated in full medium with drugs for 3 hours. Cells
were fixed with formaldehyde, and stained with 7D11 (540 ng/mL) / AF 594
goat anti-mouse and AF 647 phalloidin. Z-stacks were recorded using a Zeiss
LSM510 Meta confocal system. Green fluorescent cores were detected with
the spot detection function of Imaris (Bitplane) using the quality parameter.
Detected spots with a mean green intensity <20 were omitted and spots with
a mean red fluorescent intensity <50 were classified as released cores (ntotal
∼ 750 cores in 10 cells/condition and experiment).
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3.1 Summary
A two-step, automated, high-throughput RNAi silencing screen was used to
identify host cell factors required during vaccinia virus infection. Validation
and analysis of clustered hits revealed previously unknown processes during
virus entry including a new mechanism for genome uncoating. Viral core
proteins were found to be ubiquitinated already during virus assembly. After
entering the cytosol of an uninfected cell, the viral DNA was released from
the core through the activity of the cell’s proteasomes. Next, a Cullin3-based
ubiquitin ligase-mediated round of ubiquitination and proteasome action was
needed to initiate viral DNA replication. In addition to identifying novel cell
functions required for poxvirus infection, these studies highlight the capacity
of large-scale RNAi screens to direct detailed cell biological investigation of
virus-host cell interaction.
3.2 Introduction
Poxviruses are enveloped DNA viruses characterized by their large size, in-
tricate structure, and a complex cytoplasmic replication cycle [71]. Vaccinia
virus (VACV), the prototypic poxvirus used in this study, served as a vaccine
during the eradication of smallpox, one of the most devastating diseases of
the 20th century [71]. The potential deployment of the smallpox virus as
a biological weapon, risks associated with resumed vaccination, and recent
monkey pox outbreaks warrant continued research towards new anti-poxvirus
agents [58, 88].
The VACV life cycle begins with macropinocytic internalization of virus
into host cells [99, 148]. This is followed by low pH dependent membrane
fusion to release the viral core into the cytosol [239]. Post-penetration steps
include loss of core-associated lateral bodies, core expansion, and transcrip-
tion of early viral genes within the expanded core [51, 117, 161, 178]. Early
mRNAs generate about 100 different viral proteins, including unidentified
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factors required for DNA uncoating [112, 138]. During the subsequent un-
coating process, cores disappear as visible structures, the viral DNA is re-
leased and replicated, intermediate and late genes are expressed, and cytoso-
lic virus factories formed. While many of the cellular factors and functions
required for initial entry have been described [99, 127, 148, 211, 239], the
cellular factors that participate in viral genome uncoating remain largely
undefined. In the last few years, large-scale RNAi screening has become a
powerful tool for the analysis of pathogen-host interactions. This approach
has been previously applied to a variety of pathogens (reviewed in [37]). For
VACV, a Drosophila kinome screen was used to identify and describe a role
for AMPK during infection [160].
Our goal was to elucidate the host factors in tissue culture cells needed in
the VACV life cycle. Using a large-scale RNAi screen we have defined crit-
ical cellular processes that the virus exploits during infection. By focusing
on the identified protein clusters involved in ubiquitin-mediated proteasome
degradation, we have uncovered roles for proteasomes, ubiquitination, and a
Cullin3-based ubiquitin ligase in uncoating of viral genomes and their sub-
sequent replication. Ultimately, this information could facilitate the devel-
opment of novel antiviral agents that would target the host rather than the
virus directly.
3.3 Results
3.3.1 RNAi screening identifies 188 cellular factors re-
quired for VACV infection
We used an automated, high-content, high-throughput RNA interference
(RNAi) screen in human tissue culture cells (HeLa) to identify host cell
factors and processes required during the VACV life cycle. Using the mature
virus form of a recombinant VACV that expresses EGFP under a synthetic
early/late viral promoter (VACV-EGFP) [148], we could readily distinguish
infected from non-infected cells. Automated fluorescence microscopy and
image analysis was employed to score for cell factors required during the
replication cycle up to and including translation of late viral genes.
To avoid some of the pit-falls encountered in previous virus infection
screens [37, 156], we chose to screen a set of 7,000 genes selected for their
potential to be inhibited by small compounds (the 7,000 drug-able genome
library; Qiagen). Although covering only one-third of human genes, these
represent a well-studied and well-annotated cross-section of the full genome;
and for these factors, reagents are more readily available for follow-up studies.
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In addition, we improved image analysis, hit visualization, and hit validation.
To increase reliability, we introduced a fully automated computational
pipeline for high-content image analysis [27, 224]. Over 200 quantitative
features were extracted from each of 624 million individual cells from 1.45
million images [27]. Using these features as a basis, several iterations of su-
pervised machine learning were applied to identify virus infection, mitosis,
apoptosis, and technical phenotypes [189, 224] (Supplementary Information
for details). Cell number and density (population context) effects were nor-
malized to improve both reproducibility of screening results in different cell
lines and consistency of phenotypes obtained by different siRNAs targeting
the same genes [225].
The RNAi screen was carried out in two steps as detailed in Figure 3.1 A
and in materials and methods. Three non-overlapping siRNAs against each
gene were used in a primary screen, and three additional siRNAs in a sec-
ondary follow-up screen. Both screens were repeated independently three
times. The primary screen using the 7000 drug-able genome led to the iden-
tification of 276 genes in which two or three of the three siRNAs reduced
VACV infection relative to controls (Le. for the majority the median over
the triplicates of at least two siRNAs had a median absolute deviation less
than -1.5 over the whole screen).
The secondary screen, directed against the genes identified as hits in
the primary screen, was performed using siRNAs from a different vendor
(Ambion). It confirmed 68 % of the hits from the primary screen with a
correlation coefficient of 0.34 between the validated RNAi phenotypes of
the two screens (P = 2.8 · l0−6). A stringent, control-based analysis of non-
targeting control siRNAs gave a false positive rate of 0.06 % in the secondary
screen giving further confidence in the confirmed host-factors.
The final hit list had 188 genes representing a broad range of cell func-
tions. Among them, several proteins have been previously implicated in
VACV infection: EGFR, RAC1, PAK1, laminin (LAMAl and 2), the protea-
some, Tsgl01, profilin, and RIPK3 [40, 42, 66, 93, 132, 136, 148, 151, 202,
233, 256]. Others, such as ribosomal proteins, were expected as hits for any
virus. However, the majority had no prior connection to VACV infection.
To extract information regarding critical processes in the infection cycle,
the list was submitted to rigorous bioinformatic analysis. For this, we devel-
oped an algorithm that combined functional-and interaction-based informa-
tion (Supplementary Information; Network Visualization). This algorithm is
applicable for the visualization and analysis of any gene list. The hits were
first assigned to ”functional annotation clusters” representing sets of proteins
that share common annotations within public databases (DAVID [100]). As
shown in Figure 3.5, the genes were enriched within 13 clusters and several
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Figure 3.1 (A) Outline of screening and bioinformatic procedures. (B) Host factors
in larger functional clusters that interact or share functional annotations are depicted.
Individual genes were assigned to the highest enriched functional annotation cluster in
which they were present (Figure 3.1 B). Functional clusters identified by DAVID with
simplified annotations are pictured as white boxes with dashed outlines. Yellow lines
between genes of different clusters indicate high-confidence (>0.9) STRING interactions,
while those between genes within the same functional cluster include lower confidence
(>0.35) STRING interactions. Selected genes not found within a functional annotation
cluster are indicated as inverted arrowheads. Functional gene clusters are pictured in their
approximate cellular location.
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highly connected, functional annotation networks.
The function-based information was combined with data on physical in-
teractions between individual host factors (STRING [231]). The result of the
combined analysis is shown for 126 of the 188 host factors in Figure 3.1 B.
Automatic annotation was used to visualize the interaction networks (yellow
to red lines) both within and between functional annotation clusters (grey
dashed boxes). Without going into detail, it was evident that although repli-
cation and assembly of progeny virus occurs in the cytoplasm of host cells,
VACV depends on cytoplasmic, as well as, nuclear functions. The cytoplas-
mic functions included membrane trafficking, signalling, proteolysis, and ion
transport. Factors in the tyrosine kinase and actin clusters have already been
shown to be necessary for phosphatidylserine-mediated macropinocytosis of
the virus during entry [148, 150].
3.3.2 Breakdown requires proteasome activity but is
independent of new ubiquitination
The value of a screen depends ultimately on whether it leads to concrete new
insights and novel mechanisms. In the follow-up, we focused on two promi-
nent clusters; the proteasome and ubiquitination (Figure 3.1 B). siRNA-
mediated depletion of proteasome subunits caused a nearly complete block
in infection (Figure 3.2 A). For confirmation, we determined the virus yield
in the presence of MG132, a proteasome inhibitor, and UBEI-41, an inhibitor
of the cellular E1 ubiquitin conjugating enzyme UBA1. Both decreased viral
yield by -3 logs, similar to cycloheximide (CHX), a protein synthesis inhibitor
(Figure 3.1 B). When infection with VACV strains that express EGFP specif-
ically from an early (E-EGFP-VACV), or a late (L-EGFP-VACV) promoter
was analysed by flow cytometry using, we found that the inhibitors blocked
late, but not early viral gene expression (Figure 3.2 C).
This suggested that the virus life-cycle prior to early gene expression, such
as virus binding and endocytosis, were not impacted by these inhibitors. To
confirm this, we tested whether the effects of MG132 and UBEI-41 could
be circumvented by forcing fusion of virions at the plasma membrane with
low pH. This treatment results in deposition of viral cores into the cyto-
plasm, effectively by-passing the need for endocytosis [148]. Consistent with
a post-penetration block, the inhibitors could not be by-passed upon low
pH treatment (Figure 3.2 D). Similar results regarding viral yield, gene ex-
pression, and inhibition after by-pass were observed with the more specific
proteasome inhibitor, Velcade (Figure 3.6).
Having ruled out a role for the proteasome and UBA1 in virus endocytosis
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and penetration, we addressed genome uncoating. The efficient release of
viral DNA from internalized cores is of interest because poxvirus particles
and cores are extremely stable when exposed to desiccation, denaturants,
proteases, extremes of temperature, etc. [68, 137, 140].
Using a virus in which the core protein AS was tagged with EGFP
[148], and by immuno-fluorescence staining of the viral membrane protein
Ll [210], we followed the fate of individual viruses and cores by fluorescence
microscopy. HeLa cells were incubated at a multiplicity of infection (MOl)
of 10 for 4 h, a time sufficient for virions to enter and undergo genome
uncoating. External virions that still contained the viral membrane were
yellow, and internalized, released viral cores devoid of membrane were green.
When the cores in control cells were quantified Figure 3.7, few were observed
(25-50 per cell; green) (Figure 3.2 E; UNTR). However, in the presence of
CHX, which prevents core breakdown and genome uncoating [113], intact
cytoplasmic cores numbered 275-320 per cell (Figure 3.2 E; CHX). The same
was observed when the proteasome was inhibited with MG132 (250-300/cell)
(Figure 3.2 E; MG132). UBEI-41 had virtually no impact on core breakdown
(50-60 cores/cell) (Figure 3.2 E; UBEI-41). This suggested that protein syn-
thesis and the proteasome were needed for uncoating, but UBA1 was not.
3.3.3 VACV core proteins are packaged in a K48- ubiq-
uitinated state to mediate proteasome depen-
dent genome uncoating
Using a similar fluorescence-based assay, Satheshkumar and co-workers have
in a previous study reported that inhibition of proteasome activity has a
minor impact on core breakdown [202]. They concluded that proteasomes
were required for the subsequent viral DNA replication step. For clarification,
we investigated the state of cytoplasmic cores after entry in the presence of
MG 132 using electron microscopy.
The images confirmed that viral cores remained intact (Figure 3.2 F,
MG 132; Figure 3.8). While core expansion occurred Figure 3.10, it was
evident that the genome (the electron dense material within the cores) was
not released (3.2 F; blow-up). Electron microscopy also showed that while
UBEI-41 did not inhibit core breakdown, it prevented formation of viral DNA
replication factories (Figure 3.2 F; UBEI-41; Figure 3.8). This was consistent
with previous reports that ubiquitination is needed for DNA replication [202,
233]. Taken together, the results suggested somewhat paradoxically that
proteasomes were needed for breakdown of the core whereas ubiquitination,
which normally serves to prepare substrates for degradation, was required
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for a subsequent step, one preceding DNA replication.
To monitor release of incoming viral DNA as a consequence of core break-
down, we used immunofluorescence staining for the viral protein I3L that is
bound to the viral DNA [260]. That antibodies directed against this protein
can be used to detect uncoated parental VACV DNA in the absence of viral
replication has been demonstrated [63, 260]. While unable to access the anti-
gen in intact cores (Figure 3.10), antibodies to I3L stained cytoplasmic viral
DNA after release from incoming cores (Figure 3.3 A). Later in infection, it
also stained the I3L complexed with viral DNA in the large perinuclear virus
factories.
When control cells were infected for 4 h at a MOl of 10, and the viral
DNA visualized by anti-I3L, replication factories and cytoplasmic 13 staining
were seen (Figure 3.3 A; UNTR). With CHX present to prevent early gene
expression and genome release, only 5 % of cells had I3L-positive spots in
the cytoplasm. In the presence of cytosine arabinoside (AraC), an inhibitor
of viral DNA replication, 78 % of cells contained cytoplasmic I3L spots indi-
cating that incoming viral DNA had been released, but not replicated. Cells
infected in the presence of MG132 were positive for diffuse cytoplasmic I3L
Figure 3.2 (following page) Proteasome but not E1-activating enzyme function is re-
quired for VACV genome uncoating. (A) RNAi mediated silencing of proteasome subunits
PSMAl and PSMB3 impair VACV infection (RII average representative images from the
screen are displayed). (B) Proteasome (MG132) and E1-activating enzyme (UBEI-41)
inhibitors block VACV production (MOI 1; 24 hour p.i.; 10 µM AraC, 10 µg/mL CHX,
25 µM MG132, and 50 µM UBEI-41 used throughout). (C) MG132 and UBEI-41 al-
low for early but not late VACV gene expression. Cells were infected with VACV (MOI
1) expressing EGFP from either an early (E-EGFP-VACV), or a late (L-EGFP VACV)
promoter. Infections were performed in the presence of the indicated inhibitors. Cells
were harvested 6 hour p.i. and analysed for the number of early or late EGFP expressing
cells, respectively. Cells infected in the presence of CHX or AraC were used as controls.
(D) MG132 and UBEI-41 inhibit VACV infection after internalization. VACV-EGFP
MVs (MOI 1) were bound to cells for 1 hour in the presence of inhibitors. Cells were then
washed, treated with pH 7.4 or pH 5.0 media for 5 min, washed, and media containing
the inhibitors added back. Cells were analysed by flow cytometry for EGFP at 6 hour
p.i. (E) VACV core degradation is proteasome, but not E1 activating enzyme dependent.
Cells were infected with WR-EGFP-A5 (MOI 10) in the presence of CHX, MG132, or
UBEI-41. At 4 hour p.i. cells were fixed and external virions identified by immunofluores-
cence against the viral membrane protein L1R. Experiments were performed in triplicate
and the average number of cores per cell under each condition displayed as mean ± SEM
(right)(see Figure 3.5). (F) EM shows that MG132 and UBEI-41 inhibit distinct stages of
the VACV life cycle. Cells treated as in F (MOI 10; 4 hour p.i.) were analysed by EM.
Blow-up of virion (MG132) indicates that the electron dense viral genome is still within
the core. All experiments have been performed in triplicate and displayed as the mean
± STDV (B-D) or representative images displayed (F-G).
3.3. RESULTS 69
70 CHAPTER 3. RNAI SCREENING IN VACV INFECTION
staining, but did not contain I3L-positive viral DNA spots. This showed
that even though expression of I3L (an early protein) had occurred, viral
genomes had not been released (Figure 3.3 A). In contrast, UBEI-41-treated
cells displayed diffuse cytoplasmic I3L staining and I3L-positive spots as seen
in AraC-treated cells, confirming that viral genomes were released but not
replicated. Collectively, these results showed that the proteasome and UBA1
acted in distinct steps in the early infection cycle; proteasomes in core break-
down and DNA release, and UBA1 (and thus ubiquitination) in replication
of released viral DNA.
That core degradation was not dependent on UBA1 suggested that ubiq-
uitin must have been added to core proteins prior to virus entry. Proteomic
analysis of isolated VACV virions have indicated that ubiquitin accounts for
1-3 mole percent of total protein [43]. However, the location of this ubiquitin
within the viral particle, and the potential role of this host protein in the
virus life cycle has not been investigated.
Immunoblot analysis on highly purified VACV virions confirmed that they
contained a striking amount of ubiquitin (Figure 3.3 B; left). The molecular
weight of the detected bands indicated that these were ubiquitin-conjugated
proteins, and not free ubiquitin. To assess the location of the ubiquitin-
conjugated proteins, virions were separated into membrane and core fractions
[154]. Immunoblot analysis on these fractions indicated and the vast majority
of the ubiquitinated factors were components of the viral core (Figure 3.3 B;
right). Using lysine-48- and lysine-63-linked poly-ubiquitin specific antibod-
ies, we showed that only lysine-48-linked ubiquitinated proteins were present
(Figure 3.3 C). Since lysine-48-linked ubiquitin chains mark proteins for pro-
teasomal degradation [45, 124], it was evident that this was the mechanism
that triggered proteasome-mediated genome uncoating.
Since ubiquitination of core proteins must occur during virion produc-
tion in infected cells, we asked whether infectious virus could be produced if
ubiquitination was inhibited late in infection. Addition of either AraC at 6
hour had little effect on late viral gene expression (Figure 3.3 D, white), and
only marginally reduced the 24 hour virus yield (Figure 3.3 E; white). As
late genes are expressed from newly replicated genomes, this indicates that
by 6 hour p.i. viral DNA replication and late gene expression is sufficient for
significant virus production. When UBEI-41 was added at 6 hour p.i., again
there was no impact on late viral gene expression (Figure 3.3 D, grey). How-
ever, unlike AraC, that had little effect on virus yield, addition of UBEI-41
after 6 hour prevented the production of infectious virus (Figure 3.3 E; grey).
We were, in fact, unable to isolate virus particles from infected cells treated
with UBEI-41 from 6 hour p.i. (Figure 3.8). This indicated that there are
at least two steps in the VACV infectious cycle that require ubiquitination:
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not only viral DNA replication after genome uncoating but also assembly of
progeny virus.
3.3.4 A Cullin-3 ubiquitin ligase complex is required
for VACV genome replication
While responsible for genome uncoating (Figure 3.2 and 3.3), it remained
unclear whether the proteasome was also required for a second step, namely
to initiate genome replication as previously described [202, 233]. After con-
firming that both MG132 and UBEI-41 prevented VACV replication site
formation (Figure 3.4 A), we used an AraC release approach to test for ef-
fects on replication. Cells were infected in the presence of AraC for 6 hour to
allow uncoating but stop replication of incoming genomes. AraC was then
washed out or replaced with either UBEI-41 or MG132. Infection was allowed
to proceed for an additional 6 hour after which cells were analysed for viral
Figure 3.3 (following page) (A) MG132 prevents VACV genome release and UBEI-41
blocks viral DNA replication. Cells were infected (MOI 10) in the absence of inhibitors
(UNTR), or in the presence of MG132 or UBEI-41. Cells were fixed 4 hour p.i. and
immunoflouresence against the viral 13 DNA binding protein performed. Cells treated
with CHX, which prevents genome release, or AraC, which allows for release of parental
genomes but not their replication served as controls for the assay. The number of cells
positive for parental DNA staining under each condition is displayed as the mean ± STDV
(right). (B) VACV core proteins are packaged in a polyubiquitinated state. Immunoblots
directed against total (mono and poly) ubiquitin were performed on 1.0, 2.5, and 5.0 µg
of purified VACV MVs (left), or on 2.5 µg of whole (W) VACV MVs, or MVs separated
into core (C), and membrane (M) fractions (right). As a control for detection of ubiquitin,
100 µg of cell lysate (Cells) was used. Experiments were performed in triplicate and
representative blots shown. (C) Viral core proteins are positive for K-48-, but not K63-
linked ubiquitin chains. Immunoblots directed against K-48 or K63-specific ubiquitin
chains were performed on whole (W), core (C), and membrane (M) fractions of VACV
MVs. 100 µg of cell lysate was used as a control for each antibody (Cells). (D) Late
addition of MG132 or UBEI-41 does not impede late viral gene expression. Cells were
infected (MOI 1) with VACV-EGFP-LATE. Either 10 µM AraC or 50 µM UBEI-41 were
added at the indicated times. Infection was allowed to proceed for a total of 12 hour
before cells were harvested and analysed by flow cytometry for EGFP expression. Values
are displayed as the percentage of cells expressing late genes relative to untreated infected
control cells at 12 hour p.i. (E) Inhibition of E1-ligase function at 6 hour p.i. impedes
production of infectious virus. Cells were infected with VACV MVs (MOI 1) and AraC or
UBEI-41 added at either the time of infection 0 hour (0) or after 6 hour (6). Cells were
harvested 24 hour p.i. and progeny virus was purified by banding Figure 3.12 followed
by titration for plaque forming units/mL. (A-C) Experiments were performed in triplicate
and representative images shown. (D and E) Experiments were performed in triplicate
and displayed as the mean ± STDV.
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replication sites (Figure 3.4 B). In control cells without a second inhibitor
(No Inh.), replication site formation was normal. However, in the presence
of UBEI-41 or MG132, the formation of viral replication sites did not occur.
Apparently, the initiation of DNA replication required both a ubiquitination
step and proteasome-mediated degradation.
Reasoning that a cellular ubiquitin ligase was likely to be involved, we
turned to the hits in the RNAi screen. The ubiquitin functional annotation
cluster (Figure 3.1 B) contained two components of the BCR E3 ubiquitin-
ligase complex; Cullin3 (Cul3) and RING-box protein 1 (Rbx1). Images
from the screen indicated that depletion of these factors completely blocked
infection (Figure 3.4 C). A requirement for Cul3 and Rbxl was validated with
three independent siRNAs each. Depletion of either factor decreased the 24
hour viral yield by 2 logs. Silencing of Cullin-l (Cull), a component of the
SCF E3 ubiquitin-ligase complex that was not a hit in the screen, had no
impact (Figure 3.4 C and D, left). The knock-down efficiency of these siRNAs
was confirmed by western blot (Figure 3.4 D; right). Subsequent experiments
were performed using the siRNA with the strongest knock-down efficiency
(Cul3-1, Rbx1-3, and Cul1-2). Depletion of Cul3 or Rbx1 was found to
significantly decreased late, but not early gene expression (Figure 3.4 E)
mirroring the effect of AraC and confirming a defect in DNA replication.
In line with this, Cul3 and Rbx1 knock-down inhibited the formation of
cytoplasmic DNA replication factories (Figure 3.4 F). We concluded that
UBA1, a Cul3 ubiquitin ligase, and the proteasome were required to initiate
the replication of uncoated VACV DNA.
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Figure 3.4 (following page) (A) MG132 and UBEI-41 block VACV DNA replication
site formation. Cells were infected with VACV MVs (MOI 1) in the presence of 10 µM
AraC, 25 µM MG132, or 50 µM UBEI-41. Cells were fixed and stained for DNA at 4 hour
p.i., Representative images (left); Mean ± STDV of triplicate experiments (right). (B)
MG132 and UBEI-41 block VACV DNA replication after uncoating. Cells were infected
with VACV MVs (MOI 1) in the presence of 10 µM AraC. At 6 hour p.i. cells were washed
and released from AraC (No Inh.), or shifted into 25 µM MG132 or 50 µM UBEI-41. Cells
were fixed at 12 hour p.i. and assessed for the presence of cytoplasmic DNA replication
sites. (C) RNAi against Cul3 or Rbx1, but not Cul1, impairs VACV infection (Average
RII and representative images from screen shown). (D) Silencing of Cul3 or Rbx1, but
not Cul1, reduces virus production. Cells were reverse transfected with 20 nM of three
independent siRNAs directed against either Cul3, Rbx1, or Cul1. After 72 hour cells
were infected with VACV MVs (MOI 1). 24 hour later cells were harvest and lysates
tittered for plaque forming units/mL (left). Immunoblot analysis of Cul3, Rbx1, and Cull
after siRNA mediated silencing with 20 nM siRNA for 72 hour (right; representative blots
shown). (E) Silencing of Cul3 and Rbx1, but not Cul1, reduces late but not early viral
gene expression. Cells were subjected to siRNA mediated silencing as in (D) followed
by infection with VACV (MOI 1) expressing EGFP specifically from an early, or a late
promoter. Cells were harvested 6 hour p.i. and analysed for the number of cells expressing
early and late EGFP, respectively. Cells infected in the presence of CHX or AraC were used
as controls. (F) Cul3 and Rbxl are required for VACV DNA replication site formation.
Cells in which Cul3, Rbx1, or Cull had been silenced (20 nM siRNA; 72 hour) were infected
with VACV MVs (MOI 1). At 4 hour p.i. cells were fixed, stained with Draq5, and analysed
for the presence of viral DNA replication sites. (A, B, D-F) Experiments were performed
in triplicate and displayed as mean ± STDV. (G) Model of VACV core ubiquitination,
core degradation/genome uncoating, and genome replication. During assembly of VACV
MVs, viral core proteins are ubiquitinated in a K-48 linked fashion. Upon infection of
naive cells, fusion of viral and cellular membranes releases the ubiquitinated viral core
into the cytoplasm. A first round of cellular proteasome action directs the degradation
of the ubiquitinated core and concomitant genome release. A Cul3-based ubiquitin ligase
and second round of proteasome action serves to initiate replication of the released viral
genomes. Ubiquitination events: New (red); Non-accessible (yellow); Accessible (green);
proteasomes (grey bullets); cullin-based ubiquitin ligase complex (grey crescents).
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3.4 Discussion
In summary, our results demonstrated that large-scale RNAi screening can,
despite inherent problems and pitfalls (off-target effects, insufficient knock-
down, cell population context effects, incomplete genome annotation, etc.)
[37, 156] serve as a valuable tool in the study of pathogen/host interactions.
The positive outcome relied in this case on a robust image-based assay, on
supervised classification of cellular phenotypes, a separation of indirect and
direct effects of siRNAs, and on improved bioinformatics analysis to identify
gene clusters [225].
This allowed us to identify among the 188 hits several clusters in which
multiple hits occurred in the same pathway or complex. Regarding the va-
lidity of the final hit list, we are encouraged by how many of the hits cor-
responded to factors identified earlier as essential genes in VACV infection.
Follow-up studies with the clusters as a starting point revealed a unique role
for ubiquitination, the proteasome, and Cul3 in virus assembly, uncoating,
and DNA replication (Figure 3.4 G). These studies showed that the list is a
valuable starting point for further functional studies.
Our results indicated that ubiquitination comes into play as an essential
process already during the assembly of VACV particles in virus factories lo-
cated in the cytoplasm of producer cells. Core proteins undergo extensive
K48-linked polyubiquitination. This is consistent with the accumulation of
ubiquitin observed in poxvirus replication sites and the detection of ubiquitin
within purified VACV particles [43, 167]. The polyubiquitination is proba-
bly an essential step for virus assembly because inhibition of the E1 ligase
prevented the purification of viral particles. VACV encodes one ubiquitin
ligase, p28, which localizes to VACV replication sites [167].
However as this protein is not required for virus production in tissue
culture, it is unlikely to be the ligase responsible for the ubiquitination of viral
core proteins. Future work is needed to identify the core components that
are ubiquitinated as well as the ubiquitin ligase(s) responsible. During egress
from the viral factory, the viral membrane may protect the ubiquitinated core
proteins from the degradation machinery. It is also evident that the ubiquitin
tags remain inaccessible to proteasomes until cores are “activated”after entry
into the cytosol of the next host cell.
After macropinocytic internalization of VACV into a new host cell, and
low pH dependent membrane fusion, the poly-ubiquitinated core is released
into the cytosol, where it immediately undergoes activation marked by ma-
jor expansion in size, a step that does not require early gene expression
[51, 108, 178]. The expanded cores serve as the site for early gene transcrip-
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tion [113, 138]. That they are not yet substrates for proteasome-mediated
uncoating suggests that the ubiquitin chains are not accessible. For degra-
dation of the core and uncoating of the DNA, the early genes have to be ex-
pressed. One or more of the early proteins are likely responsible for making
the ubiquitinated core proteins accessible as substrates for the proteasome.
The core particle is destroyed, and some of the core components such as
the AS protein are degraded. As a result of the proteolysis, the viral DNA
genome is released and core itself is no longer a recognizable structure in the
cytosol. That UBA1 activity is not required, indicates that the ubiquitin
present in the core is sufficient to mediate genome uncoating. Although pro-
teasome function has been implicated in the regulation of viral trafficking,
replication, egress, and immune evasion (reviewed in [13]), a direct role for
proteasomes in the uncoating of other viruses or viral capsids has not to our
knowledge been observed before. It was previously reported that viral DNA
replication requires ubiquitination and proteasome activity [201, 233].
Our results extend these findings to show that replication of the viral
DNA depends on Cul3 and Rbx1, two components of an important, multi-
functional E3-ligase family [184]. VACV encodes at least four Cul3 substrate
adapters, A55R, C2L, C5L, and F3L [15, 75, 185] and reviewed in [14]. Al-
though each of these is required for VACV virulence, they are not essential
for replication in tissue culture. This indicates that they are not the adapter
proteins used by Cul3 to facilitate VACV DNA replication. While the sub-
strates are not yet identified, one possibility involves the remaining DNA
associated proteins. The proteasome thus plays a central role in at least
two steps in the replication cycle of VACV. Collectively, RNAi screening
and these findings are likely to provide a starting point for detailed cell and
molecular biology analysis of poxvirus-host cell interactions, and they may
facilitate the development of novel anti-poxvirus agents that target the host
cell rather than viral factors.
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3.6 Supplementary Figures
[h]
Figure 3.5 Supplementary Figure; Network view of 73 functional annotation clusters
identified by DAVID (version 6.7) within the 188 host factors required for VACV infec-
tion. Network nodes represent individual functional annotation clusters. Node sizes reflect
the number of factors in each cluster (see legend). Node color represents the enrichment
relative to the total genes screened (see legend and supplementary information). Lines
between the functional clusters indicate shared genes. The line thickness defines the per-
centage (33-10 %) of genes in the smaller cluster that are shared with the larger cluster.
Solid lines represent all edges of at least 75 % similarity, while dashed lines represent
the single strongest edge of 33 % or higher for otherwise unconnected clusters. Individ-
ual networks are outlined in dashed grey lines. The largest network (1) consists of 98
genes, occurring 233 times in 25 functional annotation clusters, and is centred around
both ATP/GTP binding genes and proteasomal genes. The second largest network (2);
consists of 93 genes, occurring 191 times in 18 functional annotation clusters and contains
transcriptional regulators and nuclear lumen annotated genes involved in mRNA and pro-
tein transport. Smaller networks include: (3) Membrane intrinsic genes including cation
channels and G-protein coupled receptors; (4) Ion binding genes with (Ring-type) zinc-
finger domains, EGF binding domains, and DNA polymerases; (5) positive and negative
regulators of kinase activity and; (6) apoptosis. Highly enriched clusters not in larger net-
works included the spliceosome, nuclear mRNA splicing, and the ribosome. Less enriched
functional clusters included chemotaxis, cell-migration, mitosis, axon-guidance, laminin
G, lipid degradation, heparin binding, and vesicle (membrane) annotated genes.
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Figure 3.6 Supplementary Figure; Flow cytometry analysis assay for MV early and late
gene expression. Confluent monolayers of HeLa cells were infected with WR E/L EGFP
at an MOI of 1. Cells were harvested for flow cytometry at 6 hour p.i. A typical plot of
cell number versus EGFP fluorescence (log scale) is shown. For each sample, 10,000 viable
cells were counted in a flow fluorocytometer (FACSCalibur BD Biosciences) using emission
filter 520-550 nm for green fluorescence. To gate for early versus late gene expressing
cells, infections in the presences of CHX (light blue), which prevents early and late gene
expression, or AraC (dark blue), which allows for early but prevents late gene expression
were performed with each experiment. These cell populations were used to set gates for
early (M1) and late (M2) gene expressing cell populations. As an example, the effect of
MG132 (yellow), which prevents late but not early gene expression is shown.
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Figure 3.7 Supplementary Figure; Proteasome inhibition by Velcade blocks VACV pro-
duction. Proteasome inhibitor (Velcade) blocks VACV production (MOI 1; 24 hour p.i.;
10-100 nM Velcade). (B) Velcade has no impact on early, but inhibits late VACV gene
expression (MOI 1; 6 hour p.i.). Cells infected in the presence of CHX or AraC served
as controls for gating early and late gene expressing cells (see Figure 3.6). (C) Velcade
inhibits VACV infection after internalization. VACV-EGFP (MOI 1) was bound to cells
for 1 hour in the presence of 100 nM Velcade. Cells were washed, treated with pH 7.4 or
pH 5.0 media for 5 min, after which media containing 100 nM Velcade was added back.
Cells were analysed by flow cytometry for EGFP at 6 hour p.i. (D) Velcade blocks VACV
DNA replication site formation. Cells were infected with VACV MVs (MOI 1) in the
presence of 10 µM AraC or 100 nM Velcade. Cells were fixed and stained for DNA at 4
hour p.i. Representative images (left); Mean ± STDV of triplicate experiments (right).
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Figure 3.8 Supplementary Figure; Quantification of internalized cores. Ten confocal Z
sections were collected for each cell and displayed as a maximum projection. In the merged
image virus cores are (green), the virus membrane (red), and intact virions (yellow).
To quantify the stabilized intracellular cores (total cores), the virus membrane signal
(membrane), was subtracted from core images. Thus, both the red signal and overlapping
red and green signals were removed from the core channel leaving only intracellular cores
(cores with no membrane). These images were inverted and subjected to auto thresholding.
Cores were then quantified with the image J particle analysis plug-in with settings (size
pixel 0.05-5; circularity 0.0-1.0) which assured that only individual cores were counted
with 94 % accuracy. 20 cells per condition from 3 independent experiments were analysed.
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Figure 3.9 Supplementary Figure; Quantification of internalized cores visualized by EM.
(A) The number of stabilized cores in control cells and cells infected in the presence of
cycloheximide (CHX), MG132, or UBEI-41 in micrographs of 0.1 µm thin epoxy sections
were quantified by point counting. For each sample condition, 25 micrographs were ac-
quired at a magnification of 5800x on a 2k x 2k camera (pixel size = 8.36 nm). A square
lattice grid (2 cm grid spacing) was placed on printed micrographs to cover each micro-
graph completely. The number of cores per grid point in the cytosol were counted and
analysed as published by [83]. (B) Cores are stabilized in the absence of proteasome but
not UBA1 function. The average number of cores observed per cell and per unit volume
in untreated, CHX, MG132 and UBEI-41 EM samples.
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Figure 3.10 Supplementary Figure; Determination of core expansion. Intact external
virions, cores within external virions, and internalized cytoplasmic cores were measured for
both width and length. Representative EM micrographs of mock, cycloheximide (CHX),
and MG132 treated infected cells were used for measurements. Under both conditions core
expansion (activation) was determined to be unaffected. A minimum of 40 cytoplasmic
cores and 80 intact virions from each condition were measured.
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Figure 3.11 Supplementary Figure; The I3 protein is not accessible in intact VACV MVs.
VACV MVs which package the A5 core protein as a mCherry fusion were left untreated
(UNTR) or were treated with 1 % NP40/50 mM DTT to remove the viral membrane.
These virions were bound to a cover-slip and stained with anti-I3L antibody, followed by
secondary staining with a 488-coupled secondary antibody. The I3 protein could only be
detected in samples that had been treated with NP40/DTT.
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Figure 3.12 Supplementary Figure; VACV virions cannot be isolated in the presence of
UBEI-41. HeLa cells were infected at an MOI of 1 with VACV-EGFP-A5. At 6 hour p.i.
UBEI-41 (50 µM) was to one set of cells, a time when late gene expression was determined
to be unaffected (Figure 3.3 D). Infections were allowed to proceed for a total of 24 hour
before cells were harvested and progeny virions were collected and band purified over a
25-50 % sucrose gradient. Virions could not be obtained from samples treated with UBEI-
41. Virions from untreated (UNTR) cells were purified in parallel for comparison (white
band). One mL was collected from the same region of both gradients and tittered to
determine the number of infectious particles produced. For the untreated sample ∼1 · 109
infectious particles were recovered. When the same region of the UBEI-41 treated gradient
was measured by plaque titration ∼1 · 106 infectious particles were recovered.
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Chapter 4
Vaccinia virus lateral bodies
deliver immediate effector
proteins into host cells
The results of this section will be submitted to a peer review journal, soon.
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4.1 Abstract
Vaccinia virus, the model poxvirus, is a DNA virus with a complex structure.
Infectious particles consist of the viral genome in a proteinaceous core, two
lateral bodies of so far unknown function, and one or two viral membranes.
During entry, both infectious forms of the virus release the viral core and
the lateral bodies into the host cell cytosol by a fusion event. Using electron
and fluorescence microscopy in combination with biochemical approaches,
we defined the morphological and chemical changes that the core undergoes
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after entry (activation). We identified F18 as a major structural protein of
the lateral bodies, which are left back at the membrane after fusion. We
found that the decomposition of lateral bodies by the host cell proteasome
releases at least one immediate effector protein into the host cell, the dual
specific viral phosphatase VH1. Only when the phosphatase is released from
lateral bodies, VH1 catalyses the dephosphorylation of activated Stat1 and
thus prevents the antiviral response of the type II interferon IFNγ. We thus
identified a new viral delivery mechanism for immediate effector proteins that
is very likely used to release additional, so far unknown, effector proteins.
4.2 Introduction
The ultimate goal of a virus particle is to transport the viral genome from
one infected cell to the next. Within a viral particle, the viral DNA or RNA
genome is typically organized in a proteinaceous core or capsid, which is
surrounded by a lipid bilayer in enveloped viruses. While efficient packaging
of the genome is obligatory for virus production, successful infection of a
new host cell requires the disassembly of capsids or cores to release the viral
genome. These antagonistic processes occur in the same host cells at different
time points. Subtle changes in the viral particles or the host cell ensure that
incoming viral cores or capsids are unstable and disassembly is energetically
favourable. Instability may be generated by maturation steps of the viral
particle, or by modification of the cellular environment of the host cells. The
latter modifications may take place either in host cells producing progeny
viruses or in newly infected cells [79].
Vaccinia virus (VACV) is the prototypic poxvirus and a close relative of
variola virus, the causative agent of smallpox [53]. Both infectious forms of
VACV, mature virions (MVs) and extracellular virions (EVs), contain the
DNA genome packaged in a proteinaceous viral core. The viral core with
two proteinaceous lateral bodies is enveloped by one or two viral membranes
in MVs and EVs, respectively.
During morphogenesis, immature virions (IV, see Figure 1.3 and 1.4)
surrounded by a single viral membrane are formed in the cytoplasmic viral
factory. After membrane closure, the amorphous protein and DNA content
of an IV undergoes dramatic rearrangements that involve the proteolytic
cleavage of core proteins by the viral protease I7 and possibly G1 [24, 7, 8],
as well as the formation of disulfide-bonds catalysed by the viral redox (see
Figure 1.5) system involving E10, A2.5, and G4 [262, 217, 216]. Morpho-
genesis results in the formation of MVs and MV-like particles with a typical
dumbbell-shaped core and two lateral bodies. The single membrane contains
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the viral entry/fusion complex (EFC), which catalyses or regulates fusion of
the viral membrane with cellular membranes during entry [213]. A fraction
of the matured viral particles, the MV-like particles, undergo further wrap-
ping events that lead to the formation of EVs, which are surrounded by an
additional membrane (see Figure 1.2 on page 4) [194].
Both MVs and EVs are internalised into host cells by virus-induced ma-
cropinocytosis [148, 210]. Acidification of macropinosomes triggers the nec-
essary events to promote penetration of cellular membranes. In the case
of MVs, low pH activates the EFC and directly induces fusion of the MV
membrane with the limiting macropinosomal membrane [239]. After macro-
pinocytosis of EVs, acidic pH triggers the disruption of the EV membrane,
exposing the MV-like particle still surrounded by one membrane [210]. The
EFC subsequently mediates fusion of the latter membrane with macropinoso-
mal membranes. In both cases, the ultimate goal is the release of the viral
core into the host cell cytosol [211].
Released cores undergo at least two distinct disassembly steps, activation
and uncoating, that ultimately release the viral DNA genome from the core
structure. During activation, viral cores undergo morphological changes and
start the transcription of early viral genes. VACV cores within an MV or an
EV are dumbbell shaped and are closely associated with the lateral bodies,
which usually fill the indentations of the core. Viral cores released into the
host cell cytoplasm exhibit an oval morphology and are no longer associated
with lateral bodies [51]. The viral RNA polymerase and early transcription
factors are pre-assembled on early promoters in the packaged genome and
start to transcribe early genes immediately after core release [275]. While a
relationship between morphological changes and the onset of transcription is
imaginable, this has not been formally shown to date. The composition and
function of lateral bodies after fusion remains elusive.
Released viral cores accumulate in the perinuclear region of the host cell
and this localisation has been attributed to microtubule-dependent transport
of VACV-induced cell contractions [30, 212]. Early viral mRNAs have been
reported to move along microtubules as well, and accumulate in distinct sites
of early gene translation [142].
In a second disassembly step, the genuine uncoating, viral DNA genomes
are finally released in the cytosol [113]. This requires the expression of early
viral proteins as well as the activity of host factors, e.g. the proteasome
[112, 153] (see Chapter 3 on page 61).
Little is known about the exact timing or core activation, whether cellular
and viral factors are required for this process, or whether the molecular
changes are intrinsically laid down in the matured viral core. Indeed, not even
the molecular components of the lateral bodies nor the exact architecture of
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the core wall have been clarified to date. Three of the major core proteins
have been shown to exhibit intermolecular disulfide bonds, which are reduced
in the course of infection [104, 135]. While the exact time point of reduction
is unclear, reduction of core components has been linked to morphological
changes of the latter [135]. Early gene transcription is known to require the
import of NTPs, and – at least in the context of the viral core – depends on
the presence or function of L3, VP8, H1, E6, E8, and F18, all of which do
not contain any known enzymatic functions that contribute to transcription
directly [269, 265, 134, 20, 118, 264].
In this study, we used fluorescence microscopy and electron microscopy
in combination with biochemical approaches to study viral core activation
and the function of lateral bodies after fusion. We found that expansion
of viral cores occurs during or immediately after fusion and may not require
any cellular factors. We identified a number of disulfide-bonded core proteins
and found that some of them are reduced during activation. We identified
F18 as a major lateral body component and found that lateral bodies are
decomposed by the activity of the host cell proteasome. Only when this took
place, effector proteins packaged into lateral bodies, like the dual-specific
phosphatase VH1, were released and became catalytically active. We thus
identified a pathway, with which poxviruses, similar to herpes viruses, deliver
immediate effector proteins into the host cell cytosol prior to any viral gene
expression.
4.3 Results
4.3.1 Cores rapidly undergo morphological changes dur-
ing or after fusion
Morphological differences between VACV cores in MVs or EVs and cores
released into the host cell cytosol have been observed repeatedly [51, 127].
However, viral cores are only transiently present in the host cell cytosol and
disappear upon further uncoating. To accumulate viral cores, HeLa cells
were infected with WR wt MVs for 3 h in the presence of actinomycin D
(ActD), which prevents early viral gene transcription and thus uncoating.
Both MVs in endocytic vesicles and free viral cores in the cytoplasm could
be identified in epoxy-embedded and post-stained sections (see Figure 4.1 A).
Cores in MVs exhibited a dumbbell shape, the indentations of which were
filled with electron dense material that in some cases formed clearly visible
lateral bodies (see Figure 4.1 C and Supplementary Figure 4.2 A). Cytosolic
cores, in contrast, were oval, had an increased width, and lacked any visible
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lateral bodies or associated electron dense material (see Figure 4.1 A and
Supplementary Figure 4.2).
To increase the number of cytosolic cores and synchronise core activation,
we next bound MVs to HeLa cells in the cold and subsequently induced fusion
by a short (5 min) pH 5 treatment. 30 min post fusion, we indeed observed
large amounts of cytosolic cores close to the plasma membrane (see Figure
4.1 B). More importantly, activated cores exhibited the same morphological
changes as activated cores in a normal infection, indicating that the release
of viral cores at the plasma membrane permits proper activation (see Figure
4.1 B/C and Supplementary Figure 4.2).
Synchronization of MV fusion allowed us to address the timing of acti-
vation in more detail. When HeLa cells were fixed immediately after acid-
induced fusion, we were able to visualise viral cores, which had just been
released into the cytosol (see Figure 4.1 C). Remnants of the viral membrane
and the lateral bodies were clearly visible as well. Released viral cores were
already oval and wider, indicating that core activation had taken place dur-
ing or immediately after fusion. Moreover, lateral bodies remained associated
with the viral membranes that had merged with the plasma membrane and
had not yet flattened into the plane of the plasma membrane.
Using classical thin section electron microscopy, characteristic changes
of the core morphology could be observed right after acid-induced fusion at
the plasma membrane (see Figure 4.1 C). Since the observed changes were
comparable after fusion of MVs with macropinosomal membranes and after
artificially induced MV fusion, it is likely that core expansion also happens
during or right after fusion with the limiting membranes of a macropinosome.
To test whether the detectable changes could be an artifact of the sample
preparation, which involved sample dehydration prior to embedding, we also
analysed core morphology using a sample preparation protocol developed by
Tokuyasu [235, 220]. This technique involves much milder sample fixation
/ preparation and cryo-sectioning from gelatin-embedded sample pellets. 30
min post fusion, both MVs and cytosolic cores could be detected by electron
microscopy (see Figure 4.1 D-F and Supplementary Figure 4.2 C-E). Impor-
tantly, similar morphological features of released cores compared to cores
within MV particles were detected.
A common method to prepare VACV cores in vitro is to treat purified
MVs with mild detergents and reducing agents [65, 108]. We treated MVs
with NP-40 and DTT and subjected the resulting in vitro cores to Tokuyasu
preparation (see Figure 4.1 F), and compared them to unmodified MVs (see
4.1 E/F [top panels]). In agreement with the literature, in vitro cores lacked
the viral membrane, but still contained lateral bodies [65]. The visibility of
lateral bodies in MVs and in vitro cores, however, depended on the orien-
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Figure 4.1 Morphological changes during VACV core activation. (A-D) WR wt MVs
were bound to HeLa cells on ice (MOI 100) and cells were either incubated at 37 ◦C in
the presence of 5 µg/mL ActD for 3 h (A), or treated with pH 5 medium for 5 min at
37 ◦C, followed by 30 min at 37 ◦C (B), or no further incubation (C/D). Samples were
prepared following the protocols for epoxy-embedding (A-C) or sample preparation after
Tokuyasu combined with anti-DNA immunogold-labelling (D/F). Typical images of thin
sections are shown; scale bar = 100 nm; Nu: nucleus. Cytosolic cores are highlighted
with black arrows. (F) Representative thin sections of MVs prepared by the Tokuyasu
method (E) and immunogold-labelled with anti-DNA antibodies (F); scale bar = 100 nm.
(G) Quantification of core length and width in MVs, cytosolic cores and in vitro cores
as described in material and methods (N = 100). Boxes denote interquartile range, lines
within boxes denote median, whiskers denote 10th and 90th percentiles, and round symbols
denote outliers.
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Figure 4.2 Supplementary Figure; Morphological changes during VACV core activation.
(A-E) Representative thin projections of either epoxy-resin embedded MVs (A) and in
vitro cores (B) or MVs (C) and in vitro cores (D) prepared by the Tokuyasu method and
immunogold-labelled with anti-DNA antibodies (E); scale bar = 100 nm. (F) Bar diagram
are shown percentage class values (“Dumbbell”, “Oval”and “Intermediate” Shape) of MVs,
in vivo and un- and treated in vitro cores.
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tation of the sections and lateral bodies were even more pronounced after
membrane removal (see Figure 4.1 F [bottom panels]). In vitro cores more-
over, exhibited a more oval morphology that resembled cores found in the
cytosol. To compare the morphological changes that cores underwent, we
analysed cores in MVs, cores found in the cytosol during infection, and in
vitro-generated cores. We measured the core widths in the centre of the core
and also classified cores based on their shape as dumbbell, oval, or interme-
diate (see 4.1 G and Supplementary Figure 4.2 F). Cores within MVs had a
mean width of 48 nm and 60 % of all cores were classified as dumbbell shaped.
In contrast, cores found in the cytoplasm exhibited a mean width of 103 nm
and 66 % of all cores were classified as oval. With a mean width of 113 nm
and 57 % cores classified as oval in vitro cores more resemble free cores in
the cytosol. This suggests that membrane removal, and perhaps reduction of
viral proteins, may be sufficient to permit the observed morphology during
activation.
We were thus able to verify changes in core morphology using a tech-
nique that preserved the hydration state of the samples. Moreover, we could
describe the observed differences using objective measurements and classifi-
cations. Using these, we showed that cores generated in vitro exhibit features
of activated cores.
4.3.2 F18 is absent in cytosolic cores
In order to understand core activation in more detail, we wondered which
proteins are lost from viral cores during activation. The phosphoprotein F18
is one of the most abundant MV proteins and remains associated with in
vitro cores [200, 116]. However, a previous study found that F18 is absent in
cores released into the cytosol [178]. In order to monitor changes in protein
composition during activation, we tried to generate a recombinant virus that
encodes a fluorescent fusion protein of F18. While we were not able to mo-
dify the endogenous locus of F18R, we successfully generated a recombinant
virus that encodes the fusion protein EGFP-F18 as an additional copy in
the thymidin kinase locus under the control of the F18 promoter. EGFP-
F18 was incorporated into MVs (see Figure 4.3 B and Supplementary Figure
4.4 A) and is present in cores generated in vitro (see Supplementary Fig-
ure 4.4 A), similar to an EGFP fusion of the bona fide core protein A5 (see
Supplementary Figure 4.3 B).
To monitor the fate of EGFP-F18 during core activation, we infected
HeLa cells with WR EGFP-F18 and WR EGFP-A5 MVs for 3 hours in the
presence of ActD and stained MV membranes with antibodies against L1 (see
Figure 4.3 A/B). In both samples, some MVs positive for L1 and EGFP-F18
4.3. RESULTS 95
Figure 4.3 F18 is absent in cytosolic cores. WR EGFP-A5 (A) or WR EGFP-F18 (B)
MVs were bound to HeLa cells for 1 h (MOI 10) and cells incubated at 37 ◦C for 3 h in
the presence of 5 µg/mL ActD. Samples were stained for the MV membrane protein L1,
representative maximum projections of Z-stacks are presented. Scale bar = 10 µm (A/B).
(C/D) WR EGFP-F18 or EGFP-A5 MVs were bound to HeLa cells on ice (MOI 100)
and cells treated with pH 5 medium for 5 min at 37 ◦C, followed by 30 min at 37 ◦C.
Samples were prepared following the protocols for immunogold EM (Tokuyasu) combined
with anti-GFP immunogold-labelling. (E) MVs and cores were counted and scored for
immunogold-labelling of GFP fusion proteins. N = 100 for each criterion. scale bar =
10 µm (A/B), 500 nm (C/D), 100 nm (attached micrographs C/D), black arrows = in
vitro cores (C/D).
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or EGFP-A5 were detected bound to or internalised into infected cells. Viral
cores accumulated in the presence of ActD were visible as green punctae neg-
ative for L1 in cells infected with WR EGFP-A5. However, hardly any green
punctae negative for L1 were visible in cells infected with WR EGFP-F18.
This suggests that EGFP-F18 may be absent from accumulated cytosolic
cores.
Figure 4.4 Supplementary Figure; Characterisation of WR EGFP-F18. WR EGFP-F18
(A) or WR EGFP-A5 (B) MVs or in vitro cores were bound to cover slips, fixed, and
stained for the MV membrane protein L1. Representative image recorded by confocal
microscopy are shown. Scale bar = 5 µm (A/B).
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Since fluorescence microscopy does not allow the visualisation of un-
labelled cores, we used electron microscopy to analyse cytosolic cores of
WR EGFP-A5 and WR EGFP-F18 after acid-induced fusion (see Figure
4.3 C/D). The presence of EGFP in bound MVs and cytosolic cores was
probed by immunogold-labelling with GFP antibodies. MVs of both recom-
binant virus strains were labelled with anti-GFP antibodies, confirming that
both EGFP fusions were incorporated into particles. While the majority of
all cytosolic cores of WR EGFP-A5 were positive for GFP (94 %), only 14 %
of WR EGFP-F18 activated cores were labelled with GFP antibodies (see
Figure 4.3 E). This indicates that EGFP-F18 was indeed absent from cytoso-
lic cores. Similarly, WR wt MVs, but not cytosolic cores, could be efficiently
labelled with anti-F18 antibodies (data not shown). This, and the fact that
EGFP-F18 was highly enriched in MVs, confirmed that EGFP-F18 behaved
similar to unmodified F18.
Taken together, our data indicated that F18 was lost from the viral par-
ticles after fusion. F18 could in principle be released from viral cores in the
course of the activation process. Alternatively, it is possible that F18 – al-
though described as bona fide core protein – was part of a viral structure
that dissociates from the viral core after fusion.
4.3.3 F18 is a major lateral body component
F18 remained associated with in vitro cores, but not with viral cores found
in the cytosol. We were intrigued by this finding because this paralleled
the presence of a distinct subviral structure - the lateral body (LB). LBs
were detected in MVs and in vitro cores, but remained associated with the
cellular membrane upon fusion and were thus absent from cytosolic cores.
We therefore hypothesised that F18 is indeed localised to the LBs and – due
to its abundance (27,000 copies in an MV [116]) – may constitute a major
component of the latter.
To analyse the subviral localisation of F18, we prepared Tokuyasu sec-
tions of MVs and in vitro cores, and immunogold-labelled F18 with anti-F18
antibodies (see Figure 4.5 A/B and Supplementary Figure 4.6 A/B). We
quantified the localisation of gold particles and found that in mean 2.4 and
5.2 gold particles were visible in the position of the lateral body in MVs and
in vitro cores, respectively (see Figure 4.5 E). However, a few gold particles
were also found onto the core: a mean number of 0.8 and 1.0 gold particles
were observed per core in MVs and in vitro cores, respectively. The partial
localisation of gold labels onto the cores may be caused by the long distance
between the actual epitope and the visible gold particle, which were linked
by one IgG (ca. 10 nm) and protein A molecule. Only very few gold par-
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ticles were found outside virus particles, confirming the specificity of F18
antibodies.
To verify the localisation of F18 to lateral bodies, we treated in vitro
cores with limited amounts of trypsin - a method that had been previously
used to remove lateral bodies (see Figure 4.5 C and Supplementary Figure
4.6 C) [65, 108]. Trypsin-treated in vitro cores were negative for F18 and did
not contain intact lateral bodies, although remnants of the latter were visible
on some cores. This suggests that F18 labelling was indeed dependent on
the presence of full lateral bodies, supporting the hypothesis that F18 was
localised to lateral bodies.
Treatment of MVs with SDS under non-denaturing conditions had pre-
viously been shown to yield so-called “ghosts”[108]. These structures lacked
viral lipid membranes, but still contained the protein layer underlying the
MV membrane, the lateral bodies, as well as parts of the core wall. Viral
DNA and nucleoproteins were shown to be lost from these structures. When
MVs were subjected to mild SDS treatment, we could detect the described
“ghosts”(see Figure 4.5 D and Supplementary Figure 4.6 D), which could be
immunogold-labelled with anti-F18. Although the localisation of gold par-
ticles could not be quantified using the same categories as in the previous
samples, gold particles were predominantly found in what appeared to be
the lateral bodies.
Taken together, F18 immunogold-labelling of sections of MVs and sub-
viral structures supported the hypothesis that F18 localises to lateral bodies.
The close proximity of lateral bodies and cores, however, did not allow an
unambiguous labelling of lateral bodies entirely.
To study the fate and localisation of F18 and the viral core simultane-
ously, we next constructed a virus that incorporated EGFP-F18 as well as
a fluorescent bona fide core protein. While it was not possible to combine
EGFP-F18 with mCherry-A5, we were able to generate a virus which en-
codes EGFP-F18 and a fluorescent fusion of the DNA-binding core protein
VP8, VP8-mCherry. VP8 is encoded by gene L4R and the translated pre-
cursor protein L4 is proteolytically cleaved during morphogenesis to yield
VP8 (aa 33-251 of L4) [273]. Both fusion proteins were encoded as addi-
tional copies in the thymidine kinase locus under the control of their own
endogenous promoters (see Figure 4.6 E for a scheme of the inserted cas-
sette). Successful incorporation of both proteins into MVs was confirmed
by fluorescence microscopy (see Figure 4.5 F/G) and immunoblot analysis
(see Figure 4.6 F/G). Comparable levels of both F18 and EGFP-F18, as well
as VP8 and VP8-mCherry, were incorporated into virions as shown by im-
munoblot analysis of purified MVs (see Figure 4.6 F/G). VP8-mCherry was
proteolytically processed to the same degree as non-fluorescent VP8. EGFP-
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Figure 4.5 Visualisation of lateral bodies. (A-E) WR MVs were pelleted following the
protocol for Tokuyasu combined with anti-F18 immunogold labelling. (A-D) representative
micrographs of endogenous F18 distribution within WR wt MVs (A), in vitro cores (B), in
vitro cores treated with trypsin (C), and MV treated with SDS (D); scale bar = 100 nm.
The data in Table (E) represent counted gold particles in the respective subviral locations
on thawed, immunogold labelled cryo sections; mean values ± standard deviation of the
mean are shown. N = 50 virions, n/a = not applicable, C = core, LB = lateral bodies.
(F-H) WR VP8-mCherry EGFP-F18 MVs (F/H) or in vitro cores (G) were bound to
cover slips and fixed. Samples were either stained for the MV membrane protein L1 and
analysed by confocal microscopy (F/G), or analysed by structured illumination microscopy
without staining. Representative images are shown. Scale bar = 10 µm (F/G) or 500 nm
(H).
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Figure 4.6 Supplementary Figure; Collection of virus particles immunogold labelled for
endogenous F18. WR wt MVs (A), in vitro cores (B), in vitro cores treated with trypsin
(C), MV particles treated with SDS (D); scale bar = 200 nm. (E) Overview of the insertion
site of the VP8-mCherry and EGFP-F18 coding sequences in the tk locus. (F-G) Band-
purified WR wt and WR VP8-mCherry EGFP-F18 MVs were denatured in sample buffer
and proteins separated by SDS-PAGE. Presence of VP8 and VP8-mCherry (F) or F18 and
EGFP-F18 (G) was tested with anti-VP8, or anti-F18 antibodies, respectively.
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F18 and VP8-mCherry furthermore remained associated with in vitro cores,
as expected for both core and LB components (see Figure 4.5 G).
To analyse the distribution of EGFP-F18 and VP8-mCherry within MV
particles, we next analysed WR VP8-mCherry EGFP-F18 MVs by structured
illumination microscopy (SIM) [86], a technique that allows improved resolu-
tion using conventional fluorescent proteins (see Figure 4.5 H). While VP8-
mCherry was found in the centre of the particles, EGFP-F18 fluorescence
was found more peripheral and – depending on the orientation – occurred as
two distinct spots at both sides of the core. This distribution matched the
expected pattern of VP8-mCherry in the core and EGFP-F18 in the lateral
bodies.
We next used MVs of WR VP8-mCherry EGFP-F18 to infect HeLa cells
and analysed samples by fluorescence microscopy. When MVs were bound
to HeLa cells in the cold, virtually all VP8-mCherry-containing cores co-
localised with EGFP-F18 as well as the MV membrane protein L1 (see Figure
4.7 A). When cells were infected for 3 h in the presence of ActD, some red
fluorescent cores were positive for EGFP-F18 and L1, suggesting that the
cores were part of intact MVs that had not yet undergone fusion (see Figure
4.6 B). The majority of red punctae, however, did not associate with L1 and
EGFP-F18, confirming that the cores that accumulated after fusion were
negative for EGFP-F18. This furthermore indicates that VP8-mCherry and
EGFP-F18 act like the endogenous VP8 and F18, respectively.
In case EGFP-F18 is indeed localised to the lateral bodies as hypothe-
sized, then the EGFP-F18 fluorescence would be expected to dissociate from
the red fluorescent core as one distinct structure. Indeed, some punctae
that were only green fluorescent were detected 3 h post infection. They
were, however, outnumbered by the red fluorescent cores, suggesting that
free lateral bodies were unstable. Similar green punctae were also observed
5 min post acid-induced fusion (data not shown). When F18 or EGFP-F18
in MVs was analysed by SDS-PAGE and immunoblot, we had repeatedly
noticed a ladder of high molecular weight bands of F18 that were shifted by
ca. 8 kDa, a pattern similar to proteins known to be conjugated to ubiquitin
and oligoubiquitin-chains (see Figure 4.8 E). It was thus possible that ubiq-
uitinated F18 was marked to be rapidly degraded by the proteasome. To
test whether EGFP-F18 was degraded by the proteasome, we infected HeLa
cells in the presence of the proteasome inhibitor MG132 3 h p.i. (see Figure
4.7 C) [195], VP8-mCherry containing cores as well as EGFP-F18 contain-
ing structures accumulated. This indicates that EGFP-F18 is indeed part
of a distinct structure that is lost from the core upon fusion and that this
structure is degraded or dissociated in a proteasome-dependent manner.
In conclusion, our experiments with WR VP8-mCherry EGFP-F18 con-
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Figure 4.7 Visualisation of lateral bodies. WR VP8-mCherry EGFP-F18 MVs were
bound to HeLa cells on ice (A-C: MOI 15, D: MOI 100). (A-C) Cells were either fixed
directly (A), or incubated at 37 ◦C for 3 h in the presence of ActD (B), or ActD and
MG132 (C). Samples were analysed by confocal microscopy and maximal projections of
representative Z-stacks are presented. Examples of an MV (arrow), a cytosolic core (closed
arrowhead), and a free lateral body (open arrowhead) are highlighted in the insets. Scale
bar = 10 µm. (D) Cells were treated with pH 5 medium at 37 ◦C for 5 min, fixed and
prepared for immunogold EM (Tokuyasu) combined with anti-F18 immunogold labelling.
The micrograph shows viral cytosolic cores (black arrows) and the lateral bodies left behind
after fusion. The inset shows a single lateral body found in an in vitro cores preparation,
subjected to the same immunogold labelling and represent in the same scale. Scale bar =
100 nm.
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Figure 4.8 Verification of identified disulfide-bonded core proteins. WR wt MVs were
alkylated with NEM and boiled in sample buffer w/o reducing agents, with 100 mM DTT,
5 % β-mercaptoethanol (β-ME), or both. Proteins were separated on 10 % (A–D) or 15 %
(E) SDS-PAGE gels, transferred to nitrocellulose membranes and 4a (A), 4b (B), A5 (C),
VP8 (D), and F18 (E) detected by Western blot. Positions of monomeric reduced proteins
are indicated on the left.
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firmed the localisation of F18 determined by EM and demonstrated that
EGFP-F18-positive structures dissociated from the core as distinct objects,
presumably lateral bodies.
Our initial morphological studies had shown that lateral bodies remained
at the plasma membrane after acid-induced fusion. Since they were not
very electron dense, LBs were difficult to identify in Tokuyasu samples. We
therefore applied WR VP8-mCherry EGFP-F18 MVs and a correlative light
and electron microscopy (CLEM, see Figure 4.9) setup to identify viral cores
and lateral bodies at the plasma membrane in Tokuyasu sections. When this
technique was combined with anti-F18 immunogold-labelling, we were able
to identify viral cores and LBs 5 min after acid-induced fusion (see Figure
4.7 D and 4.9 E). More importantly, the distance between cores and LBs was
great enough to unambiguously determine that F18-staining was only found
in the LBs, but not in the cores. This proves that F18 is indeed localised to
LBs, which are left behind upon fusion.
4.3.4 F18 degradation releases the LB protein H1 and
thereby regulates H1 activity
F18 can be phosphorylated on serine residues 53 and 62 by cellular proline-
directed kinases and can be dephosphorylated by the viral dual-specific phos-
phatase VH1 [134, 264]. In fact, F18 in virions is hyper-phosphorylated in
the absence of VH1 [134]. MVs lacking VH1 exhibit defects in early gene ex-
pressions similar to MVs incorporating a mutant version of F18 that cannot
be phosphorylated. While VH1 has only been shown to be present in in vitro
Figure 4.9 (following page) Appearing of single fusion events by correlative light and
EM approach. WR wt MVs were bound to HeLa cells for 1 h on ice (MOI 100) treated with
pH 5.0 medium for 5 min and fixed directly. Samples were subjected to correlative light and
electron microscopy (CLEM). Ninety-nm thin cryo-serial sections were cut and transferred
to a copper finder grid at RT. After several PBS washing steps, acquiring of fluorescence
images was performed in a new designed light microscopy chamber for wet, thawed sections.
Subsequently, immunogold-labelling of GFP was executed on identical thawed sections
(D, insert and E) as previously described [235, 220]. (A/D) show the fluorescent signal in
serial sections of cultured cells with adherent virions expressing EGFP-F18. The cartoon
(top right) illustrates a simplified fusion event. (D) represents CLEM of fluorescent and
transmission electron microscopy (TEM) and a higher magnification of a representative
F18 immunogold-labelled virion in (D, insert). (C) shows a sequentially acquired and
merged fluorescent image showing the separation of VP8-mCherry and EGFP-F18. (E)
An enlarged TEM area of a single fusion event in which a lateral body was positive labelled
for EGFP-F18 (black arrow). Scale bars are as follows: (A) = 100 µm, (D) = 5 µm and (D
insert, E) = 200 nm. Attention: Figure is presented in a colour vision deficiency version.
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cores, their functional relationship suggests that F18 and VH1 may occur in
close proximity in the virion. To test whether VH1 localises to LBs, we gener-
ated a virus expressing VH1-HA from the endogenous locus and analysed the
distribution of VH1-HA by electron microscopy and immunogold-labelling
with anti-HA antibodies.
When MVs of WR VH1-HA were artificially fused to HeLa cells, we were
able to analyse both bound MVs and virus particles shortly after fusion (see
Figure 4.10 A/B). Within a bound MV (see Figure 4.10 A), on average 4.1
gold particles were found in the position of the lateral bodies in between
the core and the MV membrane. In contrast, only around 0.2 gold parti-
cles were found in the core. In addition, anti-HA immunogold-labelling was
found in LBs left behind at the plasma membrane after acid-induced fusion,
but hardly any staining was detected in released cores (see Figure 4.10 B).
Taken together, the results of anti-HA immunogold-labelling indicate that
VH1 almost exclusively localises to the lateral bodies.
Besides its essential role in the replication cycle, VH1 has an additional
function that only becomes apparent in the presence of a cellular immune
system. In uninfected cells, IFNγ stimulation leads to the recruitment and
activation of janus kinases, which subsequently phosphorylate the antiviral
transcription factor Stat1 on tyrosine 701 (p-Stat1) (see Figure 4.11 B). p-
Stat1 dimerises and is imported into the nucleus, where it activates the tran-
scription of GAS element-dependent genes. However, VH1 brought into the
cell with the incoming virus catalyses the de-phosphorylation of p-Stat1 and
thus prevents its nuclear import and Stat1-dependent gene expression [164]
(see Figure 4.11 C). This way, VACV-infected cells suppress the expression
of antiviral proteins immediately after entry, before early gene expression.
We wondered whether VH1 has to be released from LBs to become cat-
alytically active and decided to use nuclear localisation of Stat1 in HeLa cells
as a read-out for VH1 activity. While Stat1 is mostly found in the cytosol in
untreated cells (see Figure 4.11 A), phosphorylated Stat1 dimers are trans-
ported into the nucleus upon IFNγ treatment, which can be visualised with
anti-Stat1 immunofluorescence staining (see Figure 4.11 B). As described in
the literature [87], VACV infection with WR wt prior to IFNγ-treatment
prevented nuclear localisation of Stat1 (see Figure 4.11 D) and this effect
was reverted when VH1 activity was inhibited with the broad phosphatase
inhibitor orthovanadate (see Figure 4.11 F). In the presence of the protea-
some inhibitor MG132, which leads to the stabilization of LBs, Stat1 was
mainly found in the nucleus after WR wt infection and IFNγ-treatment (see
Figure 4.11 E). This indicates that VH1 requires proteasome activity to in-
activate dephosphorylated Stat1. Since VH1 is active in the absence of any
cofactors [134], the proteasome is most likely required for the dissociation of
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Figure 4.10 VH1 localizes to lateral bodies. WR VH1-HA MVs were bound to HeLa
cells on ice (MOI 100) and fusion induced by a 5 min treatment with pH 5 medium at
37 ◦C. Samples were then fixed and prepared for immunogold EM (Tokuyasu) combined
with anti-HA immunogold labelling. Representative thin projections of bound MVs (A)
and a fusion event (B) are shown; black arrow: VH1 positive lateral bodies; scale bar =
100 nm.
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Figure 4.11 Dephosphorylation of P-Stat1 by VH1 requires proteasome activity. WR
wt MVs were bound to HeLa cells on ice (MOI 20), followed by incubation at 37 ◦C for
1 h. Cells were subsequently fed with medium containing 1000 U/mL human IFNγ and
incubated for an additional 1 h at 37 ◦C. The indicated drugs were present during binding
and all later steps. Cells were fixed and stained for Stat1, actin, and DNA. Samples were
analysed by confocal microscopy and representative images are shown. Scale bar = 50 µm.
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LBs to release effector proteins. This way, F18 may act as a LB scaffold-
ing protein that – through its ubiquitination – is destined for proteasomal
degradation. Upon destruction, viral effectors like VH1 are released, which
are immediately active to modify the host cell.
4.3.5 Viral core proteins are reduced during activation
Despite MV formation in the reducing environment of the cytosol, a number
of VACV core proteins have been found to be involved in inter- and intra-
molecular disulfide bonds [104, 135]. MVs produced in the presence of DTT
or treated with DTT in vitro have been shown to exhibit an oval shape
resembling activated cores [135]; we made similar observations in MVs treated
with DTT and NP-40 (in vitro cores). Two viral core proteins, 4a and VP8,
have furthermore been shown to be reduced in a not further characterised
step of infection [135].
To investigate whether core activation involves the reduction of viral core
proteins, we first set out to identify disulfide-bonded core proteins in an un-
biased biochemical approach. We applied redox 2D SDS PAGE [228] as well
as a combination of sucrose gradient and reducing SDS PAGE to specifically
identify disulfide-bonded proteins based on their different electro-mobility
or sedimentation coefficient before and after reduction (see Figure 4.12 and
Table 4.1). We identified 13 disulfide-bonded VACV proteins, of which 6
were MV membrane proteins that were not further considered. The core
proteins VP8, A5, 4a, 4b, and the RNA polymerase subunits RPO132 and
RPO147, as well as F18 were identified. VP8, 4a, 4b, and F18 were packaged
into MVs as high-molecular weight complexes. The latter migrated slowly
in non-reducing SDS-PAGE or did not even enter the gel, but migrated as
monomers upon reduction (see Figure 4.12). A5 exhibited intra-molecular
disulfide bonds that rendered denatured A5 more condensed, leading to a
faster migration in non-reducing SDS-PAGE. High molecular-weight com-
plexes of RPO132 and RPO147 were only confirmed in infected cells using
transiently transfected expression vectors for HA-tagged proteins.
To monitor the redox state of disulfide-bonded proteins during infection,
we next bound WR wt MVs to HeLa cells in the cold and incubated cells
at 37 ◦C for 3 h in the presence or absence of ActD. As controls, cells were
kept on ice, or MVs were incubated with monoclonal anti-L1 antibody 7D11
prior to binding, which blocks MV fusion. Cells were harvested and proteins
were analysed by non-reducing or reducing SDS PAGE and immunoblot with
antibodies against F18, 4b, and VP8 (see Figure 4.8 on page 103). The
majority of all three proteins ran as monomers after reduction. Under non-
reducing conditions, low molecular weight bands of F18 and 4b were detected
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Figure 4.12 Identification of disulfide-bonded VACV proteins. Disulfide-bonded VACV
proteins were identified by redox 2D SDS-PAGE (A) or sucrose velocity gradients of de-
natured proteins in combination with reducing one-dimensional SDS-PAGE (B). Proteins
were stained with colloidal Coomassie and the highlighted protein spots or band identified
by mass spectrometry (see Table 4.1 on page 112). M = molecular weight standard.
4.3. RESULTS 111
3 h post infection in the absence or presence of ActD, suggesting that proteins
were in the reduced state when samples were prepared. No low molecular
weight bands of F18 and 4b were detected when MVs were only bound or
fusion was inhibited with neutralising antibodies. The low molecular weight
band of F18, which occurred after infection, ran slower than monomeric,
unmodified F18 and was found to be shifted by ca. 8 kDa. It ran at the same
height as one of the minor bands of F18 found in reduced samples. The redox
state of VP8 did not change during infection.
To identify disulfide-bonded VACV proteins by redox 2D SDS-PAGE,
MV protein samples boiled in sample buffer were separated by SDS-PAGE
under non-reducing conditions in the first dimension, and subsequently sep-
arated by reducing SDS-PAGE in the second dimension (see Figure 4.12 A).
All proteins that did not contain any disulfide bonds exhibited the same
electrophoretic mobility in both conditions and thus occurred as a diagonal
in the 2D gel. All proteins present in complexes linked by intermolecular
disulfide bonds ran slower under non-reducing conditions and faster after re-
duction and thus were expected to occur below the diagonal in the 2D gel.
Proteins with intra-molecular disulfide bonds have a more compact structure
and thus ran faster under non-reducing conditions and slower after reduc-
tion. They were therefore expected to be found above the diagonal. Many
spots below the diagonal were revealed by colloidal Coomassie staining and in
most cases proteins rather ran as a smear in the first (non-reducing) dimen-
sion. This may be caused by the reduced solubilisation of protein complexes
before reduction or by the presence of the same proteins in high molecular
weight complexes of different size. Two protein spots were identified above
the diagonal. The respective spots or bands were cut out and the proteins
within identified by mass spectrometry (see Table 4.1 on page 112). We
identified 5 core proteins as present in intermolecular disulfide bonds: the
RNA polymerase subunits RNA pol 147 and RNA pol 132, 4a, A5, and VP8.
Furthermore, 4 MV membrane proteins were found to contain intermolecular
disulfide bonds: A25, A26, D8, and A27. L1 and possibly F9, of which only
one peptide was identified, were found to contain intra-molecular disulfide
bonds.
While large proteins or protein complexes have a reduced electrophoretic
mobility and thus may not even enter a polyacrylamid gel, they have a larger
sedimentation coefficient and thus move faster in sucrose gradients during ve-
locity runs. To identify viral proteins in bigger disulfide-bonded complexes,
MVs boiled in sample buffer were therefore first separated on a 10–25 %
sucrose gradient. The gradient was fractionated, proteins reduced, and sepa-
rated by SDS-PAGE. Three prominent bands were observed throughout the
sucrose gradient after silver staining and in the upper five fractions after
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Sample Protein Peptides Gene MW [kDa] Cysteins
a Myosin-9 5 MYH9 227 21
b RNA pol 147 subunit 32 J6R 147 19
c RNA pol 132 subunit 19 A24R 133 20
d A25 23 A25L 84 23
e/o 4a (aa 1-614 of A10) 45/39 A10L 62 7
f A26 12 A26L 58 6
g/h A5 23/16 A4L 31 4
i D8 8 D8L 35 1
j VP8 (aa 33-251 of L4) 25 L4R 28 2
k lost
l/m/n A27 2/14/14 A27L 13 2
p L1 12 L1R 27 6
q F9 1 F9L 24 7
A 4a (aa 1-614 of A10) 7 A10L 62 7
B 4b (aa 62-643 of A3) 7 A3L 66 7
C F18 2 F17R 11 5
Table 4.1 Identification of disulfide-bonded proteins by mass spectrometry (proteins iden-
tified in experiments in Figure 4.12). Protein names, number of peptides identified with
>95 % confidence, gene name, theoretical molecular weight (MW), and number of cystein
residues of each identified protein are present. Sample k was lost during sample prepara-
tion.
Coomassie staining (see Figure 4.12 B). This suggested that the respective
proteins were present in high molecular weight complexes with high – but in-
homogeneous – sedimentation coefficients, and that the respective complexes
were disassembled after reduction. When MV protein samples were reduced
first and then ran on parallel gradients, almost all proteins were found in the
top fraction and few in the second fractions (data not shown). The identi-
fied bands were cut out and determined by mass spectrometry as the core
proteins 4a, 4b, and F18 (see Table 4.1 on page 112).
In order to verify that the identified core proteins indeed formed high
molecular weight complexes via intermolecular disulfide bonds, polyclonal
antibodies against F18, VP8, 4b, and 4a were used to detect the respective
core proteins by Western blot. MVs were boiled in sample buffer without
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reducing agents, with DTT, with β-mercaptoethanol, or with DTT and β-
mercaptoethanol and separated by SDS-PAGE (see Figure 4.8).
Using two different biochemical assays, we found that six core proteins
and F18 contain disulfide-bonds. Our infection experiments (data not shown)
suggest that F18 and 4b are reduced during infection and that this happens
after fusion, but before uncoating, i.e. most likely during core activation.
In summary, the core proteins F18, VP8, 4b, 4a, RNA pol 132, and RNA
pol 147 as well as the MV membrane proteins A27, D8, A26, and A25 were
found to be present in disulfide-bonded high molecular weight complexes. It
is likely that this approach did not identify all disulfide-bonded proteins, since
only abundant structural proteins could be detected by Coomassie staining.
4.3.6 Changes in core morphology may not require
host factors
Our initial morphological studies had shown that the core morphology changes
immediately after or during fusion. Generation of in vitro cores with deter-
gents and reducing agents led to a core morphology resembling activated
cores, and at least two core proteins were found to be reduced during core
activation. It was thus possible that core activation occurs when viral cores
are released into the reducing environment of the cytosol. However, it re-
mained unclear if the reduction of core proteins is directly linked to changes
in core morphology, and if host factors are involved in core activation at all.
We thus intended to study core activation after fusion with artificial lipo-
somes – a minimalistic system in the absence of any host factors and reducing
agents. For this, we first needed to test whether fusion of VACV MVs with
artificial vesicles lacking proteins or glycosaminoglycans can be induced by
low pH. To be able to monitor hemifusion, we labelled VACV MVs with
self-quenching quantities of the fluorescent lipid dye octadecyl rhodamine B
(R18), which would be de-quenched upon fusion [90]. When these virions
were bound to HeLa S3 suspension cells in the cold, hemifusion and pre-
sumably full fusion could be efficiently induced by a pH 5 buffer at 37 ◦C,
as apparent by the rapid increase of R18 fluorescence in the sample cuvette
(data not shown).
We next generated large unilamellar vesicles (LUVs) with an average di-
ameter of ca. 170 nm composed of lipids commonly found in the plasma
membrane: the phosphatidylcholine DOPC, the phosphatidylethanolamine
DOPE, sphingomyelin, and cholesterol in the ratios 8:2:1:9 [277]. When
LUVs and R18-labelled MVs were mixed and the pH was lowered to 5 at
37 ◦C, rapid R18 de-quenching was observed, suggesting that MVs can un-
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dergo hemifusion with LUVs in the absence of any fusion receptor (data not
shown).
Figure 4.13 Morphological changes of cores during fusion with LUV. (A-D) WR wt
MVs were bound to 200 nm LUVs and fusion induced by pH 5 treatment for 10 min
at 37 ◦C. Samples were prepared using (A) tensile freeze fracture EM technique, (B)
cryo-transmission electron microscopy technique, (C) cryo-electron microscopy vitreous
sections, (D) Tokuyasu method combined with labelling of endogenous F18. Selected
fusion events are shown. Of note, clear fusion events could only be detected in few cases.
This is possibly due to low fusion efficiency, as well as a too small increase in vesicle volume
during fusion; black arrowheads = transmembrane proteins of viral origin, scale bar = 200
nm (A-D).
To investigate the products of MV-LUV fusion, we incubated LUVs and
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MVs for 10 min at pH 5, fixed virions with glutaraldehyde and subsequently
analysed the samples by electron microscopy. To verify that fusion events
occurred, we employed tensile freeze fracture electron microscopy and found
that transmembrane proteins of viral origin were indeed deposited in LUV
membranes (see Figure 4.13 A). We next used cryo-transmission electron mi-
croscopy (CTEM) after plunge freezing in liquid ethane (see Figure 4.13 B),
cryo-electron microscopy of vitrified sections (CEMOVIS) [2] after high pres-
sure freezing (see Figure 4.13 C), as well as Tokuyasu sectioning combined
with anti-F18 immunogold-labelling to analyse the resulting samples (see
Figure 4.13 D). Since LUVs had a significantly smaller diameter and sur-
face area than MVs, we did not expect to be able to visualise the fusion of
one MV with a single LUV. Instead, fusion of the same virus particle with
multiple LUVs would be required to see a significant increase in the sur-
face area and thus the diameter of the fusion product. While many vesicles
were found attached to MVs, very few cores within a large vesicles – as ex-
pected after fusion of one MV with multiple LUVs – were detected. The
intra-vesicular cores appeared oval and wider than cores in MVs. However,
the number of events was too low to quantify core width and shape and to
compare it to values obtained for MVs and cytosolic cores (see Figure 4.1 on
page 92 and Supplementary Figure 4.2 D on page 93). LBs were only visi-
ble in samples prepared after Tokuyasu and even fewer sections (see Figure
4.13 D). Where visible, however, LBs seemed to be dissociated from cores
and anti-F18 immunogold-labelling confirmed the localisation of F18 to LBs.
Taken together, fusion experiments of MVs with LUVs suggested that
morphological changes of the core after fusion happened in the absence of
host factors and are thus an intrinsic property of mature cores. Although
hemifusion seemed to be induced by low pH treatment, it remains unclear,
how efficient full fusion of MVs with LUVs is in the absence of any receptors
or tethering factors. This is in part due to the fact that not all fusion events
can be visualised by EM because a single fusion does not increase the volume
of the fusion product significantly enough for unequivocal detection.
4.4 Discussion
The entry of both infectious forms of VACV, MVs and EVs, results in the
release of virus cores into the host cell cytosol. Viral cores subsequently
undergo an activation step that allows the packaged transcription machin-
ery to start early gene expression and prepare the cell for further uncoating
and virus replication. In an attempt to describe and understand core activa-
tion in structural and molecular detail, we found that VACV cores undergo
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morphological changes immediately after fusion, a step that possibly does
not involve any cellular factors. At the same time, two proteinaceous lat-
eral bodies of previously unknown composition and function, are left behind
where the viral and the cellular membrane have fused. We identified the
viral protein F18 as one of the major lateral body proteins and found that
at least one effector protein, the dual-specific phosphatase VH1, is brought
into newly infected cells in lateral bodies. Only when lateral bodies and pre-
sumably their scaffold protein F18 are degraded by the host cell proteasome,
effector proteins are released and become active. Poxvirus lateral bodies may
therefore be a transport vessel for effector proteins that become active upon
host cell-mediated release, but before viral gene expression.
Using different electron microscopy techniques, we could follow the struc-
tural changes upon fusion of an MV with cellular membranes in detail. While
LBs remain associated with the membrane upon fusion, cores are released
into the host cell cytosol. LBs probably remain bound to viral membrane
proteins deposited in the cellular membrane in the fusion process. In con-
trast, when membranes are released from MVs using NP-40 and DTT, LBs
remain attached to the core. This suggests that LBs may directly bind to
both the core and the viral membrane or the membrane associated protein
layer. Interactions may be rearranged during fusion and core activation. Al-
ternatively, binding to components of the viral membrane may be stronger
than binding to the core.
F18 is one of the most abundant proteins in an MV and was previously
described as a core or even DNA-binding protein [108]. Our analysis showed
that F18 is present in MVs, in in vitro cores still containing the lateral bodies,
as well as in lateral bodies found at the plasma membrane after acid-induced
fusion. However, F18 was absent from cores released into the cytosol, and
from in vitro cores incubated with trypsin to partially remove the lateral
bodies. Furthermore the fusion protein EGFP-F18 correctly localised to LBs
and was shown in discrete spots next to VP8-mCherry-containing cores in
MVs using structured illumination microscopy. Previous studies had shown
F18 throughout immature virions (IVs), and at the rim of the core of MVs
[240]. These findings are consistent with a recruitment of F18 to immature
virions, followed by partitioning into the lateral bodies during morphogenesis.
Indeed, VACV exhibits severe morphogenesis defects in the absence of F18,
and only few aberrant MVs lacking visible lateral bodies are formed [264].
In a seminal study by Ichihashi and colleagues, protein 13.8K and four other
proteins had already been interpreted as LB components based on electron
microscopy and SDS-PAGE [65]. While the other four proteins cannot be
identified using the given information, it seems likely that the basic protein
13.8K indeed was F18, although it was identified as A27 in a later study of
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the same group [232].
The fate of lateral bodies after release from the core could be followed by
fluorescence microscopy and free lateral bodies were stabilised in the presence
of the proteasome inhibitor MG-132. Indeed, the band-pattern of F18 on
Western Blots suggests that at least a fraction of F18 is ubiquitinated and it
is tempting to speculate that the protein is in this way primed for proteasomal
degradation.
An additional LB component that we identified in the course of this study
is the dual-specific phosphatase VH1, of which around 200 molecules are
packaged into an MV [134]. VH1 is presumably essential for the viral life
cycle, as no deletion virus could be generated [134]. Known substrates of VH1
include the viral proteins F18, A14, and A17, as well as the cellular protein
Stat1 and possibly Stat2 [134, 164, 240, 57, 123]. In the absence of VH1
during morphogenesis, the incorporated viral proteins F18, A14, and A17 are
hyperphosphorylated and early transcription is impaired. Interestingly, MVs
incorporating F18 mutants that cannot be phosphorylated exhibit normal
morphology, but also have defects in early transcription. It remains unclear,
whether VH1 activity is required during MV formation, or after viral entry.
It was speculated that some defects in early transcription in the absence of
VH1 could be partially rescued by background levels of VH1 released from
other virions [134]. This would support a role for VH1 after entry. In trans
complementation, however, was only inferred indirectly and was not shown
in the context of an infected cell.
Dephosphorylation of Stat1 by VH1 is most likely an additional immuno-
modulatory function of VH1, which is not required for virus replication in
tissue culture in the absence of IFNγ-secreting cells. Nevertheless, since
phosphorylation of Stat1 and subsequent nuclear import can be artificially
induced by IFNγ stimulation, p-Stat1 is a suitable model substrate to anal-
yse VH1 activity. Our experiments showed that VH1 requires functional
proteasomes to become active and dephosphorylate p-Stat1. Since LBs are
stabilised under the same conditions, and since recombinant VH1 can de-
phosphorylate phosphorylated F18 and A14 in the absence of any cofactors
[134], it is most likely that packaging of VH1 in lateral bodies renders the
protein inactive. Only proteasome-dependent disassembly or degradation of
LBs releases active VH1. Indeed, previous experiments had already shown
that packaged VH1 must be regulated: WR wt MVs contain phosphorylated
F18 despite the presence of VH1, suggesting VH1 in the virus is inactive
or cannot access its substrates. Recombinantly expressed VH1, however,
can dephosphorylate F18 within in vitro cores [134]. It cannot be ruled out
that the observed reduction of F18 intermolecular disulfide bonds contributes
to the disassembly of LBs. Similarly, it is possible that VH1 regulates LB
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disassembly by dephosphorylating F18. The VH1 inhibitor orthovanadate,
however, did not lead to the accumulation of lateral bodies (data not shown).
Taken together, our data on F18 and VH1 describe a pathway that allows
the delivery of host modulatory proteins into the host cell by the viral LBs.
Viral effector proteins are released from LBs by the activity of the host cell
proteasome and function without the need for any viral gene expression. In
some aspects, the poxvirus LBs thus resemble the tegument of herpes viruses.
The disassembly step catalysed by the host cell proteasome adds a level of
regulation whose advantages remain to be fully understood. This strategy
may allow the virus to package inactive viral effectors that are deleterious
in the producer cell or the virion itself. Alternatively, host cell-mediated LB
disassembly may ensure the correct timing for effector proteins. It is very
likely that VH1 is not the only viral effector delivered to host cells by the LB
pathway. Similarly, we cannot rule out that F18 itself has a direct function
in host cells, although it is most likely degraded rapidly. Curiously, a basic
11 kDa phosphoprotein present in disulfide-bonded high molecular weight
complexes was purified from MVs by Person-Fernandez et al. in 1986 [183].
This protein resembles F18 in its physical properties and was described to
bind to ribosomes and inhibit protein translation. Conditions that led to the
release of this protein from cores, though, did not lead to the separation of
LBs and cores (data not shown).
It would be of outstanding interest to identify further components of LBs
and study their function immediately after infection. The identification of
packaging signals would furthermore allow artificial targeting of effector pro-
teins into recombinant poxvirus strains used as vaccines or oncolytic agents.
In some settings, it may be advantageous to deliver a protein of interest
into cells before or in the absence of any viral gene expression. Interest-
ingly, when the first 42 amino acids of F18 were fused to the reporter protein
β-galactosidase, the respective fusion protein was incorporated and catalyt-
ically active in newly infected cells in the absence of viral gene expression
[98].
During core activation, viral cores undergo the necessary changes to begin
early gene transcription. In line with the previous literature, we have shown
that a number of structural changes of the viral core occur immediately after
fusion. Cores become oval, wider, and less electron dense. These changes
in the core can be partly mimicked during in vitro core generation with
mild detergents and reducing agents. Limited structural data after fusion of
MVs with liposomes suggests that the observed morphological changes are
indeed an intrinsic property of the mature core and occur independently of
any host factors. The observed changes are probably already laid down in
the structure of the core during maturation, and may just need membrane
4.5. MATERIAL AND METHODS 119
removal for completion. A direct link between changes in core morphology
and early gene expression, however, has not been established. In conditions
that do not allow early gene transcription despite the presence of all required
viral factors, e.g. after fusion of MVs lacking VH1 or L3, or MVs containing
ts mutants of E6 and E8, normal changes in core morphology were observed
(data not shown) [190, 134, 20, 118]. Using biochemical approaches, we found
that the viral core wall protein 4b is reduced during activation. It remains at
this point unclear, whether this contributes to changes in core morphology or
transcriptional activity. In principle, it is conceivable that early transcription
starts when viral components involved in NTP import or mRNA export are
activated upon milieu changes in the cytosol.
Alternatively, the catalytic activity of the viral RNA polymerase itself
may be subject of regulation. It is possible that the disulfide-bonded RNA
polymerase subunits RPO132 and RPO147 are redox-regulated and become
active upon reduction in the host cell cytosol, but this was not tested further.
A complete understanding of the core changes that allow early gene tran-
scription may require more detailed knowledge on core architecture and core
formation during morphogenesis. Structural changes during this process ren-
der the core unstable and prone to activation upon arrival of the cytosol of
new host cells.
In summary, our study describes the early stages of poxvirus uncoating
in more detail. Furthermore, we have identified F18 as a structural and VH1
as an effector component of VACV LBs and for the first time impute a func-
tion to these enigmatic viral structures. We suggest that LBs act as delivery
containers for viral effector proteins that become active upon proteasome-
dependent LB disassembly, and thus much earlier than early viral proteins.
Decipherment of the molecular components and functions of LB components
will not only contribute to a deeper understanding of the early stages of the
viral life cycle, but also help to understand how poxviruses modulate the
immune system. Protein delivery via LBs may also open attractive possibil-
ities to improve poxvirus-based vaccines or oncolytic viruses, and even allow
delivery of proteins into cells that do not permit early gene expression.
4.5 Material and methods
4.5.1 Cell lines
BSC-40 (African green monkey) and HeLa (human) cells were cultivated in
DMEM (Gibco BRL) supplemented with 10 % heat-inactivated FCS, gluta-
max, and penicillin-streptomycin; for BSC-40 cells non-essential amino acids
120 CHAPTER 4. VACV LBS DELIVER EFFECTOR PROTEINS
and sodium pyruvate were added as well; RK13 (rabbit) cells were culti-
vated in MEM (Gibco BRL) supplemented with 10 % heat-inactivated FCS,
glutamax, non-essential amino acids, penicillin-streptomycin, and sodium
pyruvate.
4.5.2 Viruses
Recombinant Vaccinia viruses were generated based on VACV strain Western
Reserve (WR) by transfecting infected cells with plasmids containing genomic
viral sequences as described elsewhere [148]. WR EGFP-A5 was described
previously [210]. To generate WR EGFP-F18 and WR VP8-mCherry EGFP-
F18, the endogenous promoter as well as the coding sequence of the fusion
protein were inserted into the tk locus using vectors based on pJS4 [33]
(see Appendix Figure A.1 on page 139). An intermediate virus, WR neoR
GYR-PKR, which encodes neomycin phosphotransferase (neoR) and a fusion
protein of the gyrase dimerisation domain and the protein kinase R (PKR)
catalytic domain [247] under a viral promoter in the tk locus, was constructed
to facilitate insertion into this site. Adapting a strategy described by White
et al. [263], coumermycin A1 was used to negatively select parental viruses
and greatly increased the fraction of recombinant virus, which was detected
based on the fluorescence of plaques. To generate WR VH1-HA, a vector
based on pBluescript II KS (Fermentas, St. Leon-Rot, Germany) was built,
which contains the coding sequences for GFP-neoR and GYR-PKR under
the control of viral promoters, as well as the HA coding sequence flanked
by genomic viral DNA sequences. The latter defined the insertion of HA at
the C-terminus of VH1; the overlap of the J6 and the VH1 coding sequence
was resolved by duplicating the overlapping four nucleotides. Intermediate
viruses containing the full plasmid inserted into the genome were selected
by plaque purification in the presence of 2.8 mg/mL G418. Full recombined
viruses lacking the G418 and coumermycin A1 selection cassettes were plaque
purified in the absence of G418 and the presence of 100 ng/mL coumermycin
A1. Recombinants bearing the HA coding sequence were identified by plaque
PCR.
MV particles were produced in BSC-40 cells and purified from cytoplasmic
lysates as described elsewhere [148].
To label viral membranes with octadecyl rhodamine B chloride (R18),
sedimented MVs from cytosolic extracts were incubated with R18 at a final
concentration of 22.5 µM for 2 h at room temperature. MVs were subse-
quently sedimented at 38,000 g for 40 min and purified through a 25-40 %
sucrose gradient as for purification of unlabelled MVs.
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4.5.3 Preparation of in vitro cores and other subviral
particles
In vitro cores were generated by incubating MVs with 1 % NP-40 and 50 mM
DTT in 10 mM Tris (pH 9.0) for 30 min at 37 ◦C. Cores were subsequently
sedimented for 1 h at 16,000 g and 4 ◦C in a tabletop centrifuge and re-
suspended in 1 mM Tris (pH 9.0). To partially remove lateral bodies, the
in vitro core pellet was re-suspended in PBS and treated with 20 µg/mL
trypsin at 37 ◦C for 15 min. The trypsin digest was stopped with 200 µg/mL
aprotinin on ice and virions processed for electron microscopy. To produce
VACV “ghosts”, MVs were treated with 1 % SDS in 50 mM Tris, pH 7.4,
at 37 ◦C for 30 min; sub-viral particles were sedimented and processed for
electron microscopy.
4.5.4 Antibodies
Hybridoma cells to produce the mouse anti-L1 (MAb 7D11) [269] were kindly
provided by Bernard Moss with permission of Alan Schmaljohn (University
of Maryland, Baltimore, MA, USA). MAbs were purified from hybridoma
supernatants by BioGenes (Berlin, Germany). Rabbit anti-F18 [134] was ob-
tained from Paula Traktman (Medical College of Wisconsin, Milwaukee, WI,
USA), rabbit anti-4a, anti-4b, and anti-VP8 [254] were kind gifts of Dennis
Hruby (Oregon State University, Corvallis, OR, USA). Rabbit anti-A5 [49]
was kindly provided by Mariano Esteban (Centro Nacional de BiotecnologA˜a,
Madrid, Spain). Rabbit poly-clonal anti-GFP was purchased from Rockland
(Gilbertsville, PA, USA), mouse anti-DNA (MAb AC-30-10) from Progen
Biotechnik (Heidelberg, Germany) [206], mouse anti-HA.11 (Clone 16B12)
from Covance Inc., mouse anti-Stat1 (Mab HPA000982) from Sigma Aldrich,
and rabbit anti-P-Stat1 (Tyr701) (#9171) from Cell Signaling Technology.
Rabbit polyclonal anti-mouse immuno-globulins were obtained from Dako-
Cytomation (Glostrup, Denmark), fluorophore-coupled goat anti-mouse sec-
ondary antibodies from Invitrogen (Carlsbad, CA, USA), and HRP-coupled
goat secondary antibodies from Bio-Rad (Hercules, CA, USA).
4.5.5 Drugs and reagents
Actinomycin D, aprotinin, cytosine arabinoside (AraC), coumermycin A1,
MG-132, and sodium orthovanadate (Na3VO4) were obtained from Sigma-
Aldrich; G418, fluorophore-coupled phalloidin, and octadecyl rhodamine B
chloride (R18) were purchased from Invitrogen; human recombinant inter-
feron γ was bought from eBioscience (San Diego, CA, USA); DOPC, DOPE,
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sphingomyelin, and cholesterol were obtained from Avanti Polar Lipids (Al-
abaster, AL, USA). Draq 5 (Biostatus, Shepshed, UK) was used for DNA
staining.
4.5.6 Identification of disulfide-bonded viral proteins
To identify disulfide-bonded proteins by redox 2D SDS-PAGE, samples alky-
lated with 20 mM NEM were heated in LDS sample buffer (2 % LDS, 0.51
% EDTA, 10 % glycerol, 0.22 mM SERVA Blue G250, 0.175 mM phenol red,
247 mM Tris [pH 8.5]) for 10 min at 70 ◦C. Proteins were run on a 4-12
% NuPAGE® Bis-Tris gel (Invitrogen) using MOPS electrophoresis buffer.
The whole lane was cut out and the gel piece heated in LDS buffer with
250 mM DTT for 20 min at 70 ◦C. After a washing step with LDS buffer,
proteins in the gel were alkylated in LDS buffer with 100 mM NEM for 10
min at RT and the gel piece washed in LDS buffer again. The gel piece
was placed horizontally on a 4-12 % NuPAGE® Bis-Tris gel with a 2D well
and proteins separated in the second dimension using MOPS electrophore-
sis buffer. The gel was fixed in 50 % MeOH, 7 % acetic acid, and stained
with colloidal Coomassie. Protein spots were cut out with a razor blade and
proteins identified by the Functional Genomics Center Zurich using in-gel
trypsin digestion and LC/ESI/MS/MS.
To identify disulfide-bonded proteins using sucrose velocity gradients,
samples alkylated with 20 mM NEM were heated in LDS sample buffer, di-
luted and run though a 10-25 % sucrose gradient in 10 mM Tris (pH 9.0), 0.1
% SDS (SW41 rotor, 28,000 g, 45 min, RT). 500 µL fractions were collected
and proteins precipitated with trichloro acetic acid. After a washing step
with 80 % ice cold acetone, precipitated proteins were dissolved in 2 x LDS
buffer with 200 mM DTT, heated for 10 min at 70 ◦C and separated on 4-12
% NuPAGE® Bis-Tris gels using MOPS buffer. Gels were fixed and stained
as above and proteins in chosen bands identified by mass spectrometry.
4.5.7 Immunoblot
Samples to be analysed by immunoblot were boiled in SDS sample buffer (2
% SDS, 10 % glycerol, 0.1 % bromophenol blue, 50 mM Tris [pH 6.8], 100 mM
DTT) for 5 min at 95 ◦C. To analyse the redox state of viral proteins, samples
were alkylated with 20 mM NEM prior to denaturation and boiled in SDS
sample buffer with or without DTT. Subsequently, proteins were separated
on 10 or 15 % discontinuous SDS-PAGE gels and transferred to nitrocellulose
membranes. Proteins were detected using rabbit anti-4b, anti-4a, anti-A5,
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anti-VP8, or anti-F18 (all 1:1,000) and goat anti-rabbit HRP (1:5,000) with
the ECL Plus Western Blotting Detection Reagent (GE Healthcare).
4.5.8 Infection experiments
For infection experiments, the indicated amount of MVs were bound to HeLa
cells in the cold for 1 h. Cells were subsequently incubated in full medium at
37 ◦C for the denoted time and processed for immunofluorescence microscopy
or different electron microscopy methods. When infection experiments were
performed in the presence of drugs, drugs were present during binding and
incubation. In some cases, artificial fusion with the plasma membrane was
induced after binding by a 5 min treatment with full DMEM containing
30 mM MES, pH 5.0, at 37 ◦C.
4.5.9 Immunofluorescence microscopy
To stain proteins for immunofluorescence microscopy, cells were fixed with
4 % formaldehyde (FA) and permeabilized in permeabilisation buffer (PS)
(0.05 % saponin, 1 % BSA, 0.05 % NaN3 in PBS) for 20 min. Samples
were incubated with primary antibodies in PS (anti-L1 0.54 µg/mL; anti-
Stat1 1 µg/mL) for 2 h, washed with PBS, and subsequently incubated with
fluorophore-coupled goat secondary antibodies (1:1,000) for 1 h. Where in-
dicated, filamentous actin was stained with fluorophore-coupled phalloidin
(1:100), and DNA with Draq5 (1:1,000). Samples were washed with PBS
and H2O and mounted with Immu-Mount (Thermo Fisher Scientific).
4.5.10 Sample processing for epoxy embedding EM
Infected cells were fixed in 2.5 % glutaraldehyde (GA) (50 mM sodium ca-
codylate pH 7.2, 50 mM KCl, 2.5 mM CaCl2, 2.5 mM MgCl2) for 90 min
at room temperature [19]. After several rinses in pre-warmed buffer (50 mM
sodium cacodylate pH 7.2, 50 mM KCl, 2.5 mM CaCl2, 2.5 mM MgCl2),
the specimens were postfixed in fresh prepared reduced osmium tetroxide
(1.5 % KFeCN, 2 % OsO4, 50 mM sodium cacodylate pH 7.2, 50 mM KCl,
2.5 mM CaCl2, 2.5 mM MgCl2) for 1 h on ice [144], subsequently rinsed in
water on ice. Afterwards cells were again fixed in 2 % osmium tetroxide
(50 mM sodium cacodylate pH 7.2, 50 mM KCl, 2.5 mM CaCl2, 2.5 mM
MgCl2) for 30 min on ice, rinsed in ddH2O, and stained overnight at 4
◦C
in aqueous 0.5 % uranyl acetate. The specimens were then dehydrated in
graded ethanol series and propylene oxide, followed by embedding in Epon
812 (Serva, Heidelberg, Germany).
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Ultrathin sections (50-60 nm) from cell monolayers were obtained using an
Leica EM FC7 ultramicrotome (Leica, Vienna, Austria) and counter stained
with aqueous uranyl acetate and lead citrate [191], if required for increased
contrast. Sections were examined with a CM10 Philips transmission electron
microscope at 80 kV with an Olympus Veleta 2k x 2k side-mounted TEM
CCD camera.
4.5.11 Sample processing for immunogold EM
Samples were fixed by adding an equal volume of a 2x fixative (8 % FA, 0.2
% GA in PHEM, pH 6.9) [207] to the culture medium. After 5-10 min this
mixture was removed and replaced with 1x fixative (4 % FA, 0.1 % GA in
PHEM, pH 6.9) for 90-120 min at RT. Cells were scraped and sedimented
(300 g). In vitro samples were pelleted by centrifugation at 10,500 g.
The pellets were washed by centrifugation and re-suspending and incubated
in PBS-glycine for 10 min at RT. Samples were then re-suspended carefully in
10 % gelatin/PBS, incubated for 10 min at 37 ◦C, pelleted by centrifugation
and immediately placed on ice until the gelatin was hardened. The pellet
was cut into 1 mm3 pieces. Gelatin-embedded samples were infiltrated with
2.3 M sucrose [235] and kept at 4 ◦C over night on a rotating wheel, mounted
onto sample pins and plunge frozen by hand in liquid nitrogen.
50-60 nm cryo-sections were obtained with diamond knives (Diatome Ltd.,
Bienne, Switzerland) in a Leica EM FC7/UC7-ultramicrotome (Leica, Vi-
enna, Austria), at -120 ◦C. Copper grids were coated with 1 % Formvar [67]
and a thin carbon layer. Sections were thawed in a drop of “pick-up solu-
tion”(2 % methyl cellulose mixed with 2.3 M sucrose in a ratio of 1:2), trans-
ferred to coated copper grids and stored covered by the “pick-up solution”[80]
at 4 ◦C.
For immunogold-labelling, 50-60 nm cryo-sections were thawed and incu-
bated with primary antibodies against endogenous F18 (1:200), GFP (final
concentration: 2.5 µg/mL), DNA (final concentration: 0.33 µg/mL), with the
secondary poly-clonal antibody rabbit anti-mouse IgGs (final concentration:
0.5 µg/mL) and subsequently with 10 nm protein A gold (1:60, PAG, CMC,
Utrecht, The Netherlands) as described in [82, 220] and stained/embedded
in 4 % uranyl acetate / 2 % methyl cellulose mixture (ratio 1:9) [236].
4.5.12 Analysis of the core length and width
Analysis of the core length and width was performed as follows. Regions of
interest (ROIs) were traced in ImageJ by exactly following the core outlines.
All ROIs were processed in Matlab using Dynamo [31]. An adapted Dynamo
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algorithm performed the following steps. The core length was defined as
the greatest distance between any two points on a single drawn ROI, which
determine the main axis. This axis is then divided in three segments. Then,
the maximal and minimal widths perpendicular to the main axis in those
segments were measured, inducing a rough classification. Three classes were
defined as “oval”(maximum in central segment is larger than both maxima
in the lateral segments), “dumbbell”(maximum in central segment is smaller
than maxima in both lateral segments) and “intermediate”shape (all other
cases, see Figure 4.2 F).
Values for average length and width are shown in Figure 4.1 G. The mini-
mal width was determined with in the 2nd third segment of each core length.
Boxes denote interquartile range, lines within boxes denote median, whiskers
denote 10th and 90th percentiles, and round symbols denote outliers. The
box plot was created using GraphPad Prism version 5.0d for Mac OS X,
GraphPad Software, San Diego, CA, USA, www.graphpad.com.
4.5.13 Analysis of Stat1 localisation
To analyse Stat1 localisation as a readout for VH1 activity, WR wt MVs
(MOI 25) were bound to HeLa cells on cover slip at 4 ◦C for 1h in the
presence of the indicated drugs. Cells were incubated at 37 ◦C for one hour
with drugs, and subsequently fed with fresh medium containing drugs and
1000 U/mL IFNγ. After 1 h at 37 ◦C, cells were fixed, and processed for
immunofluorescence staining with anti-Stat1 as described above.
4.5.14 Fusion assay – large unilamellar vesicles
To prepare large unilamellar vesicles (LUVs), 5 mg lipids dissolved in chlo-
roform/methanol (DOPC, DOPE, sphingomyelin, and cholesterol in a molar
ratio of 8:2:1:9) were mixed and dried under an Argon stream. Lipids were
further dried in a speed vacuum concentrator over night and then hydrated
for two hours at RT in 1 mL PBS. LUVs were prepared by extrusion through
a polycarbonate filter with 200 nm pore size using an Avanti Mini-Extruder
(21 strokes). WR wt MVs (109 pfu) were added to the LUV suspension and
incubated for 1 h at 4 ◦C. The pH was lowered to 5.0 by adding 105 µL
1 M MES and the mixture was incubated at 37 ◦C for 10 min. The reac-
tion mixture was diluted with 4 mL 2x PHEM, and both virions and LUVs
sedimented by ultra-centrifugation (SW55, 38,000 g, 4 ◦C, 30 min). Samples
were subsequently processed for electron microscopy as described below.
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4.5.15 Sample processing for tensile freeze fracture replica
A droplet of 2 µL sample was placed on the cleaned copper holder and man-
ually plunged into liquid propane [1]. The frozen sample was fractured at
-125 ◦C in a vacuum of about 10−5 Pa with a liquid nitrogen-cooled knife
in a Balzers 400 freeze-etching device. The fractured sample was replicated
with a 1-1.5 nm deposit of platinum-carbon, and coated with a 20 nm car-
bon film. The Pt/C replica was cleaned with 2 % SDS, washed with ddH2O,
transferred onto copper EM grid and observed with a Philips CM10 EM (see
above).
4.5.16 Sample processing for cryo-electron microscopy
of vitreous sections (CEMOVIS)
For CEMOVIS, samples were prefixed with 0.5 % GA in 1x PHEM buffer
[207] for 15 min and supplemented with an equal volume of 40 % dex-
tran/PBS [10] (average molecular mass 40 kDa; Sigma-Aldrich, Buchs, Switzer-
land). They were then introduced into copper tubes and vitrified with an
EMPACT 2 high-pressure freezer (Leica, Vienna, Austria) [230]. Afterwards,
tubes were mounted in the tube holder of an Leica EM FC7/UC7 cryo-
ultramicrotome (Leica, Vienna, Austria) and trimmed to a pyramidal shape,
as previously described [3].
40-50 nm feed cryo-sections were cut with a 45◦ diamond knife (Diatome,
Biel, Switzerland) under standard cutting conditions [279]. They were col-
lected on Quantifoil® (Micro Tools GmbH, Jena, Germany) holey carbon
films (copper 200 mesh grids, R3.5/1) or Quantifoil® with hexagonal ge-
ometry (slot grids) with the help of Leica EM CRION device and stored in
liquid nitrogen.
4.5.17 Sample processing for plunge freezing
Samples were prepared by adsorbing 3 µL of the virion fused liposome sus-
pension onto Quantifoil® R3.5/1 holey carbon film mounted on 200 mesh
copper grids (Quantifoil® Micro Tools GmbH, Jena, Germany). Prior to
adsorption, the grid was rendered hydrophilic by glow discharge in a reduced
atmosphere of air for 15 sec. The specimen was applied and after 30 sec
incubation on the surface, the grid was blotted and quick-frozen in liquid
ethane using a robotic plunge freezer Vitrobot (FEI Company, Eindhoven,
The Netherlands).
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4.5.18 Cryo-Transmission Electron Microscopy (Cryo-
TEM) imaging
For cryo-TEM imaging (CEMOVIS or plunge freezing) grids were either
transferred to a Gatan 626 cryo-holder (Gatan, Pleasanton, CA, USA) kept
below -170 ◦C and inserted into a FEI CM200FEG or – using the fully auto-
mated FEI AutoLoader™ unit – into a Titan Krios™ cryo-electron microscope
(FEI, Eindhoven, Netherlands), both equipped with a field emission gun. The
accelerating voltages were 200 and 300 kV, respectively. Specimens were irra-
diated with a low electron dose (< 20 e-/A˚2). Electron diffraction was used
to check whether the frozen water embedding the sample was vitreous or
crystalline. Crystalline sections were discarded. Micrographs were recorded
with a TemCam-F416 (4k x 4k, 16 µpixel, CMOS camera, Tietz Video and
Image Processing Systems, Gauting, Germany) or Ultrascan 4000 (4k x 4k,
CCD mounted in front of GIF) from Gatan Company (Gatan Company,
Pleasanton, CA, USA) at different magnifications. No image processing was
performed.
4.5.19 Flow cytometry infection assay
Confluent 12-wells of HeLa cells were infected for flow cytometry-based in-
fection assays. Pretreatment with inhibitors was performed for 15-60 min in
DMEM. MVs (2·106 pfu in 0.5 mL) were prepared in DMEM (+ inhibitors).
After 30 min at 37 ◦C, cells were washed and overlayed with 1 mL full MEM
(+ inhibitors). 4 h post infection, cells were prepared for flow cytometry.
Cells were analysed using a BD FACSCalibur flow cytometer and the BD
CellQuest Pro software or the FlowJo software package.
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Chapter 5
Conclusion and Outlook
5.1 Host cell entry of vaccinia virus EVs
Like all viruses, poxvirus MVs (matured virus) and EVs (enveloped virus) are
metabolically inactive transport carriers of the viral genome and accessory
enzymes. They are completely dependent on the cellular machinery to gain
access to their site of replication, the cytosol. A summary of the entry
processes of MVs and EVs is presented in Figure 5.1 (see page 130).
MV infection presumably represents the event that initiates primary in-
fection of a host organism with a poxvirus. Depending on the poxvirus,
primary infection may happen after inhalation of MV-containing material
or after exposure of skin lesions to MVs [53]. By exposing phosphatidylser-
ine (PS), MVs stimulate macropinocytosis in their host cells and are sub-
sequently internalised with the bulk fluid. Acidification of macropinosomes
possibly inactivates fusion inhibitory proteins in the MV membrane, which
subsequently allow the entry fusion complex (EFC) to mediate fusion of the
viral membrane with cellular membranes [239, 148, 152, 35]. It is possible
that other mechanisms can regulate virus fusion or inactivation of fusion
inhibitors because not all vaccinia virus (VACV) strains and not all other
poxviruses undergo acid-induced fusion [150, 256].
Cell-associated and released EVs are thought to spread VACV infection
within a host. While entry of cell-associated EVs on actin tails into adjacent
cells has not yet been studied, this thesis focussed on the infection of host
cells by free EVs. Infection of epithelial cells by free EVs presumably hap-
pens when infected cells release EVs into body fluids, which then infect new
tissues within the organism. Since it is unlikely that medical intervention
can prevent primary infection, spread of infection through body fluids is the
step in a poxvirus infection that would need to be controlled to treat a dis-
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Figure 5.1 Visualisation of VACV pathway for MVs and EVs. VACV MVs and EVs
enter host cells in a stepwise process that includes binding (A), internalisation (B) by
macropinocytosis, as well as EFC activation and fusion (D) in the case of MVs, or EV
membrane disruption (C), and fusion (D) in the case of EVs. Released cores are activated
(E) and subsequently start early gene expression. Representative electron micrographs are
shown for MVs (top) and EVs (bottom), EGFP-A5 is immuno-gold labelled in the case
of MVs and F13-GFP in the case of EVs; scale bars = 100 nm. In top row image (D), a
schematic of membranes and viral cores is inset. Critical cellular components are shown in
blue, arrows with solid lines represent physical movement, arrows with dashed lines depict
signalling events [211].
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ease caused by poxviruses. We found that EVs – like MVs – actively trigger
macropinocytosis to be internalised into host cells with both their mem-
branes. However, they possibly induce macropinocytosis through a different
mechanism than MVs. EV membranes are disrupted upon acidification of
macropinosomes and thus exposes an MV-like particle that contains the EFC
in the membrane. Since EVs lack the described fusion inhibitory complexes
[246], the EFC may already be in an active state and subsequently mediate
fusion. This would release the viral core into the host cell cytoplasm and
allow for successful infection.
Fusion proteins of many viruses are sensitive to neutralising antibodies.
While RNA viruses with a high mutation rate can evade the humoral immune
response to some extent by mutation, this is not possible for DNA viruses
that exhibit a low mutation rate. One strategy to protect fusion proteins
from the humoral immune system is to adopt the active conformation only
upon certain cues at the desired site of fusion. However, this still renders
fusion proteins sensitive to neutralising antibodies that prevent the required
conformational changes or block fusion sterically. Another strategy is to pre-
vent exposure of viral fusion proteins to the humoral immune response. This
may be accomplished by cell-to-cell spread that does not involve release of
viral particles [203], or by intracellular long-distance transport, e.g. along
axons as in the case of several neurotropic viruses [203]. Poxviruses have
evolved another strategy: They produce infectious particles surrounded by
two membranes. The second membrane of EVs shields critical components
of the inner membrane from the humoral immune response and, by the incor-
poration of host complement control genes [251, 252], is even well protected
against non-specifc destruction by the host complement system. A mecha-
nism of EV entry that involves endocytosis of intact EVs is thus consistent
with such a protective role of the EV membrane. EV membranes are only
lost inside the macropinosomes of host cells, i.e. when the underlying MV-
like particles are no longer accessible to the humoral immune system of the
host.
It is at present unclear how VACV EVs trigger macropinocytosis. While
both MV and EV infection requires the activity of EGFR, EV infection was
not sensitive to the PS-binding protein annexin V, which blocks MV infec-
tions. This suggests that EVs trigger macropinocytosis through a different
mechanism than MVs. Even though EV and WV membranes were reported
to contain significant amounts of PS [226], this lipid is preferentially found in
the cytosolic leaflet of cellular membranes and would therefore be expected
to be in the inner leaflet of EV membranes. Theoretically, we cannot rule out
that PS exposed in EV membranes was already bound by PS-binding pro-
teins present in the serum, such as Gas6, and could therefore not be blocked
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Figure 5.2 Entry pathway of VACV MVs and early/late replication steps. Purple =
cellular components involved in the endocytic processes.
by annexin V. Since macropinocytosis is a signalling-induced process, it is
possible that clustering of receptors triggers the respective signalling events.
EVs have been shown to use different attachment factors than MVs [250]
and those factors may be candidates for the triggering mechanism. However,
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they have not been identified yet and therefore cannot be tested.
The fate of newly formed macropinosomes, their maturation, and their
cross-talk with the classical endosomal system is poorly characterised. Viruses
have been used to define many endocytic pathway and allowed researchers
to follow the fate of virions as traceable cargo [143]. While our EV infec-
tion experiments confirm that macropinosomes can be acidified by vATPases,
VACV MVs rather than EVs should be used to further characterise the fate
of macropinosomal cargo because they are easier to obtain and due to their
stability comprise the more homogeneous and more defined macropinocytic
cargo.
The molecular mechanism of EV disruption is not understood and needs
further investigation. Rupture of continuous biological membranes is a pro-
cess that is energetically highly unfavourable and is e.g. involved in endoso-
mal escape of non-enveloped viruses [242], or in the proposed mechanism of
action of some antimicrobial peptides [174]. A similar process was proposed
to play a role in VACV crescent formation [41]. However, no molecular basis
for the triggered rupture of membranes by proteins that are embedded in
the membrane itself has been described. Intriguingly, electron micrographs
suggest that disrupted membranes form an intact bilayer sheet that remains
associated with the underlying particle [128]. This is in line with our observa-
tion that F13-GFP, which is inserted into the EV membrane via its palmitate
moiety [84], and the transmembrane protein B5 remain associated with the
underlying particle upon rupture. The employed mechanism therefore does
not involve membrane solubilisation or a complete destabilisation of mem-
branes, but rather a regulated process that opens the closed EV membrane
and results in a membrane sheet.
EV disruption by low pH or by anionic polysaccharides may involve simi-
lar mechanisms because both require the EV protein A34. However, it cannot
be ruled out that the only function of A34 is to recruit sufficient amounts of
B5 to the EV membrane, which has also been shown to be required for EV
disruption by GAGs [128]. Interestingly, EV neutralising antibodies directed
against B5 were shown to block EV infection and comet tail formation in
monolayers [4]. The latter process has been attributed to the formation of
satellite plaques by EVs released into the medium by producer cells. Roberts
et al. proposed that acidic residues in the membrane-proximal stalk of B5
are required for artificial EV disruption by anionic polysaccharides, although
they do not show the successful incorporation of the generated B5 mutants
into EVs [193]. The authors further demonstrated that the interaction be-
tween B5 and A34 was sensitive to large poly-anions or poly-cations. They
speculated that the disruption of this interaction would release the negatively
charged stalk region of B5 close to the membrane, which could destabilise
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membranes by electrostatic repulsion of negatively charged lipid head-groups.
Since many modifications of EV proteins result in reduced amounts of
EVs and their analysis is rather complex, a reductionist approach to study
EV disruption may be helpful. If EV membrane proteins such as B5 or A34
could be reconstituted in liposome membranes after heterologeous expression
or purification from EV membranes, the protein requirements for membrane
disruption upon different triggers could be studied.
We speculated that fusion of MV-like particles exposed after EV mem-
brane disruption may not require additional hints since the fusion inhibitory
proteins A25 and A26 are missing in EVs. However, it remains to be deter-
mined whether fusion of MV-like particles is regulated. Interestingly, infec-
tion of mostly disrupted EVs in the absence of MV-neutralising antibodies
was still sensitive to inhibitors of macropinocytosis, but was not blocked by
bafilomycin A1 (BafA, see Figure 5.2). This suggests that disrupted EVs
were still endocytosed by macropinocytosis and did not fuse with the plasma
membrane. However, it remains unclear whether the insensitivity towards
bafilomycin A1 suggests acid-independent fusion, since MV infection in our
hands was only mildly affected by bafilomycin A1, while we at the same time
determined a clear pH optimum of 5.0 for fusion in our fusion assay.
While this thesis contributed to the understanding of the cellular entry
pathway of VACV EVs, mechanistic details on the involved processes, i.e.
macropinocytosis, acid mediated EV disruption, and fusion of MV-like par-
ticles, still demand further clarification. It remains to be seen to what extent
our findings on the entry of free EVs hold true for cell-associated EVs that
are projected to adjacent cells on the tip of actin tails. Furthermore EV as
well as MV entry into polarised cells or cells embedded into a tissue need to
be studied to fully understand the role of MVs and EVs in vivo.
Roughly summarised, there is a quite clear understanding how MVs and
EVs using macropinocytosis to enter a host cell by non-specific uptake of
fluids. However all further maturation and traffic steps of macropinocytosis
as well as the connection with early / late endosomes are still unclear and
must be examined in the future. In this context, VACV will be a powerful
tool.
5.2 RNAi screening in VACV infection
The ubiquitin-proteasome protein degradation system is involved in many
essential cellular processes including cell cycle regulation, cell differentiation,
and the unfolded protein response [146]. Ubiquitylation is further a widely
used post-translational protein modification that regulates many biological
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processes, including immune responses. The role of ubiquitin in immune reg-
ulation was originally uncovered. Recent studies have revealed crucial roles
of ubiquitylation in many aspects of the immune system, including innate
and adaptive immunity and antimicrobial autophagy. In addition, rising ev-
idence indicates that (i) microbial pathogens exploit the ubiquitin pathway
to evade the host immune system [111] and (ii) viruses use various strategies
to hijack the ubiquitination pathway and target cellular proteins for degra-
dation (or disruption of function) in order to evade cellular innate antiviral
response [36]. It should be also noted however that the cellular autophagy
machinery is not required for vaccinia virus replication and maturation [278].
As previously reported, inhibition of the ubiquitin-proteasome system
prevents vaccinia virus DNA replication and expression of intermediate and
late genes [201].
In our present study, our results strongly indicated that ubiquitination
comes into play as an essential process already during the assembly of VACV
particles in virus factories located in the cytoplasm of host cells. Core pro-
teins undergo extensive K48-linked polyubiquitination. This is consistent
with the accumulation of ubiquitin observed in poxvirus replication sites and
the detection of ubiquitin within purified VACV particles. The polyubiqui-
tination is probably an essential step for virus assembly.
5.3 Core activation
Most enveloped viruses that organise their genome in a capsid or core struc-
ture have to solve the same problem: assembly in producer cells and un-
coating in newly infected cells occurs in the same cellular compartment. In
most cases, viral cores undergo an irreversible maturation step at some point
between initial assembly and uncoating that renders viral capsids or cores
unstable and favours uncoating in newly infected cells. In rare cases, the
compartment of capsid assembly itself may have different properties than
the equivalent compartment during uncoating [79].
VACV MV and EV entry pathways converge when the VACV cores are
deposited in the host cell cytosol by fusion. Immediately after fusion, cores
undergo morphological changes described as activation. Those go along with
the removal of lateral bodies, possibly reduction of disulfide-bonded core pro-
teins, and onset of early gene expression. Therefore, a defined program of
immediate early steps is already berthed in the core structure and does not
require early gene expression. In other words, VACV cores and lateral bodies
wrapped into the MV or MV-like membrane are metastable. A number of
maturation steps that occur after membrane closure in immature virions (IV)
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(see Figure 1.3) have primed the resulting MV (or EV) for these processes.
Maturation of MVs or MV-like particles results in the reorganisation of the
packaged viral proteins, which transforms an IV filled with amorphous pro-
teinaceous material and a DNA nucleoid into an MV with defined structures:
a core that contains DNA-protein complexes surrounded by the core wall as
well as two lateral bodies. On a molecular level, structural proteins are pro-
cessed by two viral proteases and disulfide bonds are formed in core and
membrane proteins. In addition, several viral proteins are phosphorylated
during assembly or maturation and some of the incorporated viral proteins
are post-translationally modified by ubiquitination.
A detailed knowledge of virus assembly and maturation would be required
to fully understand the molecular mechanisms that underlay core activation.
However, we found that cellular factors or the cytosolic environment are re-
quired for core activation and dissociation of lateral bodies from the incoming
core. We established an in vitro system that includes acid-induced fusion of
MVs with liposomes. This system may help to define the exact requirements
for the observed processes.
Treatment of MVs with detergents and reduction of solvent-accessible
disulfide bonds is not enough to dissociate lateral bodies from cores. How-
ever, lateral bodies could be removed from cores by a short treatment of
in vitro cores with proteases such as trypsin or proteinase K [65, 108, 125].
Whether dissociation of lateral bodies from cores after fusion requires prote-
olytic processes or other cellular activities or components will be tested.
While it is imaginable that changes in the core structure are required
to support early gene expression and prepare the core for uncoating, it is
less clear what removal of lateral bodies does to the core or to the host cell.
Lateral bodies could be a simple structural component of MVs or EVs, or
they could negatively regulate activities in the viral core until the cytosol of
the host cell is reached. In both cases, removal of the lateral bodies after
penetration would be enough. Alternatively, lateral bodies could contain
effector proteins that are released into the host cell cytosol. These factors
could modify the host cell in an extent that supports infection, similar to
tegument proteins of herpes viruses, which are fully formed and active and
control viral entry, gene expression, and immune evasion [26, 25].
We have observed a number of changes that VACV cores undergo when
they are released into the host cell cytosol by fusion. We are able to describe
the early stages of poxvirus uncoating in more detail. Furthermore, we have
identified F18 as a structural and dual-specific phosphatase VH1 as an effec-
tor component of VACV LBs and for the first time assign a function to these
elusive viral structures.
Hence, we propose that LBs act as delivery containers for viral effector
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proteins that become active upon proteasome-dependent LB disassembly, and
thus much earlier than early viral proteins. Decipherment of the molecular
components and functions of LB factors will not only contribute to a deeper
understanding of the early stages of the viral life cycle, but also help to
understand how poxviruses modulate the immune system. Protein delivery
via LBs may also open attractive possibilities to improve poxvirus-based
vaccines or oncolytic viruses, and even allow delivery of proteins into cells
that do not allow early gene expression.
5.4 Virus uncoating process
We found, that 6 core proteins F18, VP8, 4b, 4a, RNA pol 132, and RNA
pol 147 were identified and confirmed to contain inter-molecular disulfide
bonds. While proteins of similar molecular weight had been shown to occur
in disulfide-bonded protein complexes before [108, 108], only VP8 and 4a had
been identified and assigned to the respective gene [135].
Although not in our close thoughts, 4 viral MV membrane proteins, A27,
D8, A26, and A25, were identified to contain intermolecular disulfide bonds.
Intermolecular disulfide bonds in A26 [94], A27 [94], and D8 [135] have al-
ready been described and similarly, intramolecular disulfide bonds in L1 [216]
and F9 [216] are known from literature.
At least two of the disulfide-bonded core proteins, F18 and 4b, were
shown to be reduced after fusion and in the absence of viral gene expression.
Another core protein that formed intermolecular disulfide bonds to other core
proteins, VP8, however, did not become reduced. VP8 has been observed
to be released from viral cores with the viral DNA during uncoating [178]
and thus may be buried within the core and be impenetrable to solvent or
oxidoreductases.
The finding that in vitro cores generated in 50 mM DTT and 1 % NP-40
still exhibit characteristics of cores in MVs (dumbbell shape, associated with
lateral bodies) suggests that reduction of solvent-accessible core disulfide
bonds alone is not sufficient for core activation and loss of lateral bodies.
However, it remains to be determined to what extent core disulfide bonds
indeed are reduced during this treatment. While disulfide bonds can be
reduced when MV samples are boiled in sample buffer containing SDS and
DTT, it is unclear if disulfide bonds are accessible to the reducing agents
under non-denaturing conditions. Reduction of core proteins may also require
the rearrangement of core components by other means, or the activity of
cellular or viral oxidoreductases.
Worthy of note, the viral core protein A14 has been shown to form
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disulfide-bonded dimers in the lumenal domain of the virus [154] and was
proposed to be one major component of the basal protein layer below the
MV membrane by Ichihashi [104]. The basal protein layer has to be disrupted
or dissolved in the line of core release and it may therefore be of interest to
follow the redox state of this protein during entry as well.
To understand the role of disulfide-bonded core proteins and their reduc-
tion, it has to be more specifically analysed whether reduction coincides with
morphological changes or transcriptional activity. Furthermore, it would be
crucial to test whether reduction of core proteins requires cellular or viral
proteins, or the reducing environment of the cytosol. More extensive fusion
experiments of MVs with liposomes may take forward to follow core protein
reduction under more controlled conditions.
Appendix A
Appendix
A.1 Plasmid
Figure A.1 Plasmid used to generate recombinant VACV strains by a combination of
positive selection. L4R (VP8) here is under the control of a synthetic early / late vaccinia
virus promoter, F18 is under the control of the late promoter. The purple areas (TK
L and TK R) define the regions of the plasmid that are the homologue to the vaccinia
virus genome and determine the insertion site. The genes in this range [J1, J2, and J3
(partially)] are also shown. J2, thymidine kinase is destroyed during the insertion, but not
required for replication in cell culture. The coding sequences for the fluorescent fusions of
F18 and VP8 are thus inserted in addition to the endogenous genes. F18 and EGFP-F18,
as well as VP8 and VP8-mCherry, are therefore expressed simultaneously.
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A.2 Hallway
Figure A.2 Hallway Poster at C-CINA. Visualization of Vaccinia virus pathway.
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Figure A.3 CINA Hallway Poster, Arts & Science; A Homage to Andy Warhol;
Immunogold-labelling of viral F18-protein on ultra-thin cryo sections (Vaccinia virus).
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